Novel b0at1 inhibitor

MYPI2025006127A0Undetermined Publication Date: 2024-10-06TANABE PHARMA CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025006127
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-28
Filing Date
2024-04-05
Publication Date
2024-10-06

AI Technical Summary

Technical Problem

Current treatments for amino acid metabolic disorders, such as phenylketonuria and Hartnup disease, rely heavily on dietary therapy and enzyme supplementation, lacking fundamental therapeutic options to normalize neutral amino acid metabolism and alleviate symptoms effectively.

Method used

Development of a novel compound with excellent B0AT1 inhibitory activity, represented by specific chemical formulas, which can be used as an active ingredient in pharmaceuticals to inhibit the neutral amino acid transporter B0AT1, thereby addressing the metabolic disorders.

Benefits of technology

The compound effectively inhibits B0AT1, providing a potential therapeutic solution for amino acid metabolic disorders by normalizing neutral amino acid metabolism and alleviating symptoms associated with conditions like phenylketonuria and Hartnup disease.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention aims to provide a novel B0AT1 inhibitor. The present invention relates to a compound having a B0AT1 inhibitory action and represented by the following formula (I): wherein each symbol is as defined in the specification, or a salt thereof. In addition, the present invention relates to a B0AT1 inhibitor containing the aforementioned compound and a pharmaceutical composition containing the aforementioned compound. One embodiment of the present invention is, for example, a medicament preferable for the prophylaxis and / or treatment of amino acid metabolism disorders such as phenylketonuria, urea cycle disorder, hypertyrosinemia (types 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemia, isovaleric acidemia and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Novel B0AT1 inhibitors

[0001] The present invention relates to novel compounds that have an inhibitory effect on the neutral amino acid transporter B0AT1.

[0002] The gene responsible for Hartnup disease, SLC6A19, is located at 5p15.33 and consists of 12 exons. Its gene product, the neutral amino acid transporter B0AT1, consists of 634 amino acids and has 12 transmembrane domains (Non-Patent Documents 1 and 2). B0AT1 is the primary transporter of neutral amino acids in the small intestine and kidney, responsible for the absorption of glycine, leucine, phenylalanine, and other amino acids in the small intestine and their reabsorption in the kidney (Non-Patent Documents 3-5). B0AT1 knockout mice are known to exhibit elevated urinary amino acid levels (Non-Patent Document 6), and clinically, B0AT1 dysfunction results in severe neutral amino aciduria, also known as Hartnup disease (Non-Patent Document 7). Therefore, it has been suggested that inhibiting B0AT1 may improve (alleviate) various diseases or pathologies involving neutral amino acids as transport substrates.

[0003] Furthermore, specific examples of the therapeutic effects of inhibiting the function of B0AT1 have also been reported, such as the improvement of the pathological condition of a phenylketonuria model mouse by congenitally deleting B0AT1 or by administering a nucleic acid compound that binds to mRNA to subsequently suppress its expression (Non-Patent Document 4).

[0004] In light of this background, compounds that inhibit B0AT1 have attracted attention as pharmaceuticals for preventing and / or treating various diseases or pathological conditions involving neutral amino acids, which are transport substrates, specifically amino acid metabolism disorders.

[0005] Examples of amino acid metabolism disorders include designated intractable diseases such as phenylketonuria, urea cycle disorders, hypertyrosinemia (type 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemia, and isovaleric acidemia. Continuous dietary therapy is the main known treatment for these disorders. Other than dietary therapy, known therapies include administering drugs that increase coenzymes or enzymes, and injecting enzymes, but neither of these are fundamental treatments (e.g., Non-Patent Document 8, etc.).

[0006] Therefore, there is a need for the development of drugs for preventing and / or treating diseases, specifically amino acid metabolism disorders, whose symptoms can be alleviated by normalizing neutral amino acid metabolism through the inhibition of B0AT1.

[0007] Known compounds having B0AT1 inhibitory activity include, for example, nucleic acids having a sequence partially or completely identical to that of B0AT1 RNA (Non-Patent Document 4), the commercially available product nimesulide and its derivatives (Non-Patent Documents 9 and 10), the known compound cinromide (Non-Patent Document 11), and basic compounds discovered by library screening (Non-Patent Documents 12 and 13). Also known is a cinnamic acid glycine amide compound (Patent Document 1).

[0008] International Publication No. 2023 / 145804

[0009] Nat. Genet., 2004; 36: pp.999-1002 Nat. Genet., 2004; 36: pp.1003-1007 The Journal of Biological Chemistry 2004; 279: pp.24467-24476 JCI Insight., 2018; 3(14): pp.e121762 IUBMB Life, 2009; 61(6): pp.591-599 MOLECULAR METABOLISM, 2015: pp.406-417 Biochem. J., 2005; 389: pp.745-751 Intractable Disease Information Center, Phenylketonuria (designated intractable disease 240) (http: / / www.nanbyou.or.jp / entry / 4747) Biochemical Phamracology, 2014; 89: p.422-430Bioorganic and Medicinal chemistry letters, 2021; 53: p.128421SLAS Discovery, 2019; 24(2): p.111-120British Journal of Pharmacology, 2017; 174: p.468-482Frontiers in Pharmacology, 2020; 11: p.140

[0010] The present invention provides a novel compound having excellent B0AT1 inhibitory activity, and a pharmaceutical containing the compound as an active ingredient.

[0011] As a result of extensive investigation, the present inventors have found that a compound represented by the following formula (I):

[0012]

[0013] wherein R is an optionally substituted C 6-10 represents an aryl-ethenyl group; 1 represents a carboxy group or a group biologically equivalent to a carboxy group; L is optionally further substituted, C 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6and A represents a divalent organic group containing a group selected from the group consisting of an alkynylene group and a 3- to 14-membered divalent non-aromatic heterocyclic group; and A represents an optionally further substituted divalent nitrogen-containing heterocyclic group.] (hereinafter sometimes abbreviated as "compound (I)"), or a pharmaceutically acceptable salt thereof has an excellent inhibitory effect on the neutral amino acid transporter B0AT1, leading to the completion of the present invention.

[0014] That is, one embodiment of the present invention is, for example, as follows: [1] Formula (I):

[0015]

[0016] wherein R is an optionally substituted C 6-10 represents an aryl-ethenyl group; 1 represents a carboxy group or a group biologically equivalent to a carboxy group; L is optionally further substituted, C 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, wherein R is a halogen atom, an optionally substituted C 1-6 alkyl group, optionally substituted C 3-8 cycloalkyl group, optionally substituted C 1-6 an alkoxy group, optionally substituted C 3-8 cycloalkyloxy group, optionally substituted C 1-6 alkylsulfanyl group, optionally substituted C 3-8 a 2-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of a cycloalkylsulfanyl group and a pentafluorosulfanyl group; R 1is a carboxy group or a group bioequivalent to a carboxy group; L is -NR 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, —C(═O)—, C 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 C may have one or more divalent groups selected from the group consisting of an alkynylene group and a 3- to 14-membered divalent non-aromatic heterocyclic group at its internal or terminal positions, and each of the groups may be further substituted with 1 to 3 substituents selected from the substituent group a; 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 A is an alkynylene group or a 3- to 14-membered divalent non-aromatic heterocyclic group; and A is a group represented by the following formula:

[0017]

[0018] (In the formula, ** represents the bonding site with the carbonyl group, *** represents the bonding site with group L, and ring A 1 represents a 3- to 10-membered monocyclic ring, an 8- to 14-membered fused ring, a 6- to 16-membered spiro ring, or a 6- to 14-membered bridged ring, and may contain, as ring-constituting atoms, a heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom in addition to a nitrogen atom and a carbon atom. The compound according to the above-mentioned [1] or a pharmaceutically acceptable salt thereof. (Substituent group a): a halogen atom; a hydroxy group; a cyano group; an oxo group; a halogen atom, a hydroxy group, a cyano group, C 1-6 Alkoxy group, C 6-14 Aryl group, carboxy group, C 1-6 Alkoxy-carbonyl group, 1 to 2 C 1-6a carbamoyl group optionally substituted with an alkyl group, and C 6-14 C optionally substituted with a substituent selected from the group consisting of aryloxy groups 1-6 an alkyl group; a C group optionally substituted with a halogen atom; 1-6 an alkoxy group; a C optionally substituted with a halogen atom; 1-6 Alkylsulfonyl group; C 1-6 Alkyl-carbonyl group; C 1-6 Alkoxy-carbonyl group; halogen atom, hydroxy group, diC 1-6 Alkylamino group and C 1-6 1 to 2 C optionally substituted with a substituent selected from the group consisting of an alkoxy group 1-6 a carbamoyl group optionally substituted by an alkyl group; 1-6 an alkylamino group; a tri-substituted silyl group; a tri-substituted silyloxy group; a C optionally substituted with 1 to 3 substituents selected from the substituent group b or the substituent group b′; 6-14 a hydrocarbon ring group; a 5- to 14-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from Substituent Group b or Substituent Group b'; and a 3- to 14-membered non-aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from Substituent Group b or Substituent Group b'. (Substituent Group b): a halogen atom; a hydroxy group; a cyano group; an oxo group; a carboxy group; a halogen atom, a hydroxy group, a cyano group, and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 1-6 Alkyl group; halogen atom, hydroxy group, cyano group and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 3-8 Cycloalkyl group; halogen atom, hydroxy group, cyano group, C 1-6 Alkyl group and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 6-10 Aryl group; halogen atom, hydroxy group, cyano group, C 1-6 Alkyl group and C 1-6a 5- to 14-membered aromatic heterocyclic group optionally substituted by a substituent selected from the group consisting of an alkoxy group; a halogen atom, a hydroxy group, a cyano group, C 1-6 Alkyl group and C 1-6 a 3- to 14-membered non-aromatic heterocyclic group optionally substituted by a substituent selected from the group consisting of an alkoxy group; a halogen atom, a hydroxy group, a cyano group, and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 1-6 Alkoxy group; halogen atom, hydroxy group, cyano group and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 1-6 Alkyl sulfanyl group; halogen atom, hydroxy group, cyano group and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 3-8 a cycloalkyloxy group; a C group optionally substituted with a halogen atom; 1-6 an alkylsulfonyl group; a C optionally substituted with a halogen atom; 1-6 Alkyl-carbonyl group; C 1-6 Alkoxy-carbonyl group; halogen atom, hydroxy group, diC 1-6 Alkylamino group and C 1-6 1 to 2 C optionally substituted with a substituent selected from the group consisting of an alkoxy group 1-6 a carbamoyl group optionally substituted by an alkyl group; a halogen atom, a hydroxy group, a cyano group, and C 1-6 C, each of which may be substituted with 1 to 3 substituents selected from the group consisting of an alkoxy group; 1-6 Alkyl group, C 3-8 A sulfamoyl group substituted with one substituent selected from the group consisting of a cycloalkyl group and a non-aromatic heterocyclic group; and a pentafluorosulfanyl group. (Substituent group b'): A halogen atom; A hydroxy group; A cyano group; An oxo group; A carboxy group; A halogen atom, a hydroxy group, a cyano group, and a C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 1-6Alkyl group; halogen atom, hydroxy group, cyano group and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 3-8 Cycloalkyl groups; halogen atoms, hydroxy groups, cyano groups and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 1-6 Alkoxy group; halogen atom, hydroxy group, cyano group and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 1-6 Alkyl sulfanyl group; halogen atom, hydroxy group, cyano group and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 3-8 a cycloalkyloxy group; a C group optionally substituted with a halogen atom; 1-6 an alkylsulfonyl group; a C optionally substituted with a halogen atom; 1-6 Alkyl-carbonyl group; C 1-6 Alkoxy-carbonyl group; halogen atom, hydroxy group, diC 1-6 Alkylamino group and C 1-6 1 to 2 C optionally substituted with a substituent selected from the group consisting of an alkoxy group 1-6 a carbamoyl group optionally substituted by an alkyl group; a halogen atom, a hydroxy group, a cyano group, and C 1-6 C, each of which may be substituted with 1 to 3 substituents selected from the group consisting of an alkoxy group; 1-6 Alkyl group, C 3-8 [3] In the formula (I), R is a halogen atom, a C optionally substituted by a halogen atom, a sulfamoyl group substituted by one substituent selected from the group consisting of a cycloalkyl group and a non-aromatic heterocyclic group, and a pentafluorosulfanyl group. 1-6 R is a 2-(E)-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of an alkyl group and a pentafluorosulfanyl group; 1 is a carboxy group or a group bioequivalent to a carboxy group; L is —NR 2- (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, —C(═O)—, C 6-10 Arylene group, C 3-10 Cycloalkylene group, C 2-6 C may have one or more divalent groups selected from the group consisting of alkynylene groups and 3- to 8-membered divalent non-aromatic heterocyclic groups at its internal or terminal positions, and may be further substituted with 1 to 3 substituents selected from the substituent group a. 1-6 an alkylene group, C optionally further substituted with 1 to 3 substituents selected from the substituent group a 6-10 an arylene group, C optionally further substituted with 1 to 3 substituents selected from the substituent group a 3-10 a cycloalkylene group, C optionally further substituted with 1 to 3 substituents selected from the substituent group a 2-4 an alkynylene group, or a 3- to 8-membered divalent non-aromatic heterocyclic group optionally further substituted with 1 to 3 substituents selected from the substituent group a; and

[0019]

[0020] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula,

[0021]

[0022] represents a single bond or a double bond, and each Y is independently a nitrogen atom or CR 3 (where R 3 is a hydrogen atom or C 1-6 represents an alkyl group; Z represents an oxygen atom, a sulfur atom, NR 4 or CR 5 R 6 (where R 4 , R 5 and R 6 are each independently a hydrogen atom or C 1-6represents an alkyl group; n represents an integer of 0 to 2; m represents an integer of 0 to 2; n 1 and n 2 each independently represents an integer of 0 to 2; m 1 and m 2 each independently represents an integer of 0 to 2, ** represents the bonding site with the carbonyl group, and *** represents a bonding site to the group L.) The compound according to the above [1], or a pharmaceutically acceptable salt thereof, wherein R is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula (I): 1-6 R is a 2-(E)-phenyl-ethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of an alkyl group and a pentafluorosulfanyl group; 1 is a carboxy group or a group bioequivalent to a carboxy group; L is —NR 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, —C(═O)—, C 6-10 Arylene group, C 3-10 Cycloalkylene group, C 2-6 C may have one or more divalent groups selected from the group consisting of alkynylene groups and 3- to 8-membered divalent non-aromatic heterocyclic groups at its internal or terminal positions, and may be further substituted with 1 to 3 substituents selected from the substituent group a. 1-6 an alkylene group, C optionally further substituted with 1 to 3 substituents selected from the substituent group a 6-10 an arylene group, C optionally further substituted with 1 to 3 substituents selected from the substituent group a 3-10 a cycloalkylene group, C optionally further substituted with 1 to 3 substituents selected from the substituent group a 2-4an alkynylene group, or a 3- to 8-membered divalent non-aromatic heterocyclic group optionally further substituted with 1 to 3 substituents selected from the substituent group a; and

[0023]

[0024] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula,

[0025]

[0026] represents a single bond or a double bond, and each Y is independently a nitrogen atom or CR 3 (where R 3 is a hydrogen atom or C 1-6 represents an alkyl group; Z represents an oxygen atom, a sulfur atom, NR 4 or CR 5 R 6 (where R 4 , R 5 and R 6 are each independently a hydrogen atom or C 1-6 represents an alkyl group; n represents an integer of 0 to 2; m represents an integer of 0 to 2; n 1 and n 2 each independently represents an integer of 0 to 2; m 1 and m 2 each independently represents an integer of 0 to 2, ** represents the bonding site with the carbonyl group, and *** represents a bonding site to group L. [4] The compound according to the above [1], wherein L is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula (I): 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, C 3-10C may have one or more divalent groups selected from the group consisting of a cycloalkylene group and a 3- to 8-membered divalent non-aromatic heterocyclic group at its internal or terminal position, and may be further substituted with 1 to 3 substituents selected from the substituent group a. 1-6 an alkylene group, C optionally further substituted with 1 to 3 substituents selected from the substituent group a 3-10 [5] The compound according to the above [3] or [3'], wherein L is a cycloalkylene group, or a 3- to 8-membered divalent non-aromatic heterocyclic group optionally further substituted with 1 to 3 substituents selected from the above substituent group a, or a pharmaceutically acceptable salt thereof. 1-6 [6] The compound according to the above [3] or [3'], or a pharmaceutically acceptable salt thereof, wherein A in formula (I) is a compound of the following formula:

[0027]

[0028] (The definitions of each symbol in the formula are as defined above.) [7] The compound according to the above [5], or a pharmaceutically acceptable salt thereof, wherein A in formula (I) is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0029]

[0030] (The definitions of each symbol in the formula are the same as those defined above, except that Z is CR 5 R 6 In the case where the substituent is C which may be further substituted, the substituent which may be further substituted is C which may be substituted with 1 to 3 substituents selected from the substituent group b or the substituent group b′ among the substituents in the substituent group a. 6-14a hydrocarbon ring group; a 5- to 14-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from substituent group b or substituent group b'; and a 3- to 14-membered non-aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from substituent group b or substituent group b'. [8] The compound according to the above [5], wherein A in formula (I) is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0031]

[0032] (wherein each symbol has the same meaning as defined above) The compound according to the above-mentioned [5], or a pharmaceutically acceptable salt thereof, wherein A in formula (I) is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0033]

[0034] (wherein each symbol has the same meaning as defined above) The compound according to the above [5], or a pharmaceutically acceptable salt thereof, wherein A in formula (I) is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0035]

[0036] (wherein each symbol has the same meaning as defined above) The compound according to the above-mentioned [5], or a pharmaceutically acceptable salt thereof.

[10] In the formula (I), R 1 is a carboxy group, an optionally substituted C 1-6The compound according to any one of the above [1] to [9], [3'] and [9'], wherein R is an alkoxy-carbonyl group, or an optionally substituted carbamoyl group, or a pharmaceutically acceptable salt thereof.

[11] 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 3-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid; N,N-dimethyl-3-[5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]propanamide; 1-[7-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,8-dihydro-5H-2,7-naphthyridin-3-yl]piperidine-4-carboxylic acid; 3-[3-bromo-5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]propanoic acid; 2-[[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]oxy]acetic acid; 2-[2-[2-[[(E)-3-[4-(pentafluoro-λ6-sulfanyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; (1R*, 2R*)-2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]cyclopropane-1-carboxylic acid and both enantiomers thereof; 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid;2-[7-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[7-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,8-dihydro-5H-2,7-naphthyridin-3-yl]acetic acid; 3-[3-bromo-5-[2-[[(E)-3-[4-(pentafluoro-λ6-sulfanyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]propanoic acid; 2-[2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]amino]acetic acid; 2-[2-[2-[[(E)-3-(4-iodophenyl)prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[5-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid;2-[8-cyano-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-(2-fluoro-4-iodophenyl)prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-(4-iodophenyl)prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[[5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridin-2-yl]sulfanyl]acetic acid; 2-[7-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-cyano-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[5-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; (E)-N-[2-[6-(2-amino-2-oxoethyl)-3,4-dihydro-1H-isoquinolin-2-yl]-2-oxoethyl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide; 2-[5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-[1,3]thiazolo[4,5-c]pyridin-2-yl]acetic acid;(E)-N-[2-[6-[2-(methylamino)-2-oxoethyl]-3,4-dihydro-1H-isoquinolin-2-yl]-2-oxoethyl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide; 4-[4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3-phenylpiperazin-1-yl]butanoic acid and both enantiomers thereof; 2-[[1-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2,3-dihydroindol-4-yl]oxy]acetic acid; 1-[1-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperidin-3-yl]bicyclo[2.1.1]hexane-5-carboxylic acid; 2-[[8-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]oxy]-2-methylpropanoic acid; 3-[[8-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]oxy]-2,2-dimethylpropanoic acid; 4-[4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(3S)-3-(4-bromophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(3-bromophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid;3-[[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]methyl]cyclobutane-1-carboxylic acid and both enantiomers thereof; 4-[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]-2,2-dimethylbutanoic acid; 4-[3-(3-cyclopropylphenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid and both enantiomers; 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]butanoic acid; 4-[(3S)-3-(4-cyclopropylphenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(4-chloro-3-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(3,4-difluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(3,4-difluorophenyl)-2-methyl-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid;4-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(4-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(3-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-2-ethyl-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-5-phenylpiperazin-1-yl]butanoic acid; and 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]-2,2-dimethylbutanoic acid, or a pharmaceutically acceptable salt thereof.

[12] 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid;3-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid; N,N-dimethyl-3-[5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]propanamide; 2-[2-[2-[[(E)-3-[4-(pentafluoro-λ6-sulfanyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; (1R*, 2R*)-2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]cyclopropane-1-carboxylic acid and both enantiomers thereof; 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid; 2-[7-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[2-[2-[[(E)-3-(4-iodophenyl)prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[5-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid;2-[8-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-cyano-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-(2-fluoro-4-iodophenyl)prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[7-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[5-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-[1,3]thiazolo[4,5-c]pyridin-2-yl]acetic acid; 4-[(3S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3-phenylpiperazin-1-yl]butanoic acid; 1-[1-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperidin-3-yl]bicyclo[2.1.1]hexane-5-carboxylic acid;4-[(3S)-3-(4-bromophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(3-bromophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 3-[[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]methyl]cyclobutane-1-carboxylic acid and both enantiomers thereof; 4-[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid and both enantiomers thereof; 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]butanoic acid; 4-[(3S)-3-(4-cyclopropylphenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(4-chloro-3-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(3,4-difluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid;4-[(2R,5S)-5-(3,4-difluorophenyl)-2-methyl-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(4-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(3-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-2-ethyl-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-5-phenylpiperazin-1-yl]butanoic acid; and 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]-2,2-dimethylbutanoic acid, or a pharmaceutically acceptable salt thereof.

[13] 2-[7-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid; 2-[2-[2-[[(E)-3-(4-iodophenyl)prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[5-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[7-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid;2-[5-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 4-[(3S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3-phenylpiperazin-1-yl]butanoic acid; 1-[1-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperidin-3-yl]bicyclo[2.1.1]hexane-5-carboxylic acid; 4-[(3S)-3-(4-bromophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(3-bromophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]butanoic acid; 4-[(3S)-3-(4-cyclopropylphenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(3,4-difluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(3,4-difluorophenyl)-2-methyl-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid;4-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(4-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(3-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-2-ethyl-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-5-phenylpiperazin-1-yl]butanoic acid; and 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]-2,2-dimethylbutanoic acid, or a pharmaceutically acceptable salt thereof.

[14] 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid;3-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid; N,N-dimethyl-3-[5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]propanamide; 2-[2-[2-[[(E)-3-[4-(pentafluoro-λ6-sulfanyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid; 2-[8-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 4-[(3R)-3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]butanoic acid;3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(3-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-2-ethyl-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-5-phenylpiperazin-1-yl]butanoic acid; and 4-[(3S)-3-(4-cyclopropylphenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid, or a pharmaceutically acceptable salt thereof.

[15] A B0AT1 inhibitor comprising the compound according to any one of [1] to

[14] , [3'], and [9'] above, or a pharmaceutically acceptable salt thereof. [15'] The B0AT1 inhibitor according to

[15] above, which is an agent for preventing and / or treating amino acid metabolism disorders. [15"] The B0AT1 inhibitor according to the above-mentioned [15'], wherein the amino acid metabolism disorder is phenylketonuria, urea cycle disorder, hypertyrosinemia (type 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemia, or isovaleric acidemia.

[16] A pharmaceutical composition comprising the compound according to any of the above-mentioned [1] to

[14] , [3'], and [9'] or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[17] The pharmaceutical composition according to the above-mentioned

[16] , for the prevention and / or treatment of a disease whose symptoms can be alleviated by B0AT1 inhibitory action.

[18] The pharmaceutical composition according to

[17] above, wherein the disease whose symptoms can be alleviated by B0AT1 inhibitory activity is an amino acid metabolism disorder.

[19] The pharmaceutical composition according to

[18] above, wherein the amino acid metabolism disorder is phenylketonuria, urea cycle disorder, hypertyrosinemia (type 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemia, or isovaleric acidemia.

[20] The pharmaceutical composition according to

[18] above, wherein the amino acid metabolism disorder is phenylketonuria.

[21] The pharmaceutical composition according to any of

[16] to

[20] above, wherein the pharmaceutical composition is administered in combination with another drug.

[22] The pharmaceutical composition according to

[21] above, wherein the other drug is a B0AT1 inhibitor.

[23] The pharmaceutical composition of the above-mentioned

[21] , wherein the other drug is a vitamin preparation, a drug for alleviating various symptoms of amino acid metabolism disorders, an antidepressant, an anti-anxiety drug, or a drug for treating ADHD.

[24] The pharmaceutical composition of any of the above-mentioned

[21] to

[23] , wherein the pharmaceutical composition of any of the above-mentioned

[16] to

[20] and the other drug are administered separately.

[25] The pharmaceutical composition of any of the above-mentioned

[21] to

[23] , wherein the pharmaceutical composition of any of the above-mentioned

[16] to

[20] and the other drug are administered simultaneously or sequentially.

[26] A method for preventing or treating amino acid metabolism disorders in a mammal, comprising administering to the mammal an effective amount of a compound of any of the above-mentioned [1] to

[14] , [3'], and [9'], or a pharmaceutically acceptable salt thereof.

[27] A method for preventing or treating a disease selected from the group consisting of phenylketonuria, urea cycle disorder, hypertyrosinemia (type 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemia, and isovaleric acidemia, comprising administering to a mammal an effective amount of the compound according to any one of the above [1] to

[14] , [3'], and [9'], or a pharmaceutically acceptable salt thereof.

[28] A method for preventing or treating amino acid metabolism disorders in a mammal, comprising administering to the mammal effective amounts of the pharmaceutical composition according to any one of

[16] to

[20] above and another drug simultaneously or sequentially.

[29] A method for preventing or treating a disease selected from the group consisting of phenylketonuria, urea cycle disorders, hypertyrosinemia (type 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemia, and isovaleric acidemia, comprising administering to the mammal effective amounts of the pharmaceutical composition according to any one of

[16] to

[20] above and another drug simultaneously or sequentially.

[30] Use of the compound according to any one of [1] to

[14] , [3'], and [9'] above, or a pharmaceutically acceptable salt thereof, for the manufacture of an agent for treating or preventing amino acid metabolism disorders.

[31] Use of the compound according to any one of the above [1] to

[14] , [3'] and [9'] or a pharmaceutically acceptable salt thereof for the manufacture of an agent for the treatment or prevention of a disease selected from the group consisting of phenylketonuria, urea cycle disorders, hypertyrosinemia (type 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemia and isovaleric acidemia.

[32] Use of the compound according to any one of the above [1] to

[14] , [3'] and [9'] or a pharmaceutically acceptable salt thereof for the prevention or treatment of amino acid metabolism disorders.

[33] The compound according to any one of the above-mentioned [1] to

[14] , [3'] and [9'], or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of a disease selected from the group consisting of phenylketonuria, urea cycle disorders, hypertyrosinemia (type 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemia, and isovaleric acidemia.

[34] A method for producing the compound according to any one of the above-mentioned [1] to

[14] , [3'] and [9'], or a pharmaceutically acceptable salt thereof.

[35] A prodrug of the compound according to any one of the above-mentioned [1] to

[14] , [3'] and [9'], or a pharmaceutically acceptable salt thereof.

[0037] Compound (I) of the present invention or a pharmaceutically acceptable salt thereof has excellent inhibitory activity against B0AT1. Therefore, pharmaceutical compositions containing said compound are useful for treating and / or preventing diseases whose symptoms can be alleviated by B0AT1 inhibitory activity.

[0038] The definitions of the terms and symbols used in this specification are explained below.

[0039] In this specification, the term "halogen atom" means a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom.

[0040] In the present specification, the term "alkyl (group)" refers to a linear or branched monovalent group having one or more carbon atoms formed by removing one hydrogen atom from any carbon atom of an alkane. When there is no particular limitation on the range of the carbon number, the term "alkyl (group)" refers to a C 1-20 alkyl groups, among which C 1-6 Alkyl groups are preferred.

[0041] In this specification, "C 1-20 The term "alkyl (group)" means an alkyl group having 1 to 20 carbon atoms, and examples thereof include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, and eicosyl.

[0042] In this specification, "C 1-6 The term "alkyl (group)" refers to an alkyl group having 1 to 6 carbon atoms, and examples thereof include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, sec-pentyl (pentan-2-yl), 3-pentyl (pentan-3-yl), tert-pentyl (1,1-dimethylpropyl), hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, and 2-ethylbutyl.

[0043] In this specification, "C 1-4 The term "alkyl (group)" refers to an alkyl group having 1 to 4 carbon atoms, and examples thereof include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.

[0044] In the present specification, "C optionally substituted with a halogen atom" means 1-6 The term "alkyl (group)" refers to an unsubstituted C 1-6 an alkyl group, or the C 1-6 C in which one or more (preferably 1 to 6, more preferably 1 to 3) hydrogen atoms in the alkyl group are substituted with halogen. 1-6 It means an alkyl group. Specific examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, neopentyl, hexyl, fluoromethyl, difluoromethyl, trifluoromethyl, 2-chloroethyl, 2-bromoethyl, 2-iodoethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 2,2,3,3-tetrafluoropropyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, 5,5,5-trifluoropentyl, and 6,6,6-trifluorohexyl. Among these, "C optionally substituted with halogen atoms" is particularly preferred. 1-4 "Alkyl (group)" is more preferred.

[0045] In the present specification, "C optionally substituted with a substituent selected from the group 1-6 The term "alkyl (group)" refers to an unsubstituted C 1-6 an alkyl group, or the C 1-6 It means a group in which one or more (preferably 1 to 6, more preferably 1 to 3) hydrogen atoms in the alkyl group are substituted with the same or different substituents selected from the substituent group. 1-4 "Alkyl (group)" is more preferred.

[0046] In the present specification, the term "cycloalkyl (group)" refers to a cyclic alkyl group, and when there is no particular limitation on the range of the number of carbon atoms, it is preferably a C 3-14 is a cycloalkyl group, more preferably C 3-8 It is a cycloalkyl group.

[0047] In this specification, "C 3-14 The term "cycloalkyl (group)" refers to a cyclic alkyl group having 3 to 14 carbon atoms, and may be monocyclic, fused, spirocyclic, or bridged. 3-14 Specific examples of the "cycloalkyl (group)" include monocyclic C cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. 3-14 Cycloalkyl; fused ring C such as 1-decalinyl, 2-decalinyl, etc. 5-14 Cycloalkyl; spirocyclic C such as spiro[3.4]octyl, spiro[4.5]decyl, spiro[3.6]decyl, etc. 6-14 Cycloalkyl; bridged formula C such as bicyclo[1.1.1]pentyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, etc. 5-14 Cycloalkyl and the like are exemplified. Among them, C 3-8 Cycloalkyl groups are preferred.

[0048] In this specification, "C 3-8 The term "cycloalkyl (group)" refers to a cyclic alkyl group having 3 to 8 carbon atoms, and examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. 3-6 Cycloalkyl groups are preferred.

[0049] In the present specification, "C optionally substituted with a substituent selected from the group 3-8 The term "cycloalkyl (group)" refers to an unsubstituted C 3-8 a cycloalkyl group, or the C 3-8 It means a group in which one or more (preferably 1 to 6, more preferably 1 to 3) hydrogen atoms in the cycloalkyl group are substituted with the same or different substituents selected from the said substituent group.

[0050] In this specification, "C 3-8 The term "cycloalkyloxy (group)" refers to the C 3-8 The cycloalkyl group means a group bonded to an oxygen atom, and specific examples include cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, cyclooctyloxy, and the like.

[0051] In the present specification, "C optionally substituted with a substituent selected from the group 3-8 The term "cycloalkyloxy (group)" refers to the unsubstituted C 3-8 a cycloalkyloxy group, or the C 3-8 The cycloalkyloxy group refers to a group in which one or more (preferably 1 to 6, more preferably 1 to 3) hydrogen atoms in the cycloalkyloxy group are substituted with the same or different substituents selected from the group of substituents.

[0052] In this specification, "C 3-8 The term "cycloalkylsulfanyl (group)" refers to the C 3-8 The cycloalkyl group means a group bonded to a sulfur atom, and specific examples include cyclopropylsulfanyl, cyclobutylsulfanyl, cyclopentylsulfanyl, cyclohexylsulfanyl, cycloheptylsulfanyl, cyclooctylsulfanyl, and the like.

[0053] In the present specification, the term "alkoxy (group)" refers to a group in which a linear or branched alkyl group is bonded to an oxygen atom, and when there is no particular limitation on the range of the carbon number, it is 1-20 is an alkoxy group, preferably C 1-6 It is an alkoxy group.

[0054] In this specification, "C 1-6 The term "alkoxy (group)" means an alkoxy group having 1 to 6 carbon atoms, and examples thereof include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, and the like. 1-4 Alkoxy groups are preferred.

[0055] In the present specification, "C optionally substituted with a halogen atom" means 1-6 The term "alkoxy (group)" refers to the unsubstituted C 1-6 an alkoxy group, or the C 1-6 It means a group in which one or more hydrogen atoms in an alkoxy group are substituted with halogen. Specific examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentyloxy, hexyloxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2-chloroethoxy, 2-bromoethoxy, 2-iodoethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, pentafluoroethoxy, 2,2,3,3-tetrafluoropropoxy, 3,3,3-trifluoropropoxy, 4,4,4-trifluorobutoxy, 5,5,5-trifluoropentyloxy, and 6,6,6-trifluorohexyloxy. Among these, "C optionally substituted with halogen atoms" is particularly preferred. 1-4 Alkoxy (group)" is more preferred.

[0056] In the present specification, "C optionally substituted with a substituent selected from the group 1-6 The term "alkoxy (group)" refers to the unsubstituted C 1-6 an alkoxy group, or the C 1-6 It means a group in which one or more (preferably 1 to 6, more preferably 1 to 3) hydrogen atoms in the alkoxy group are substituted with the same or different substituents selected from the substituent group. 1-4 Alkoxy (group)" is more preferred.

[0057] In the present specification, the term "alkylsulfanyl (group)" refers to a group in which a linear or branched alkyl group is bonded to a sulfur atom, and preferably C 1-6 It is an alkylsulfanyl group.

[0058] In this specification, "C 1-6The term "alkylsulfanyl (group)" means an alkylsulfanyl group having 1 to 6 carbon atoms, and examples thereof include methylsulfanyl, ethylsulfanyl, propylsulfanyl, isopropylsulfanyl, butylsulfanyl, isobutylsulfanyl, sec-butylsulfanyl, tert-butylsulfanyl, pentylsulfanyl, isopentylsulfanyl, neopentylsulfanyl, hexylsulfanyl, and the like.

[0059] In the present specification, "C optionally substituted with a substituent selected from the group 1-6 The term "alkylsulfanyl (group)" refers to an unsubstituted alkylsulfanyl (group) of the above C 1-6 an alkylsulfanyl group, or the C 1-6 The alkylsulfanyl group refers to a group in which one or more (preferably 1 to 6, more preferably 1 to 3) hydrogen atoms in the alkylsulfanyl group are substituted with the same or different substituents selected from the group of substituents.

[0060] In this specification, "C 1-6 The term "alkylsulfonyl (group)" refers to a sulfonyl group (-S(=O) 2 -) to the sulfur atom of the above "C 1-6 It means a group to which an "alkyl" group is attached, i.e., a straight-chain or branched-chain alkylsulfonyl group having 1 to 6 carbon atoms. 1-6 Examples of the "alkylsulfonyl (group)" include methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl, pentylsulfonyl, isopentylsulfonyl, neopentylsulfonyl, 1-ethylpropylsulfonyl, hexylsulfonyl, and the like.

[0061] In the present specification, "C optionally substituted with a halogen atom" means 1-6 The term "alkylsulfonyl (group)" refers to an unsubstituted alkylsulfonyl (group) of the above C 1-6 an alkylsulfonyl group, or the C 1-6It means an alkylsulfonyl group in which one or more (preferably 1 to 6, more preferably 1 to 3) hydrogen atoms have been substituted with halogen. Specific examples include methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, pentylsulfonyl, hexylsulfonyl, fluoromethylsulfonyl, difluoromethylsulfonyl, trifluoromethylsulfonyl, 2-chloroethylsulfonyl, 2-bromoethylsulfonyl, 2-iodoethylsulfonyl, 2-fluoroethylsulfonyl, 2,2-difluoroethylsulfonyl, 2,2,2-trifluoroethylsulfonyl, pentafluoroethylsulfonyl, 2,2,3,3-tetrafluoropropylsulfonyl, 3,3,3-trifluoropropylsulfonyl, 4,4,4-trifluorobutylsulfonyl, 5,5,5-trifluoropentylsulfonyl, and 6,6,6-trifluorohexylsulfonyl.

[0062] In this specification, "C 1-6 The term "alkyl-carbonyl (group)" refers to the C 1-6 It means a group in which an alkyl group is bonded to a carbonyl group, and specific examples include acetyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, and hexylcarbonyl.

[0063] In the present specification, "C optionally substituted with a halogen atom" means 1-6 The term "alkyl-carbonyl (group)" refers to an unsubstituted C 1-6 an alkyl-carbonyl group, or the C 1-6It means an alkyl-carbonyl group in which one or more (preferably 1 to 6, more preferably 1 to 3) hydrogen atoms have been substituted with halogen. Specific examples include acetyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, hexylcarbonyl, fluoromethylcarbonyl, difluoromethylcarbonyl, trifluoromethylcarbonyl, 2-chloroethylcarbonyl, 2-bromoethylcarbonyl, 2-iodoethylcarbonyl, 2-fluoroethylcarbonyl, 2,2-difluoroethylcarbonyl, 2,2,2-trifluoroethylcarbonyl, pentafluoroethylcarbonyl, 2,2,3,3-tetrafluoropropylcarbonyl, 3,3,3-trifluoropropylcarbonyl, 4,4,4-trifluorobutylcarbonyl, 5,5,5-trifluoropentylcarbonyl, 6,6,6-trifluorohexylcarbonyl, and the like.

[0064] In this specification, "C 1-6 The term "alkoxy-carbonyl (group)" refers to the C 1-6 It means a group in which an alkoxy group is bonded to a carbonyl group, and specific examples include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, and hexyloxycarbonyl.

[0065] In the present specification, the term "optionally substituted carbamoyl (group)" refers to a carbamoyl group (-CONH 2 ) in which one or two hydrogen atoms may be independently substituted by other substituents (mono- or di-substituted carbamoyl group). Di-substituted carbamoyl groups also include 1-pyrrolidinylcarbonyl groups and 1-piperidylcarbonyl groups.

[0066] As used herein, "a halogen atom, a hydroxy group, a diC 1-6 Alkylamino group and C 1-6 1 to 2 C optionally substituted with a substituent selected from the group consisting of an alkoxy group 1-6 The term "carbamoyl (group) optionally substituted with an alkyl group" refers to a carbamoyl group (-CONH 2) one or two hydrogen atoms are each independently a halogen atom, a hydroxy group, a diC 1-6 Alkylamino group and C 1-6 1 to 2 C optionally substituted with a substituent selected from the group consisting of an alkoxy group 1-6 It means a group which may be substituted with an alkyl group, and preferably mono- or di-C 1-6 It is an alkyl-carbamoyl group.

[0067] In this specification, "C 2-6 The "alkenyl group" is a C 2-6 It means a linear or branched monovalent group having 2 to 6 carbon atoms formed by removing one hydrogen atom from any carbon atom of an alkene, and specific examples include vinyl, 1-propenyl, allyl, isopropenyl, butenyl, and isobutenyl.

[0068] In this specification, "C 2-6 The "alkynyl group" is a C 2-6 It means a linear or branched monovalent group having 2 to 6 carbon atoms formed by removing one hydrogen atom from any carbon atom of an alkyne, and specific examples thereof include ethynyl, propargyl, 3-butynyl, 2-butynyl, 2-pentynyl, 3-pentynyl, and 4-pentynyl.

[0069] In the present specification, the term "aryl (group)" refers to a monocyclic or polycyclic (fused) hydrocarbon group exhibiting aromaticity. 6-14 An aryl group is preferred, and C 6-10 An aryl group is more preferred.

[0070] In this specification, "C 6-14 Examples of the aryl (group) include phenyl, 1-naphthyl, 2-naphthyl, biphenylyl, phenanthryl, 2-anthryl, and fluorenyl.

[0071] In this specification, "C 6-10 Examples of the "aryl (group)" include phenyl, 1-naphthyl, and 2-naphthyl, and among these, phenyl is preferred.

[0072] In the present specification, the term "aryl-carbonyl (group)" refers to a group in which the aryl group is bonded to a carbonyl group, and the range of the number of carbon atoms is not particularly limited, but preferably, 6-14 It is an aryl-carbonyl group.

[0073] In this specification, "C 6-14 The term "aryloxy (group)" refers to the C 6-14 It means a group in which an aryl group is bonded to an oxygen atom, and specific examples thereof include phenyloxy, 1-naphthyloxy, 2-naphthyloxy, biphenylyloxy, phenanthryloxy, and 2-anthryloxy. 6-10 An aryloxy group is preferred, and a phenyloxy group is particularly preferred.

[0074] In this specification, "C 6-14 The term "hydrocarbon ring (group)" means a monovalent, saturated or partially unsaturated aliphatic hydrocarbon ring (group) having 6 to 14 carbon atoms, or a monovalent aromatic hydrocarbon ring (group) having 6 to 14 carbon atoms.

[0075] In this specification, "C 6-14 The term "arylsulfonyl (group)" refers to the C 6-14 The aryl group is a sulfonyl group (-S(=O) 2 -) and examples thereof include phenylsulfonyl, 1-naphthylsulfonyl, 2-naphthylsulfonyl, etc.

[0076] In this specification, "C 6-14 The term "arylsulfonyloxy (group)" refers to the C 6-14 The aryl group is a sulfonyloxy group (-S(=O) 2 and examples thereof include phenylsulfonyloxy, 1-naphthylsulfonyloxy, 2-naphthylsulfonyloxy, etc.

[0077] In this specification, "C 6-10 The term "aryl-ethenyl group" refers to an ethenyl group (-CH=CH 2 ) is a hydrogen atom at the end of said C 6-10It means a group substituted with an aryl group, and among these, a 2-phenylethenyl group is preferred, with a 2-(E)-phenylethenyl group being particularly preferred.

[0078] In this specification, "(E)" in the chemical formula of each example compound or "(E)-" in the compound name indicates that the double bond has an E configuration.

[0079] In this specification, "C 7-18 The term "aralkyl (group)" refers to the C 6-14 The aryl group is 1-4 It means a group bonded to an alkyl group, and specific examples thereof include benzyl, phenethyl, naphthylmethyl, biphenylylmethyl, etc. Among them, C 7-10 An aralkyl group is preferred, and a benzyl group is particularly preferred.

[0080] In this specification, "C 7-18 The term "aralkyloxy (group)" refers to the C 7-18 It means an aralkyl group bonded to an oxygen atom, and specific examples include benzyloxy, phenethyloxy, naphthylmethyloxy, biphenylylmethyloxy, etc. Among these, the benzyloxy group is particularly preferred.

[0081] In the present specification, the term "acyl (group)" means a formyl group, a linear or branched alkyl-carbonyl group, or an aryl-carbonyl group. The carbon number range is not particularly limited, but preferably, a formyl group, C 1-6 alkyl-carbonyl group, or C 6-14 The aryl-carbonyl group is a preferred example of an acyl group, such as formyl, acetyl, propionyl, butyryl, isobutyryl, pentanoyl, tert-butylcarbonyl (pivaloyl), hexanoyl, heptanoyl, benzoyl, 1-naphthoyl, or 2-naphthoyl.

[0082] In the present specification, the term "acyloxy (group)" refers to a group in which the acyl group is bonded to an oxygen atom, and preferably C 1-6 alkyl-carbonyloxy group, or C 6-14 It is an aryl-carbonyloxy group.

[0083] As used herein, "diC 1-6 The term "alkylamino (group)" refers to an amino group in which two hydrogen atoms of the amino group are the same or different. 1-6 It means a group substituted with an alkyl group.

[0084] In this specification, "C 1-6 The term "alkylene (group)" refers to the C 1-6 It means a divalent group formed by removing one hydrogen atom from an alkyl group. 1-6 Specific examples of the alkylene (group) include methylene, dimethylene, methylmethylene, dimethylmethylene, trimethylene, propane-1,2-diyl, tetramethylene, pentamethylene, isopentane-2,4-diyl, and hexamethylene.

[0085] In this specification, "C 6-10 The term "arylene (group)" refers to the same as defined above. 6-10 C means a divalent group obtained by removing one hydrogen atom from an "aryl group." 6-10 Specific examples of the arylene (group) include 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 1,2-naphthylene, 1,3-naphthylene, 1,4-naphthylene, and 2,6-naphthylene.

[0086] In this specification, "C 2-6 The term "alkenylene (group)" refers to the group defined above as "C 2-6 It means a divalent group obtained by removing one hydrogen atom from an "alkenyl group." 2-3 Alkenylene is preferred. 2-3 Specific examples of the alkenylene (group) include ethenylene (-CH=CH-), propenylene (-CH=CHCH 2 -) etc.

[0087] In this specification, "C 2-6 The term "alkynylene (group)" refers to the same as defined above. 2-6 It means a divalent group obtained by removing one hydrogen atom from an "alkynyl group." 2-3 Alkynylene is preferred. 2-3 Specific examples of the alkynylene (group) include ethynylene (—C≡C—), propynylene (—C≡C—CH 2-) etc.

[0088] In this specification, "C 3-14 The term "cycloalkylene (group)" refers to the same as the "C 3-14 It means a divalent group obtained by removing one hydrogen atom from a "cycloalkyl group." 3-8 Cycloalkylene is preferred. 3-8 Specific examples of the cycloalkylene (group) include cyclopropane-1,1-diyl, cyclopropane-1,2-diyl, cyclobutane-1,3-diyl, bicyclo[2.1.1]hexane-1,2-diyl, bicyclo[1.1.1]pentane-1,3-diyl, and the like.

[0089] In the present specification, the term "3- to 14-membered divalent non-aromatic heterocyclic ring (group)" refers to a divalent group obtained by removing one hydrogen atom from the "3- to 14-membered non-aromatic heterocyclic ring (group)" described below. Among these, a 3- to 8-membered divalent non-aromatic heterocyclic ring is preferable. Specific examples of the 3- to 8-membered divalent non-aromatic heterocyclic ring (group) include aziridine-1,2-diyl, oxetane-2,4-diyl, azetidine-1,3-diyl, pyrrolidine-1,3-diyl, piperidine-1,2-diyl, piperidine-1,3-diyl, piperidine-1,4-diyl, etc.

[0090] In this specification, "C 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 The term "a divalent organic group containing an alkynylene group or a 3- to 14-membered divalent non-aromatic heterocyclic group" refers to the above-mentioned "C 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 alkynylene group, or 3- to 14-membered divalent non-aromatic heterocyclic group, 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6"C" in "an organic group having an alkynylene group or a 3- to 14-membered divalent non-aromatic heterocyclic group" 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 The moieties other than the "alkynylene group, or 3- to 14-membered divalent non-aromatic heterocyclic group" can be arbitrarily set. 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 Preferred examples of the "divalent organic group containing an alkynylene group or a 3- to 14-membered divalent non-aromatic heterocyclic group" include, for example, -NR 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, —C(═O)—, C 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 C may have one or more divalent groups selected from the group consisting of an alkynylene group and a 3- to 14-membered divalent non-aromatic heterocyclic group at its internal or terminal positions, and each of the groups may be further substituted with 1 to 3 substituents selected from the substituent group a; 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 Examples of the divalent (organic) group include an alkynylene group and a 3- to 14-membered divalent non-aromatic heterocyclic group. Here, the two bonds of the divalent (organic) group may be from the same carbon atom or different carbon atoms in the (organic) group, or may be from heteroatoms constituting the (organic) group. 3-10 cycloalkylene group," "C 2-4 alkenylene group" and "C 2-4 The "alkynylene group" refers to the same group as defined above. 3-14cycloalkylene group," "C 2-6 alkenylene group" and "C 2-6 It has the same meaning as the "alkynylene group" except for the range of the number of carbon atoms.

[0091] In this specification, examples of the "heterocyclic ring (group)" include (i) an aromatic heterocyclic group and (ii) a non-aromatic heterocyclic group, each of which contains, as ring-constituting atoms other than carbon atoms, 1 to 4 heteroatoms selected from a nitrogen atom, a sulfur atom, and an oxygen atom. (i) The aromatic heterocyclic group includes a 5- or 6-membered monocyclic aromatic heterocyclic group and an 8- to 14-membered fused aromatic heterocyclic group. (ii) The non-aromatic heterocyclic group includes a 3- to 10-membered monocyclic non-aromatic heterocyclic group, a 9- to 14-membered fused non-aromatic heterocyclic group, a 6- to 14-membered bridged cyclic non-aromatic heterocyclic group, and a 6- to 16-membered spirocyclic non-aromatic heterocyclic group.

[0092] In the present specification, examples of the "aromatic heterocyclic group" include 5- to 14-membered aromatic heterocyclic groups containing, as ring-constituting atoms other than carbon atoms, 1 to 4 heteroatoms selected from a nitrogen atom, a sulfur atom, and an oxygen atom.

[0093] Preferable examples of the "aromatic heterocyclic group" include 5- or 6-membered monocyclic aromatic heterocyclic groups such as thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, triazolyl, tetrazolyl, triazinyl, etc.; benzothiophenyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, imidazopyridyl, thienopyridyl, furopyridyl, pyrrolopyridyl, pyrazolopyridyl, oxazolopyridyl, thiazolopyridyl, imidazopyrazinyl, imidazopyrimidinyl, thienopyrimidinyl, furopyrimidinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, oxazolopyrimidinyl, thiazolopyrimidinyl, Examples thereof include 8- to 14-membered fused aromatic heterocyclic groups (fused polycyclic (preferably bicyclic or tricyclic) aromatic heterocyclic groups) such as pyrazolotriazinyl, naphtho[2,3-b]thienyl, phenoxathiinyl, indolyl, isoindolyl, 1H-indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, phenazinyl, phenothiazinyl, and phenoxazinyl.

[0094] In the present specification, examples of the "non-aromatic heterocyclic group" include 3- to 14-membered non-aromatic heterocyclic groups containing, as ring-constituting atoms other than carbon atoms, 1 to 4 heteroatoms selected from a nitrogen atom, a sulfur atom, and an oxygen atom.

[0095] Preferable examples of the "non-aromatic heterocyclic group" include aziridinyl, oxiranyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, tetrahydrothienyl, tetrahydrofuryl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, oxazolinyl, oxazolidinyl, pyrazolinyl, pyrazolidinyl, thiazolinyl, thiazolidinyl, tetrahydroisothiazolyl, tetrahydrooxazolyl, and tetrahydroisoxazolyl. 3- to 10-membered monocyclic non-aromatic heterocyclic groups (preferably 5- to 8-membered monocyclic non-aromatic heterocyclic groups) such as piperidyl, piperazinyl, tetrahydropyridyl, dihydropyridyl, dihydrothiopyranyl, tetrahydropyrimidinyl, tetrahydropyridazinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholinyl, thiomorpholinyl, azepanyl, diazepanyl, azepinyl, oxepanyl, azocanyl, and diazocanyl;Tetrahydrotriazolopyridyl, tetrahydrotriazolopyrazinyl, tetrahydropyrazolopyrazinyl, dihydropyrazolopyrrolyl, dihydropyrazolopyrazinyl, tetrahydropyrazolopyridyl, tetrahydroimidazolopyridyl, dihydroimidazolopyridyl, dihydroimidazolopyrrolyl, tetrahydroimidazolopyrazinyl, dihydropyrimidopyrrolyl, dihydropyridopyrrolyl, tetrahydropyridopyridyl, tetrahydrooxazolopyrazinyl, tetrahydropyridopyridyl, tetrahydrotriazolodiazepinyl, octahydro-1,4-oxazinopyrazinyl, dihydrobenzofuranyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, dihydrobenzothiazolyl, dihydrobenzisothiazolyl, dihydronaphtho[2,3-b]thienyl, tetrahydroisoquinolyl, dihydroisoquinolyl 8- to 14-membered fused non-aromatic heterocyclic groups (fused polycyclic (preferably bicyclic) non-aromatic heterocyclic groups) such as tetrahydroquinolyl, 4H-quinolidinyl, indolinyl, isoindolinyl, tetrahydrothieno[2,3-c]pyridyl, dihydrothiazolo[4,5-c]pyridyl, dihydrothiazolo[5,4-c]pyridyl, tetrahydrobenzoazepinyl, tetrahydroquinoxalinyl, tetrahydrophenanthridinyl, hexahydrophenothiazinyl, hexahydrophenoxazinyl, tetrahydrophthalazinyl, tetrahydronaphthyridinyl, dihydronaphthyridinyl, tetrahydroquinazolinyl, tetrahydrocinnolinyl, tetrahydrocarbazolyl, tetrahydro-β-carbolinyl, tetrahydroacridinyl, tetrahydrophenazinyl, tetrahydrothioxanthenyl, and octahydroisoquinolyl;

[0096] More preferred examples of the "non-aromatic heterocyclic group" include pyrrolidinyl, piperidyl, tetrahydrotriazolopyrazinyl (e.g., 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazinyl), tetrahydropyrazolopyrazinyl (e.g., 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazinyl), tetrahydroisoquinolyl (e.g., 1,2,3,4-tetrahydroisoquinolyl), tetrahydronaphthyridinyl (e.g., 5,6,7,8-tetrahydro-1,6-naphthyridinyl, 1,2,3,4-tetrahydro-2,6-naphthyridinyl), dihydrothiazolo[5,4-c]pyridyl (e.g., 6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridyl), dihydrothiazolo[4,5-c]pyridyl (e.g., 6,7-dihydro-4H-[1,3]thiazolo[4,5-c]pyridyl), indolinyl (e.g., 2,3-dihydroindolyl), and the like.

[0097] Other preferable examples of the "non-aromatic heterocyclic group" include 6- to 14-membered bridged ring non-aromatic heterocyclic groups such as 3,8-diazabicyclo[3.2.1]octyl, 2,5-diazabicyclo[2.2.2]octyl, 7-azabicyclo[2.2.1]heptanyl, quinuclidinyl, etc.; and 6- to 16-membered spirocyclic non-aromatic heterocyclic groups such as 2,8-diazaspiro[4.5]decyl, 2,7-diazaspiro[3.5]nonyl, 2,6-diazaspiro[3.3]heptyl, etc.

[0098] In the present specification, the term "nitrogen-containing heterocyclic group" includes nitrogen-containing aromatic heterocyclic groups and nitrogen-containing non-aromatic heterocyclic groups.

[0099] As used herein, the term "nitrogen-containing aromatic heterocyclic group" or "nitrogen-containing non-aromatic heterocyclic group" refers to the above-mentioned aromatic heterocyclic group or non-aromatic heterocyclic group, which has at least one nitrogen atom as a ring-constituting atom.

[0100] In the present specification, the term "divalent nitrogen-containing aromatic heterocyclic group" refers to a divalent group obtained by removing one hydrogen atom from the above-mentioned "nitrogen-containing aromatic heterocyclic group".

[0101] In the present specification, the term "divalent nitrogen-containing non-aromatic heterocyclic group" refers to a divalent group obtained by removing one hydrogen atom from the aforementioned "nitrogen-containing non-aromatic heterocyclic group".

[0102] In this specification, the phrase "optionally further substituted with 1 to 3 substituents selected from substituent group a (or substituent group b)" means that, in addition to the two bonds in the divalent group, 1 to 3 hydrogen atoms may each be further substituted independently with 1 to 3 substituents selected from substituent group a (or substituent group b). When substituent group a' (or substituent group b') is used in place of substituent group a, this definition similarly applies with substituent group a (or substituent group b) read as substituent group a' (or substituent group b').

[0103] As used herein, the term "trisubstituted silyl (group)" refers to a silyl group having three identical or different substituents (e.g., C 1-6 Alkyl group, C 6-10 aryl group, etc.), and examples of the group include trialkylsilyl groups such as trimethylsilyl group, triethylsilyl group, triisopropylsilyl group, and tert-butyldimethylsilyl group (preferably, triC 1-6 alkylsilyl group), tert-butyldiphenylsilyl group, triphenylsilyl group, etc.

[0104] In the present specification, the term "trisubstituted silyloxy (group)" refers to a group in which a trisubstituted silyl group is bonded to an oxygen atom, and examples of the group include trialkylsilyloxy groups such as trimethylsilyloxy group, triethylsilyloxy group, triisopropylsilyloxy group, and tert-butyldimethylsilyloxy group (preferably, triC 1-6alkylsilyloxy group), tert-butyldiphenylsilyloxy group, triphenylsilyloxy group, etc.

[0105] In this specification, the term "bioisomer" refers to a functional group that exhibits broadly similar biological effects and has chemical and physical similarities, as proposed by Thornber in 1979 in the field of medicinal chemistry. Examples of "a group bioisosteric to a carboxy group" include optionally substituted C 1-6 an alkoxy-carbonyl group, an optionally substituted carbamoyl group, a cyano group, a group represented by the following formula:

[0106]

[0107] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula, and * represents the bonding position to L.) and tautomeric groups thereof, among which optionally substituted C 1-6 An alkoxy-carbonyl group or an optionally substituted carbamoyl group is preferred.

[0108] In this specification, the term "optionally substituted" means unsubstituted or substituted with a specific substituent at any substitutable position (any hydrogen atom is replaced with a substituent). The "substituent" is not particularly limited, but examples thereof include substituents selected from the following (substituent group a), (substituent group a'), (substituent group b), or (substituent group b'). When no particular substituent group is specified, it means that the group may be substituted with one or more substituents selected from the following (substituent group c) or (substituent group c'). The number of substituents is not particularly limited as long as it is a substitutable number, but is usually 1 to 5, and preferably 1 to 3. When multiple substituents are present, the respective substituents may be the same or different.

[0109] (Substituent group a): halogen atom; hydroxy group; cyano group; oxo group; halogen atom, hydroxy group, cyano group, C 1-6 Alkoxy group, C 6-14 Aryl group, carboxy group, C 1-6 Alkoxy-carbonyl group, 1 to 2 C1-6 a carbamoyl group optionally substituted with an alkyl group, and C 6-14 C optionally substituted with a substituent selected from the group consisting of aryloxy groups 1-6 an alkyl group; a C group optionally substituted with a halogen atom; 1-6 an alkoxy group; a C optionally substituted with a halogen atom; 1-6 Alkylsulfonyl group; C 1-6 Alkyl-carbonyl group; C 1-6 Alkoxy-carbonyl group; halogen atom, hydroxy group, diC 1-6 Alkylamino group and C 1-6 1 to 2 C optionally substituted with a substituent selected from the group consisting of an alkoxy group 1-6 a carbamoyl group optionally substituted by an alkyl group; 1-6 an alkylamino group; a tri-substituted silyl group; a tri-substituted silyloxy group; a C optionally substituted with 1 to 3 substituents selected from the substituent group b or the substituent group b′; 6-14 a hydrocarbon ring group; a 5- to 14-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from substituent group b or substituent group b'; and a 3- to 14-membered non-aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from substituent group b or substituent group b'.

[0110] (Substituent group a'): halogen atom; hydroxy group; cyano group; oxo group; halogen atom, hydroxy group, cyano group, C 1-6 Alkoxy group, C 6-14 aryl groups, and C 6-14 C optionally substituted with a substituent selected from the group consisting of aryloxy groups 1-6 an alkyl group; a C group optionally substituted with a halogen atom; 1-6 an alkoxy group; a C optionally substituted with a halogen atom; 1-6 Alkylsulfonyl group; C 1-6 Alkyl-carbonyl group; C 1-6 Alkoxy-carbonyl group; halogen atom, hydroxy group, diC 1-6 Alkylamino group and C 1-61 to 2 C optionally substituted with a substituent selected from the group consisting of an alkoxy group 1-6 a carbamoyl group optionally substituted by an alkyl group; 1-6 an alkylamino group; a tri-substituted silyl group; a tri-substituted silyloxy group; a C optionally substituted with 1 to 3 substituents selected from the substituent group b or the substituent group b′; 6-14 a hydrocarbon ring group; a 5- to 14-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from substituent group b or substituent group b'; and a 3- to 14-membered non-aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from substituent group b or substituent group b'.

[0111] (Substituent group b): a halogen atom; a hydroxy group; a cyano group; an oxo group; a carboxy group; a halogen atom, a hydroxy group, a cyano group and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 1-6 Alkyl group; halogen atom, hydroxy group, cyano group and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 3-8 Cycloalkyl group; halogen atom, hydroxy group, cyano group, C 1-6 Alkyl group and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 6-10 Aryl group; halogen atom, hydroxy group, cyano group, C 1-6 Alkyl group and C 1-6 a 5- to 14-membered aromatic heterocyclic group optionally substituted by a substituent selected from the group consisting of an alkoxy group; a halogen atom, a hydroxy group, a cyano group, C 1-6 Alkyl group and C 1-6 a 3- to 14-membered non-aromatic heterocyclic group optionally substituted by a substituent selected from the group consisting of an alkoxy group; a halogen atom, a hydroxy group, a cyano group, and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 1-6 Alkoxy group; halogen atom, hydroxy group, cyano group and C 1-6C optionally substituted with a substituent selected from the group consisting of alkoxy groups 1-6 Alkyl sulfanyl group; halogen atom, hydroxy group, cyano group and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 3-8 a cycloalkyloxy group; a C group optionally substituted with a halogen atom; 1-6 an alkylsulfonyl group; a C optionally substituted with a halogen atom; 1-6 Alkyl-carbonyl group; C 1-6 Alkoxy-carbonyl group; halogen atom, hydroxy group, diC 1-6 Alkylamino group and C 1-6 1 to 2 C optionally substituted with a substituent selected from the group consisting of an alkoxy group 1-6 a carbamoyl group optionally substituted by an alkyl group; a halogen atom, a hydroxy group, a cyano group, and C 1-6 C, each of which may be substituted with 1 to 3 substituents selected from the group consisting of an alkoxy group; 1-6 Alkyl group, C 3-8 a sulfamoyl group substituted with one substituent selected from the group consisting of a cycloalkyl group and a non-aromatic heterocyclic group; and a pentafluorosulfanyl group.

[0112] (Substituent group b'): a halogen atom; a hydroxy group; a cyano group; an oxo group; a carboxy group; a halogen atom, a hydroxy group, a cyano group and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 1-6 Alkyl group; halogen atom, hydroxy group, cyano group and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 3-8 Cycloalkyl groups; halogen atoms, hydroxy groups, cyano groups and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 1-6 Alkoxy group; halogen atom, hydroxy group, cyano group and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups1-6 Alkyl sulfanyl group; halogen atom, hydroxy group, cyano group and C 1-6 C optionally substituted with a substituent selected from the group consisting of alkoxy groups 3-8 a cycloalkyloxy group; a C group optionally substituted with a halogen atom; 1-6 an alkylsulfonyl group; a C optionally substituted with a halogen atom; 1-6 Alkyl-carbonyl group; C 1-6 Alkoxy-carbonyl group; halogen atom, hydroxy group, diC 1-6 Alkylamino group and C 1-6 1 to 2 C optionally substituted with a substituent selected from the group consisting of an alkoxy group 1-6 a carbamoyl group optionally substituted by an alkyl group; a halogen atom, a hydroxy group, a cyano group, and C 1-6 C, each of which may be substituted with 1 to 3 substituents selected from the group consisting of an alkoxy group; 1-6 Alkyl group, C 3-8 a sulfamoyl group substituted with one substituent selected from the group consisting of a cycloalkyl group and a non-aromatic heterocyclic group; and a pentafluorosulfanyl group.

[0113] (Substituent group c): a halogen atom; a hydroxy group; a carboxy group; a nitro group; a cyano group; C 1-6 Alkyl group and C 1-6 an amino group optionally substituted by 1 to 2 substituents selected from the group consisting of alkoxy-carbonyl groups; C optionally substituted by 1 to 3 substituents selected from the substituent group a or the substituent group a′; 1-6 an alkyl group; a C optionally substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′; 1-6 Alkoxy group; C 1-6 an alkoxy-carbonyl group; a C optionally substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′; 1-6 an alkylsulfonyl group; C optionally substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′; 3-8a cycloalkyl group; an acyl group optionally substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′; an acyloxy group optionally substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′; a C group optionally substituted with 1 to 3 substituents selected from the substituent group b; 6-14 an aryl group; C optionally substituted with 1 to 3 substituents selected from the substituent group b 6-14 an aryloxy group; C optionally substituted with 1 to 3 substituents selected from the substituent group b 6-14 an arylsulfonyl group; C optionally substituted with 1 to 3 substituents selected from the substituent group b 6-14 an arylsulfonyloxy group; C optionally substituted with 1 to 3 substituents selected from the substituent group b 7-18 an aralkyl group; C optionally substituted with 1 to 3 substituents selected from the substituent group b 7-18 Aralkyloxy group; hydroxy group, diC 1-6 Alkylamino group and C 1-6 1 to 2 C optionally substituted with a substituent selected from the group consisting of an alkoxy group 1-6 a carbamoyl group optionally substituted with an alkyl group; a hydroxy group, a diC 1-6 Alkylamino group and C 1-6 1 to 2 C optionally substituted with a substituent selected from the group consisting of an alkoxy group 1-6 a carbamoyloxy group optionally substituted with an alkyl group; an oxo group; a thioxo group; a mono- or di-C 1-6 an alkylamino group; an azido group; a tri-substituted silyl group; a tri-substituted silyloxy group; an aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from substituent group b; and a non-aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from substituent group b.

[0114] (Substituent group c'): a halogen atom; a hydroxy group; a carboxy group; a nitro group; a cyano group; C 1-6 Alkyl group and C 1-6an amino group optionally substituted by 1 to 2 substituents selected from the group consisting of alkoxy-carbonyl groups; C optionally substituted by 1 to 3 substituents selected from the substituent group a or the substituent group a′; 1-6 an alkyl group; a C optionally substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′; 1-6 Alkoxy group; C 1-6 an alkoxy-carbonyl group; a C optionally substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′; 1-6 an alkylsulfonyl group; C optionally substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′; 3-8 a cycloalkyl group; an acyl group optionally substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′; an acyloxy group optionally substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′; a C group optionally substituted with 1 to 3 substituents selected from the substituent group b; 6-14 an aryl group; C optionally substituted with 1 to 3 substituents selected from the substituent group b′; 6-14 an aryloxy group; C optionally substituted with 1 to 3 substituents selected from the substituent group b′; 6-14 an arylsulfonyl group; C optionally substituted by 1 to 3 substituents selected from substituent group b′; 6-14 an arylsulfonyloxy group; C optionally substituted by 1 to 3 substituents selected from substituent group b′; 7-18 an aralkyl group; C optionally substituted with 1 to 3 substituents selected from the substituent group b′; 7-18 Aralkyloxy group; hydroxy group, diC 1-6 Alkylamino group and C 1-6 1 to 2 C optionally substituted with a substituent selected from the group consisting of an alkoxy group 1-6 a carbamoyl group optionally substituted with an alkyl group; a hydroxy group, a diC 1-6 Alkylamino group and C 1-6 1 to 2 C optionally substituted with a substituent selected from the group consisting of an alkoxy group 1-6a carbamoyloxy group optionally substituted with an alkyl group; an oxo group; a thioxo group; a mono- or di-C 1-6 an alkylamino group; an azido group; a tri-substituted silyl group; a tri-substituted silyloxy group; an aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from substituent group b'; and a non-aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from substituent group b'.

[0115] In the present specification, the term "a pharmaceutically acceptable salt thereof" means a salt that can be used as a medicine. When the compound (I) of the present invention has an acidic or basic group, it can be converted into a basic salt or an acid salt by reacting it with a base or an acid, and therefore the term refers to such a salt. The salt is preferably water-soluble.

[0116] Examples of the pharmaceutically acceptable "basic salt" of compound (I) of the present invention include alkali metal salts such as sodium salt, potassium salt, lithium salt, etc.; alkaline earth metal salts such as magnesium salt, calcium salt, etc.; ammonium salts such as ammonium salt, tetramethylammonium salt, etc.; organic base salts such as N-methylmorpholine salt, triethylamine salt, tributylamine salt, diisopropylethylamine salt, dicyclohexylamine salt, N-methylpiperidine salt, pyridine salt, 4-pyrrolidinopyridine salt, picoline salt, etc.; basic amino acid salts such as lysine salt, arginine salt, etc., and preferably alkali metal salts (particularly sodium salt or potassium salt) and basic amino acid salts.

[0117] Examples of the pharmaceutically acceptable "acid salt" of compound (I) of the present invention include hydrohalides such as hydrofluoride, hydrochloride, hydrobromide, hydroiodide, etc.; inorganic acid salts such as nitrate, perchlorate, sulfate, phosphate, etc.; lower alkanesulfonates such as methanesulfonate, trifluoromethanesulfonate, ethanesulfonate, etc.; arylsulfonates such as benzenesulfonate, p-toluenesulfonate, etc.; organic acid salts such as acetate, malate, fumarate, succinate, citrate, ascorbate, tartrate, oxalate, maleate, etc.; and the like, and preferably hydrohalides (particularly hydrochloride).

[0118] In the present specification, "salts thereof" refers to all salts including the above-mentioned "pharmaceutically acceptable salts thereof".

[0119] As used herein, "prevention" includes preventing the onset of a disease, delaying the onset of a disease, and preventing the occurrence of a pathological condition. A "prophylactically effective amount" refers to a dose of an active ingredient sufficient to achieve the purpose of prevention.

[0120] As used herein, "treatment" includes curing a disease, improving the pathology of a disease (e.g., one or more symptoms), and inhibiting the progression of a disease (or its severity). A "therapeutically effective amount" refers to a dose of an active ingredient sufficient to achieve the therapeutic purpose. Therefore, "improvement" is a concept encompassed by "treatment."

[0121] As used herein, the term "subject" refers to a subject to which a pharmaceutical (pharmaceutical composition) containing an effective amount of an active ingredient is administered to prevent and / or treat (or improve) a disease or the pathology of a disease. The "subject" includes humans and non-human animals, particularly mammals (e.g., humans, mice, rats, guinea pigs, hamsters, rabbits, cats, dogs, cows, sheep, monkeys, etc.).

[0122] As used herein, the term "B0AT1 inhibitor" refers to a drug comprising a compound that inhibits B0AT1, a transporter responsible for the reabsorption of neutral amino acids such as phenylalanine in the kidney. In particular, compound (I) of the present invention, or a pharmaceutically acceptable salt thereof, exhibits excellent inhibitory activity against B0AT1. The inhibitory activity against B0AT1 can be measured, for example, by the method described in Non-Patent Document 11 (SLAS Discovery, 2019; 24(2): pp. 111-120) or the method described in the test examples below.

[0123] As used herein, the term "diseases whose symptoms can be alleviated by B0AT1 inhibitory action" refers to diseases caused by elevated levels of neutral amino acids in the blood due to mutations in genes involved in the amino acid metabolic pathway, etc. Specific examples of such diseases include amino acid metabolism disorders such as phenylketonuria, urea cycle disorders, hypertyrosinemia (type 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemia, and isovaleric acidemia.

[0124] (Compound of the Present Invention (Compound (I))) Hereinafter, each group in the above formula (I) of compound (I) will be explained.

[0125] R 1 represents a carboxy group or a group biologically equivalent to a carboxy group.

[0126] R 1 is preferably a carboxy group, an optionally substituted C 1-6 an alkoxy-carbonyl group, an optionally substituted carbamoyl group, a cyano group, or a group represented by the following formula:

[0127]

[0128] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula, and * represents the bonding position to L), and more preferably a carboxy group, an optionally substituted C 1-6 It is an alkoxy-carbonyl group, or an optionally substituted carbamoyl group.

[0129] L is optionally further substituted; C 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 It represents a divalent organic group including a group selected from the group consisting of an alkynylene group and a divalent 3- to 14-membered non-aromatic heterocyclic group.

[0130] L is preferably —NR 2- (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, —C(═O)—, C 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 C may have one or more divalent groups selected from the group consisting of an alkynylene group and a 3- to 14-membered divalent non-aromatic heterocyclic group at its internal or terminal positions, and may be further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 an alkynylene group or a 3- to 14-membered divalent non-aromatic heterocyclic group, more preferably -NR 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, —C(═O)—, C 6-10 arylene groups (e.g., 1,2-phenylene, 1,3-phenylene, 1,4-phenylene), C 3-10 cycloalkylene groups (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl), C 2-6 C which may have one or more divalent groups selected from the group consisting of alkynylene groups and 3- to 8-membered divalent non-aromatic heterocyclic groups (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) at its internal or terminal positions, and which may be further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or substituent group a′; 1-6 an alkylene group, C optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′;6-10 an arylene group (e.g., 1,2-phenylene, 1,3-phenylene, 1,4-phenylene), C which may be further substituted with 1 to 3 substituents selected from the above-mentioned Substituent Group a or Substituent Group a′; 3-10 a cycloalkylene group (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl), C optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 2-4 an alkynylene group, or a 3- to 8-membered divalent non-aromatic heterocyclic group (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) optionally further substituted with 1 to 3 substituents selected from the above-mentioned Substituent Group a or Substituent Group a′, and more preferably —NR 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, C 3-10 C optionally having one or more divalent groups selected from the group consisting of cycloalkylene groups (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl) and 3- to 8-membered divalent non-aromatic heterocyclic groups (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) at its internal or terminal positions, and optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or substituent group a′. 1-6 an alkylene group, C optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 3-10a cycloalkylene group (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl), or a 3- to 8-membered divalent non-aromatic heterocyclic group (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) optionally further substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a', particularly preferably a C group optionally further substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a'. 1-6 It is an alkylene group.

[0131] A represents a divalent nitrogen-containing heterocyclic group which may be further substituted.

[0132] A is preferably a group represented by the following formula:

[0133]

[0134] (In the formula, ** represents the bonding site with the carbonyl group, *** represents the bonding site with group L, and ring A 1 represents a 3- to 10-membered monocyclic ring, an 8- to 14-membered fused ring, a 6- to 16-membered spiro ring, or a 6- to 14-membered bridged ring, and may contain, as ring-constituting atoms, a heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom in addition to a nitrogen atom and a carbon atom. In one more preferred embodiment, a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0135]

[0136] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula,

[0137]

[0138] represents a single bond or a double bond, and each Y is independently a nitrogen atom or CR 3 (where R 3 is a hydrogen atom or C 1-6 represents an alkyl group; Z represents an oxygen atom, a sulfur atom, NR 4 or CR 5 R 6 (where R 4 , R 5 and R 6 are each independently a hydrogen atom or C 1-6 represents an alkyl group; n represents an integer of 0 to 2; m represents an integer of 0 to 2; n 1 and n 2 each independently represents an integer of 0 to 2; m 1 and m 2 each independently represents an integer of 0 to 2, ** represents the bonding site with the carbonyl group, and *** represents a bonding site to group L), a divalent nitrogen-containing non-aromatic heterocyclic group (e.g., a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0139]

[0140] (wherein each symbol has the same meaning as defined above), and in another more preferred embodiment, the divalent nitrogen-containing non-aromatic heterocyclic group is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0141]

[0142] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula,

[0143]

[0144] represents a single bond or a double bond, and each Y is independently a nitrogen atom or CR 3 (where R 3 is a hydrogen atom or C 1-6represents an alkyl group; Z represents an oxygen atom, a sulfur atom, NR 4 or CR 5 R 6 (where R 4 , R 5 and R 6 are each independently a hydrogen atom or C 1-6 represents an alkyl group; n represents an integer of 0 to 2; m represents an integer of 0 to 2; n 1 and n 2 each independently represents an integer of 0 to 2; m 1 and m 2 each independently represents an integer of 0 to 2, ** represents the bonding site with the carbonyl group, and *** represents a bonding site to group L), a divalent nitrogen-containing non-aromatic heterocyclic group (e.g., a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0145]

[0146] (wherein each symbol has the same meaning as defined above), more preferably a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0147]

[0148] (The definitions of each symbol in the formula are as defined above.) A divalent nitrogen-containing non-aromatic heterocyclic group (e.g., a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0149]

[0150] (wherein each symbol has the same meaning as defined above), and even more preferably a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0151]

[0152] (The definitions of each symbol in the formula are as defined above.) A divalent nitrogen-containing non-aromatic heterocyclic group (e.g., a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0153]

[0154] (The definitions of each symbol in the formula are the same as those defined above, except that Z is CR 5 R 6 In the case where the substituent is C which may be further substituted, the substituent which may be further substituted is C which may be substituted with 1 to 3 substituents selected from the substituent group b or the substituent group b' among the substituents of the substituent group a or the substituent group a'. 6-14 a hydrocarbon ring group; a 5- to 14-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from substituent group b or substituent group b'; and a 3- to 14-membered non-aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from substituent group b or substituent group b'), and particularly preferably a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0155]

[0156] (The definitions of each symbol in the formula are as defined above.) A divalent nitrogen-containing non-aromatic heterocyclic group (among which, preferably, a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0157]

[0158] (wherein each symbol has the same definition as defined above) is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the formula:

[0159] R is optionally substituted C 6-10 It represents an aryl-ethenyl group.

[0160] R is preferably a halogen atom, an optionally substituted C 1-6 alkyl group, optionally substituted C 3-8cycloalkyl group, optionally substituted C 1-6 an alkoxy group, optionally substituted C 3-8 cycloalkyloxy group, optionally substituted C 1-6 alkylsulfanyl group, optionally substituted C 3-8 a 2-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of a cycloalkylsulfanyl group and a pentafluorosulfanyl group, more preferably a halogen atom or a C 1-6 and a 2-(E)-phenylethenyl group which may be substituted with 1 to 3 substituents selected from the group consisting of an alkyl group and a pentafluorosulfanyl group.

[0161] The following compound is suitable as compound (I): [Compound (IA)] R 1 is a carboxy group, an optionally substituted C 1-6 an alkoxy-carbonyl group, an optionally substituted carbamoyl group, a cyano group, or a group represented by the following formula:

[0162]

[0163] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula, and * represents the bonding position to L), or a tautomeric group thereof; 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, —C(═O)—, C 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 C may have one or more divalent groups selected from the group consisting of an alkynylene group and a 3- to 14-membered divalent non-aromatic heterocyclic group at its internal or terminal positions, and may be further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 1-6 Alkylene group, C 6-10Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 A is an alkynylene group or a 3- to 14-membered divalent non-aromatic heterocyclic group; A is a group represented by the following formula:

[0164]

[0165] (In the formula, ** represents the bonding site with the carbonyl group, *** represents the bonding site with group L, and ring A 1 represents a 3- to 10-membered monocyclic ring, an 8- to 14-membered fused ring, a 6- to 16-membered spiro ring, or a 6- to 14-membered bridged ring, and may contain, as ring-constituting atoms, a heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom in addition to a nitrogen atom and a carbon atom; and R is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula: 1-6 alkyl group, optionally substituted C 3-8 cycloalkyl group, optionally substituted C 1-6 an alkoxy group, optionally substituted C 3-8 cycloalkyloxy group, optionally substituted C 1-6 alkylsulfanyl group, optionally substituted C 3-8 Compound (I) or a pharmaceutically acceptable salt thereof, wherein the compound (I) is a 2-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of a cycloalkylsulfanyl group, and a pentafluorosulfanyl group.

[0166] [Compound (IB)] R 1 is a carboxy group, an optionally substituted C 1-6 an alkoxy-carbonyl group or an optionally substituted carbamoyl group; 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, —C(═O)—, C 1-6 Alkylene group, C 6-10Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 C may have one or more divalent groups selected from the group consisting of an alkynylene group and a 3- to 14-membered divalent non-aromatic heterocyclic group at its internal or terminal positions, and may be further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 A is an alkynylene group or a 3- to 14-membered divalent non-aromatic heterocyclic group; A is a group represented by the following formula:

[0167]

[0168] (In the formula, ** represents the bonding site with the carbonyl group, *** represents the bonding site with group L, and ring A 1 represents a 3- to 10-membered monocyclic ring, an 8- to 14-membered fused ring, a 6- to 16-membered spiro ring, or a 6- to 14-membered bridged ring, and may contain, as ring-constituting atoms, a heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom in addition to a nitrogen atom and a carbon atom; and R is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula: 1-6 alkyl group, optionally substituted C 3-8 cycloalkyl group, optionally substituted C 1-6 an alkoxy group, optionally substituted C 3-8 cycloalkyloxy group, optionally substituted C 1-6 alkylsulfanyl group, optionally substituted C 3-8 Compound (I) or a pharmaceutically acceptable salt thereof, wherein the compound (I) is a 2-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of a cycloalkylsulfanyl group, and a pentafluorosulfanyl group.

[0169] [Compound (IC)] R 1 is a carboxy group, an optionally substituted C 1-6 an alkoxy-carbonyl group, an optionally substituted carbamoyl group, a cyano group, or a group represented by the following formula:

[0170]

[0171] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula, and * represents the bonding position to L), or a tautomeric group thereof; 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, —C(═O)—, C 6-10 arylene groups (e.g., 1,2-phenylene, 1,3-phenylene, 1,4-phenylene), C 3-10 cycloalkylene groups (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl), C 2-6 C which may have one or more divalent groups selected from the group consisting of alkynylene groups and 3- to 8-membered divalent non-aromatic heterocyclic groups (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) at its internal or terminal positions, and which may be further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or substituent group a′; 1-6 an alkylene group, C optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 6-10 an arylene group (e.g., 1,2-phenylene, 1,3-phenylene, 1,4-phenylene), C which may be further substituted with 1 to 3 substituents selected from the above-mentioned Substituent Group a or Substituent Group a′; 3-10a cycloalkylene group (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl), C optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 2-4 an alkynylene group, or a 3- to 8-membered divalent non-aromatic heterocyclic group (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) which may be further substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′;

[0172]

[0173] (In the formula, ** represents the bonding site with the carbonyl group, *** represents the bonding site with group L, and ring A 1 represents a 3- to 10-membered monocyclic ring, an 8- to 14-membered fused ring, a 6- to 16-membered spiro ring, or a 6- to 14-membered bridged ring, and may contain, as ring-constituting atoms, a heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom in addition to a nitrogen atom and a carbon atom; and R is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula: 1-6 alkyl group, optionally substituted C 3-8 cycloalkyl group, optionally substituted C 1-6 an alkoxy group, optionally substituted C 3-8 cycloalkyloxy group, optionally substituted C 1-6 alkylsulfanyl group, optionally substituted C 3-8 Compound (I) or a pharmaceutically acceptable salt thereof, wherein the compound (I) is a 2-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of a cycloalkylsulfanyl group, and a pentafluorosulfanyl group.

[0174] [Compound (ID)] R 1 is a carboxy group, an optionally substituted C 1-6 an alkoxy-carbonyl group, an optionally substituted carbamoyl group, a cyano group, or a group represented by the following formula:

[0175]

[0176] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula, and * represents the bonding position to L), or a tautomeric group thereof; 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, C 3-10 C optionally having one or more divalent groups selected from the group consisting of cycloalkylene groups (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl) and 3- to 8-membered divalent non-aromatic heterocyclic groups (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) at its internal or terminal positions, and optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or substituent group a′. 1-6 an alkylene group, C optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 3-10a cycloalkylene group (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl), or a 3- to 8-membered divalent non-aromatic heterocyclic group (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) optionally further substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a';

[0177]

[0178] (In the formula, ** represents the bonding site with the carbonyl group, *** represents the bonding site with group L, and ring A 1 represents a 3- to 10-membered monocyclic ring, an 8- to 14-membered fused ring, a 6- to 16-membered spiro ring, or a 6- to 14-membered bridged ring, and may contain, as ring-constituting atoms, a heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom in addition to a nitrogen atom and a carbon atom; and R is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula: 1-6 alkyl group, optionally substituted C 3-8 cycloalkyl group, optionally substituted C 1-6 an alkoxy group, optionally substituted C 3-8 cycloalkyloxy group, optionally substituted C 1-6 alkylsulfanyl group, optionally substituted C 3-8 Compound (I) or a pharmaceutically acceptable salt thereof, wherein the compound (I) is a 2-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of a cycloalkylsulfanyl group, and a pentafluorosulfanyl group.

[0179] [Compound (IE)] R 1 is a carboxy group, an optionally substituted C1-6 an alkoxy-carbonyl group, an optionally substituted carbamoyl group, a cyano group, or a group represented by the following formula:

[0180]

[0181] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula, and * represents a bonding position to L; and L is a group selected from the group consisting of C which may be further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′. 1-6 A is an alkylene group; A is a group represented by the following formula:

[0182]

[0183] (In the formula, ** represents the bonding site with the carbonyl group, *** represents the bonding site with group L, and ring A 1 represents a 3- to 10-membered monocyclic ring, an 8- to 14-membered fused ring, a 6- to 16-membered spiro ring, or a 6- to 14-membered bridged ring, and may contain, as ring-constituting atoms, a heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom in addition to a nitrogen atom and a carbon atom; and R is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula: 1-6 alkyl group, optionally substituted C 3-8 cycloalkyl group, optionally substituted C 1-6 an alkoxy group, optionally substituted C 3-8 cycloalkyloxy group, optionally substituted C 1-6 alkylsulfanyl group, optionally substituted C 3-8 Compound (I) or a pharmaceutically acceptable salt thereof, wherein the compound (I) is a 2-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of a cycloalkylsulfanyl group, and a pentafluorosulfanyl group.

[0184] [Compound (IF)] R 1is a carboxy group, an optionally substituted C 1-6 an alkoxy-carbonyl group, an optionally substituted carbamoyl group, a cyano group, or a group represented by the following formula:

[0185]

[0186] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula, and * represents the bonding position to L), or a tautomeric group thereof; 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, —C(═O)—, C 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 C may have one or more divalent groups selected from the group consisting of an alkynylene group and a 3- to 14-membered divalent non-aromatic heterocyclic group at its internal or terminal positions, and may be further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 A is an alkynylene group or a 3- to 14-membered divalent non-aromatic heterocyclic group; A is a group represented by the following formula:

[0187]

[0188] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula,

[0189]

[0190] represents a single bond or a double bond, and each Y is independently a nitrogen atom or CR 3 (where R 3 is a hydrogen atom or C 1-6represents an alkyl group; Z represents an oxygen atom, a sulfur atom, NR 4 or CR 5 R 6 (where R 4 , R 5 and R 6 are each independently a hydrogen atom or C 1-6 represents an alkyl group; n represents an integer of 0 to 2; m represents an integer of 0 to 2; n 1 and n 2 each independently represents an integer of 0 to 2; m 1 and m 2 each independently represents an integer of 0 to 2, ** represents the bonding site with the carbonyl group, and *** represents a bonding site to group L), a divalent nitrogen-containing non-aromatic heterocyclic group (e.g., a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0191]

[0192] (wherein each symbol has the same meaning as defined above) is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the formula (I); and R is a halogen atom, an optionally substituted C 1-6 alkyl group, optionally substituted C 3-8 cycloalkyl group, optionally substituted C 1-6 an alkoxy group, optionally substituted C 3-8 cycloalkyloxy group, optionally substituted C 1-6 alkylsulfanyl group, optionally substituted C 3-8 Compound (I) or a pharmaceutically acceptable salt thereof, wherein the compound (I) is a 2-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of a cycloalkylsulfanyl group, and a pentafluorosulfanyl group.

[0193] [Compound (IF')] Compound (IF') is a compound represented by the following formula:

[0194]

[0195] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula,

[0196]

[0197] represents a single bond or a double bond, and each Y is independently a nitrogen atom or CR 3 (where R 3 is a hydrogen atom or C 1-6 represents an alkyl group; Z represents an oxygen atom, a sulfur atom, NR 4 or CR 5 R 6 (where R 4 , R 5 and R 6 are each independently a hydrogen atom or C 1-6 represents an alkyl group; n represents an integer of 0 to 2; m represents an integer of 0 to 2; n 1 and n 2 each independently represents an integer of 0 to 2; m 1 and m 2 each independently represents an integer of 0 to 2, ** represents the bonding site with the carbonyl group, and *** represents a bonding site to group L), a divalent nitrogen-containing non-aromatic heterocyclic group (e.g., a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0198]

[0199] wherein each symbol in the formula is as defined above; and wherein the other symbols are as defined above in [Compound (IF)] above. Compound (I) or a pharmaceutically acceptable salt thereof.

[0200] [Compound (IG)] R 1 is a carboxy group, an optionally substituted C 1-6 an alkoxy-carbonyl group, an optionally substituted carbamoyl group, a cyano group, or a group represented by the following formula:

[0201]

[0202] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula, and * represents the bonding position to L), or a tautomeric group thereof; 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, —C(═O)—, C 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 C may have one or more divalent groups selected from the group consisting of an alkynylene group and a 3- to 14-membered divalent non-aromatic heterocyclic group at its internal or terminal positions, and may be further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 A is an alkynylene group or a 3- to 14-membered divalent non-aromatic heterocyclic group; A is a group represented by the following formula:

[0203]

[0204] (In the formula, ** represents the bonding site with the carbonyl group, *** represents the bonding site with group L, and ring A 1 represents a 3- to 10-membered monocyclic ring, an 8- to 14-membered fused ring, a 6- to 16-membered spiro ring, or a 6- to 14-membered bridged ring, and may contain, as ring-constituting atoms, a heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom in addition to a nitrogen atom and a carbon atom; and 1-6Compound (I), or a pharmaceutically acceptable salt thereof, which is a 2-(E)-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of an alkyl group, and a pentafluorosulfanyl group.

[0205] [Compound (IH)] R 1 is a carboxy group, an optionally substituted C 1-6 an alkoxy-carbonyl group or an optionally substituted carbamoyl group; 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, —C(═O)—, C 6-10 arylene groups (e.g., 1,2-phenylene, 1,3-phenylene, 1,4-phenylene), C 3-10 cycloalkylene groups (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl), C 2-6 C which may have one or more divalent groups selected from the group consisting of alkynylene groups and 3- to 8-membered divalent non-aromatic heterocyclic groups (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) at its internal or terminal positions, and which may be further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or substituent group a′; 1-6 an alkylene group, C optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 6-10 an arylene group (e.g., 1,2-phenylene, 1,3-phenylene, 1,4-phenylene), C which may be further substituted with 1 to 3 substituents selected from the above-mentioned Substituent Group a or Substituent Group a′; 3-10a cycloalkylene group (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl), C optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 2-4 an alkynylene group, or a 3- to 8-membered divalent non-aromatic heterocyclic group (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) which may be further substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′;

[0206]

[0207] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula,

[0208]

[0209] represents a single bond or a double bond, and each Y is independently a nitrogen atom or CR 3 (where R 3 is a hydrogen atom or C 1-6 represents an alkyl group; Z represents an oxygen atom, a sulfur atom, NR 4 or CR 5 R 6 (where R 4 , R 5 and R 6 are each independently a hydrogen atom or C 1-6 represents an alkyl group; n represents an integer of 0 to 2; m represents an integer of 0 to 2; n 1 and n 2 each independently represents an integer of 0 to 2; m 1 and m 2 each independently represents an integer of 0 to 2, ** represents the bonding site with the carbonyl group, and*** represents a bonding site to group L), a divalent nitrogen-containing non-aromatic heterocyclic group (e.g., a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0210]

[0211] wherein R is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the formula (wherein each symbol has the same meaning as defined above); and R is a halogen atom, a C optionally substituted by a halogen atom, 1-6 Compound (I), or a pharmaceutically acceptable salt thereof, which is a 2-(E)-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of an alkyl group, and a pentafluorosulfanyl group.

[0212] [Compound (IH')] Compound (IH') is a compound represented by the following formula:

[0213]

[0214] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula,

[0215]

[0216] represents a single bond or a double bond, and each Y is independently a nitrogen atom or CR 3 (where R 3 is a hydrogen atom or C 1-6 represents an alkyl group; Z represents an oxygen atom, a sulfur atom, NR 4 or CR 5 R 6 (where R 4 , R 5 and R 6 are each independently a hydrogen atom or C 1-6 represents an alkyl group; n represents an integer of 0 to 2; m represents an integer of 0 to 2; n 1 and n 2 each independently represents an integer of 0 to 2; m 1 and m 2each independently represents an integer of 0 to 2, ** represents the bonding site with the carbonyl group, and *** represents a bonding site to group L), a divalent nitrogen-containing non-aromatic heterocyclic group (e.g., a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0217]

[0218] wherein each symbol in the formula is as defined above; and wherein the other symbols are as defined above in [Compound (IH)] or a pharmaceutically acceptable salt thereof.

[0219] [Compound (IJ)] R 1 is a carboxy group, an optionally substituted C 1-6 an alkoxy-carbonyl group or an optionally substituted carbamoyl group; 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, C 3-10 C optionally having one or more divalent groups selected from the group consisting of cycloalkylene groups (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl) and 3- to 8-membered divalent non-aromatic heterocyclic groups (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) at its internal or terminal positions, and optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or substituent group a′. 1-6 an alkylene group, C optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 3-10a cycloalkylene group (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl), or a 3- to 8-membered divalent non-aromatic heterocyclic group (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) optionally further substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′;

[0220]

[0221] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula,

[0222]

[0223] represents a single bond or a double bond, and each Y is independently a nitrogen atom or CR 3 (where R 3 is a hydrogen atom or C 1-6 represents an alkyl group; Z represents an oxygen atom, a sulfur atom, NR 4 or CR 5 R 6 (where R 4 , R 5 and R 6 are each independently a hydrogen atom or C 1-6 represents an alkyl group; n represents an integer of 0 to 2; m represents an integer of 0 to 2; n 1 and n 2 each independently represents an integer of 0 to 2; m 1 and m 2 each independently represents an integer of 0 to 2, ** represents the bonding site with the carbonyl group, and ***represents a bonding site to group L), a divalent nitrogen-containing non-aromatic heterocyclic group (e.g., a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0224]

[0225] wherein R is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the formula (wherein each symbol has the same meaning as defined above); and R is a halogen atom, a C optionally substituted by a halogen atom, 1-6 Compound (I), or a pharmaceutically acceptable salt thereof, which is a 2-(E)-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of an alkyl group, and a pentafluorosulfanyl group.

[0226] [Compound (IJ')] Compound (IJ') is a compound represented by the following formula:

[0227]

[0228] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula,

[0229]

[0230] represents a single bond or a double bond, and each Y is independently a nitrogen atom or CR 3 (where R 3 is a hydrogen atom or C 1-6 represents an alkyl group; Z represents an oxygen atom, a sulfur atom, NR 4 or CR 5 R 6 (where R 4 , R 5 and R 6 are each independently a hydrogen atom or C 1-6 represents an alkyl group; n represents an integer of 0 to 2; m represents an integer of 0 to 2; n 1 and n 2 each independently represents an integer of 0 to 2; m 1 and m 2 each independently represents an integer of 0 to 2,** represents the bonding site with the carbonyl group, and *** represents a bonding site to group L), a divalent nitrogen-containing non-aromatic heterocyclic group (e.g., a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0231]

[0232] wherein each symbol in the formula is as defined above; and wherein the other symbols are as defined above in [compound (IJ)] or a pharmaceutically acceptable salt thereof.

[0233] [Compound (IK)] R 1 is a carboxy group, an optionally substituted C 1-6 L is an alkoxy-carbonyl group or an optionally substituted carbamoyl group; C optionally further substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′. 1-6 A is an alkylene group; A is a group represented by the following formula:

[0234]

[0235] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula,

[0236]

[0237] represents a single bond or a double bond, and each Y is independently a nitrogen atom or CR 3 (where R 3 is a hydrogen atom or C 1-6 represents an alkyl group; Z represents an oxygen atom, a sulfur atom, NR 4 or CR 5 R 6 (where R 4 , R 5 and R 6 are each independently a hydrogen atom or C 1-6represents an alkyl group; n represents an integer of 0 to 2; m represents an integer of 0 to 2; n 1 and n 2 each independently represents an integer of 0 to 2; m 1 and m 2 each independently represents an integer of 0 to 2, ** represents the bonding site with the carbonyl group, and *** represents a bonding site to group L), a divalent nitrogen-containing non-aromatic heterocyclic group (e.g., a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0238]

[0239] wherein R is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the formula (wherein each symbol has the same meaning as defined above); and R is a halogen atom, a C optionally substituted by a halogen atom, 1-6 Compound (I), or a pharmaceutically acceptable salt thereof, which is a 2-(E)-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of an alkyl group, and a pentafluorosulfanyl group.

[0240] [Compound (IK')] Compound (IK') is a compound represented by the following formula:

[0241]

[0242] (wherein the wavy line represents the bonding site of the group represented by the above chemical formula,

[0243]

[0244] represents a single bond or a double bond, and each Y is independently a nitrogen atom or CR 3 (where R 3 is a hydrogen atom or C 1-6 represents an alkyl group; Z represents an oxygen atom, a sulfur atom, NR 4 or CR 5 R 6 (where R 4 , R 5and R 6 are each independently a hydrogen atom or C 1-6 represents an alkyl group; n represents an integer of 0 to 2; m represents an integer of 0 to 2; n 1 and n 2 each independently represents an integer of 0 to 2; m 1 and m 2 each independently represents an integer of 0 to 2, ** represents the bonding site with the carbonyl group, and *** represents a bonding site to group L), a divalent nitrogen-containing non-aromatic heterocyclic group (e.g., a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0245]

[0246] wherein each symbol in the formula is as defined above; and wherein the other symbols are as defined above in [compound (IK)], or a pharmaceutically acceptable salt thereof.

[0247] [Compound (IL)] R 1 is a carboxy group, an optionally substituted C 1-6 an alkoxy-carbonyl group or an optionally substituted carbamoyl group; 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, —C(═O)—, C 6-10 arylene groups (e.g., 1,2-phenylene, 1,3-phenylene, 1,4-phenylene), C 3-10 cycloalkylene groups (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl), C 2-6C which may have one or more divalent groups selected from the group consisting of alkynylene groups and 3- to 8-membered divalent non-aromatic heterocyclic groups (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) at its internal or terminal positions, and which may be further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or substituent group a′; 1-6 an alkylene group, C optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 6-10 an arylene group (e.g., 1,2-phenylene, 1,3-phenylene, 1,4-phenylene), C which may be further substituted with 1 to 3 substituents selected from the above-mentioned Substituent Group a or Substituent Group a′; 3-10 a cycloalkylene group (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl), C optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 2-4 an alkynylene group, or a 3- to 8-membered divalent non-aromatic heterocyclic group (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) which may be further substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′;

[0248]

[0249] (The definitions of each symbol in the formula are as defined above.) A divalent nitrogen-containing non-aromatic heterocyclic group (e.g., a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0250]

[0251] wherein R is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the formula (wherein each symbol has the same meaning as defined above); and R is a halogen atom, a C optionally substituted by a halogen atom, 1-6 Compound (I), or a pharmaceutically acceptable salt thereof, which is a 2-(E)-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of an alkyl group, and a pentafluorosulfanyl group.

[0252] [Compound (IM)] R 1 is a carboxy group, an optionally substituted C 1-6 an alkoxy-carbonyl group or an optionally substituted carbamoyl group; 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, C 3-10 C optionally having one or more divalent groups selected from the group consisting of cycloalkylene groups (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl) and 3- to 8-membered divalent non-aromatic heterocyclic groups (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) at its internal or terminal positions, and optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or substituent group a′. 1-6 an alkylene group, C optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 3-10a cycloalkylene group (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl), or a 3- to 8-membered divalent non-aromatic heterocyclic group (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) optionally further substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′;

[0253]

[0254] (The definitions of each symbol in the formula are as defined above.) A divalent nitrogen-containing non-aromatic heterocyclic group (e.g., a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0255]

[0256] wherein R is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the formula (wherein each symbol has the same meaning as defined above); and R is a halogen atom, a C optionally substituted by a halogen atom, 1-6 Compound (I), or a pharmaceutically acceptable salt thereof, which is a 2-(E)-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of an alkyl group, and a pentafluorosulfanyl group.

[0257] [Compound (IN)] R 1 is a carboxy group, an optionally substituted C 1-6 L is an alkoxy-carbonyl group or an optionally substituted carbamoyl group; C optionally further substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′. 1-6 A is an alkylene group; A is a group represented by the following formula:

[0258]

[0259] (The definitions of each symbol in the formula are as defined above.) A divalent nitrogen-containing non-aromatic heterocyclic group (e.g., a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0260]

[0261] wherein R is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the formula (wherein each symbol has the same meaning as defined above); and R is a halogen atom, a C optionally substituted by a halogen atom, 1-6 Compound (I), or a pharmaceutically acceptable salt thereof, which is a 2-(E)-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of an alkyl group, and a pentafluorosulfanyl group.

[0262] [Compound (IP)] R 1 is a carboxy group, an optionally substituted C 1-6 an alkoxy-carbonyl group or an optionally substituted carbamoyl group; 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, —C(═O)—, C 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 C may have one or more divalent groups selected from the group consisting of an alkynylene group and a 3- to 14-membered divalent non-aromatic heterocyclic group at its internal or terminal positions, and may be further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6A is an alkynylene group or a 3- to 14-membered divalent non-aromatic heterocyclic group; A is a group represented by the following formula:

[0263]

[0264] (The definitions of each symbol in the formula are as defined above.) A divalent nitrogen-containing non-aromatic heterocyclic group (e.g., a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0265]

[0266] (The definitions of each symbol in the formula are the same as those defined above, except that Z is CR 5 R 6 In the case where the substituent is C which may be further substituted, the substituent which may be further substituted is C which may be substituted with 1 to 3 substituents selected from the substituent group b or the substituent group b' among the substituents of the substituent group a or the substituent group a'. 6-14 a hydrocarbon ring group; a 5- to 14-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from substituent group b or substituent group b'; and a 3- to 14-membered non-aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from substituent group b or substituent group b'; and 1-6 Compound (I), or a pharmaceutically acceptable salt thereof, which is a 2-(E)-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of an alkyl group, and a pentafluorosulfanyl group.

[0267] [Compound (IQ)] R 1 is a carboxy group, an optionally substituted C 1-6 an alkoxy-carbonyl group or an optionally substituted carbamoyl group; 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, C 3-10C optionally having one or more divalent groups selected from the group consisting of cycloalkylene groups (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl) and 3- to 8-membered divalent non-aromatic heterocyclic groups (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) at its internal or terminal positions, and optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or substituent group a′. 1-6 an alkylene group, C optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 3-10 a cycloalkylene group (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl), or a 3- to 8-membered divalent non-aromatic heterocyclic group (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) optionally further substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a';

[0268]

[0269] (The definitions of each symbol in the formula are as defined above.) A divalent nitrogen-containing non-aromatic heterocyclic group (e.g., a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula:

[0270]

[0271] (The definitions of each symbol in the formula are the same as those defined above, except that Z is CR 5 R 6In the case where the substituent is C which may be further substituted, the substituent which may be further substituted is C which may be substituted with 1 to 3 substituents selected from the substituent group b or the substituent group b' among the substituents of the substituent group a or the substituent group a'. 6-14 a hydrocarbon ring group; a 5- to 14-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from substituent group b or substituent group b'; and a 3- to 14-membered non-aromatic heterocyclic group optionally substituted with 1 to 3 substituents selected from substituent group b or substituent group b'; and 1-6 Compound (I), or a pharmaceutically acceptable salt thereof, which is a 2-(E)-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of an alkyl group, and a pentafluorosulfanyl group.

[0272] [Compound (IR)] R 1 is a carboxy group, an optionally substituted C 1-6 an alkoxy-carbonyl group or an optionally substituted carbamoyl group; 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, C 3-10 C optionally having one or more divalent groups selected from the group consisting of cycloalkylene groups (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl) and 3- to 8-membered divalent non-aromatic heterocyclic groups (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) at its internal or terminal positions, and optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or substituent group a′. 1-6 an alkylene group, C optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′;3-10 a cycloalkylene group (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl), or a 3- to 8-membered divalent non-aromatic heterocyclic group (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) optionally further substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a';

[0273]

[0274] (The definitions of each symbol in the formula are as defined above.) A divalent nitrogen-containing non-aromatic heterocyclic group represented by the formula: 1-6 Compound (I), or a pharmaceutically acceptable salt thereof, which is a 2-(E)-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of an alkyl group, and a pentafluorosulfanyl group.

[0275] [Compound (IS)] R 1 is a carboxy group, an optionally substituted C 1-6 L is an alkoxy-carbonyl group or an optionally substituted carbamoyl group; C optionally further substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′. 1-6 A is an alkylene group; A is a group represented by the following formula:

[0276]

[0277] (The definitions of each symbol in the formula are as defined above.) A divalent nitrogen-containing non-aromatic heterocyclic group represented by the formula: 1-6Compound (I), or a pharmaceutically acceptable salt thereof, which is a 2-(E)-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of an alkyl group, and a pentafluorosulfanyl group.

[0278] [Compound (IT)] R 1 is a carboxy group, an optionally substituted C 1-6 an alkoxy-carbonyl group or an optionally substituted carbamoyl group; 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, C 3-10 C optionally having one or more divalent groups selected from the group consisting of cycloalkylene groups (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl) and 3- to 8-membered divalent non-aromatic heterocyclic groups (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) at its internal or terminal positions, and optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or substituent group a′. 1-6 an alkylene group, C optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 3-10a cycloalkylene group (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl), or a 3- to 8-membered divalent non-aromatic heterocyclic group (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) optionally further substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a';

[0279]

[0280] (The definitions of each symbol in the formula are as defined above.) A divalent nitrogen-containing non-aromatic heterocyclic group represented by the formula: 1-6 Compound (I), or a pharmaceutically acceptable salt thereof, which is a 2-(E)-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of an alkyl group, and a pentafluorosulfanyl group.

[0281] [Compound (IU)] R 1 is a carboxy group, an optionally substituted C 1-6 L is an alkoxy-carbonyl group or an optionally substituted carbamoyl group; C optionally further substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′. 1-6 A is an alkylene group; A is a group represented by the following formula:

[0282]

[0283] (The definitions of each symbol in the formula are as defined above.) A divalent nitrogen-containing non-aromatic heterocyclic group represented by the formula: 1-6Compound (I), or a pharmaceutically acceptable salt thereof, which is a 2-(E)-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of an alkyl group, and a pentafluorosulfanyl group.

[0284] [Compound (IV)] R 1 is a carboxy group, an optionally substituted C 1-6 an alkoxy-carbonyl group or an optionally substituted carbamoyl group; 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group, —O—, —S—, C 3-10 C optionally having one or more divalent groups selected from the group consisting of cycloalkylene groups (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl) and 3- to 8-membered divalent non-aromatic heterocyclic groups (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) at its internal or terminal positions, and optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or substituent group a′. 1-6 an alkylene group, C optionally further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a or the above-mentioned substituent group a′; 3-10a cycloalkylene group (e.g., cyclobutane-1,3-diyl, cyclopropane-1,2-diyl, cyclopropane-1,1-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, bicyclo[2.1.1]hexane-1,2-diyl), or a 3- to 8-membered divalent non-aromatic heterocyclic group (e.g., azetidine-1,3-diyl, pyrrolidine-1,3-diyl, pyrrolidine-1,2-diyl, piperidine-1,2-diyl, piperidine-1,4-diyl, azepane-1,2-diyl) optionally further substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a';

[0285]

[0286] (The definitions of each symbol in the formula are as defined above.) A divalent nitrogen-containing non-aromatic heterocyclic group represented by the formula: 1-6 Compound (I), or a pharmaceutically acceptable salt thereof, which is a 2-(E)-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of an alkyl group, and a pentafluorosulfanyl group.

[0287] [Compound (IW)] R 1 is a carboxy group, an optionally substituted C 1-6 L is an alkoxy-carbonyl group or an optionally substituted carbamoyl group; C optionally further substituted with 1 to 3 substituents selected from the substituent group a or the substituent group a′. 1-6 A is an alkylene group; A is a group represented by the following formula:

[0288]

[0289] (The definitions of each symbol in the formula are as defined above.) A divalent nitrogen-containing non-aromatic heterocyclic group represented by the formula: 1-6Compound (I), or a pharmaceutically acceptable salt thereof, which is a 2-(E)-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of an alkyl group, and a pentafluorosulfanyl group.

[0290] Specific examples of suitable compound (I) include the compounds of Examples 1 to 403 (compounds (I-1) to (I-403)) described below, or pharmaceutically acceptable salts thereof. Among these, preferred are 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 3-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid; N,N-dimethyl-3-[5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]propanamide; 1-[7-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,8-dihydro-5H-2,7-naphthyridin-3-yl]piperidine-4-carboxylic acid; 3-[3-bromo-5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]propanoic acid; 2-[[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]oxy]acetic acid; 2-[2-[2-[[(E)-3-[4-(pentafluoro-λ6-sulfanyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; (1R*, 2R*)-2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]cyclopropane-1-carboxylic acid and both enantiomers thereof; 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid;2-[7-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[7-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,8-dihydro-5H-2,7-naphthyridin-3-yl]acetic acid; 3-[3-bromo-5-[2-[[(E)-3-[4-(pentafluoro-λ6-sulfanyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]propanoic acid; 2-[2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]amino]acetic acid; 2-[2-[2-[[(E)-3-(4-iodophenyl)prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[5-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid;2-[8-cyano-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-(2-fluoro-4-iodophenyl)prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-(4-iodophenyl)prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[[5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridin-2-yl]sulfanyl]acetic acid; 2-[7-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-cyano-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[5-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; (E)-N-[2-[6-(2-amino-2-oxoethyl)-3,4-dihydro-1H-isoquinolin-2-yl]-2-oxoethyl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide; 2-[5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-[1,3]thiazolo[4,5-c]pyridin-2-yl]acetic acid;(E)-N-[2-[6-[2-(methylamino)-2-oxoethyl]-3,4-dihydro-1H-isoquinolin-2-yl]-2-oxoethyl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide; 4-[4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3-phenylpiperazin-1-yl]butanoic acid and both enantiomers thereof; 2-[[1-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2,3-dihydroindol-4-yl]oxy]acetic acid; 1-[1-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperidin-3-yl]bicyclo[2.1.1]hexane-5-carboxylic acid; 2-[[8-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]oxy]-2-methylpropanoic acid; 3-[[8-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]oxy]-2,2-dimethylpropanoic acid; 4-[4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(3S)-3-(4-bromophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(3-bromophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid;3-[[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]methyl]cyclobutane-1-carboxylic acid and both enantiomers thereof; 4-[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]-2,2-dimethylbutanoic acid; 4-[3-(3-cyclopropylphenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid and both enantiomers; 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]butanoic acid; 4-[(3S)-3-(4-cyclopropylphenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(4-chloro-3-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(3,4-difluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(3,4-difluorophenyl)-2-methyl-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid;4-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(4-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(3-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-2-ethyl-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-5-phenylpiperazin-1-yl]butanoic acid; and 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]-2,2-dimethylbutanoic acid or a pharmaceutically acceptable salt thereof, more preferably 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid;3-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid; N,N-dimethyl-3-[5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]propanamide; 2-[2-[2-[[(E)-3-[4-(pentafluoro-λ6-sulfanyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; (1R*, 2R*)-2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]cyclopropane-1-carboxylic acid and both enantiomers thereof; 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid; 2-[7-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[2-[2-[[(E)-3-(4-iodophenyl)prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[5-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid;2-[8-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-cyano-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-(2-fluoro-4-iodophenyl)prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[7-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[5-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-[1,3]thiazolo[4,5-c]pyridin-2-yl]acetic acid; 4-[(3S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3-phenylpiperazin-1-yl]butanoic acid; 1-[1-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperidin-3-yl]bicyclo[2.1.1]hexane-5-carboxylic acid;4-[(3S)-3-(4-bromophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(3-bromophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 3-[[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]methyl]cyclobutane-1-carboxylic acid and both enantiomers thereof; 4-[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid and both enantiomers thereof; 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]butanoic acid; 4-[(3S)-3-(4-cyclopropylphenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(4-chloro-3-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(3,4-difluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid;4-[(2R,5S)-5-(3,4-difluorophenyl)-2-methyl-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(4-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(3-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-2-ethyl-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-5-phenylpiperazin-1-yl]butanoic acid;and 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]-2,2-dimethylbutanoic acid, more preferably 2-[7-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid; 2-[2-[2-[[(E)-3-(4-iodophenyl)prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[5-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid;2-[7-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[5-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 4-[(3S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3-phenylpiperazin-1-yl]butanoic acid; 1-[1-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperidin-3-yl]bicyclo[2.1.1]hexane-5-carboxylic acid; 4-[(3S)-3-(4-bromophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(3-bromophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]butanoic acid; 4-[(3S)-3-(4-cyclopropylphenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(3,4-difluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid;4-[(2R,5S)-5-(3,4-difluorophenyl)-2-methyl-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(4-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(3-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-2-ethyl-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-5-phenylpiperazin-1-yl]butanoic acid;and 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]-2,2-dimethylbutanoic acid, particularly preferred are 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 3-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid; N,N-dimethyl-3-[5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]propanamide; 2-[2-[2-[[(E)-3-[4-(pentafluoro-λ6-sulfanyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid; 2-[8-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid;4-[(3R)-3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(3-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-2-ethyl-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-5-phenylpiperazin-1-yl]butanoic acid; and 4-[(3S)-3-(4-cyclopropylphenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid or a pharmaceutically acceptable salt thereof;

[0291] When the compound (I) of the present invention has an asymmetric carbon atom in the molecule, it can exist as a plurality of stereoisomers (i.e., diastereoisomers, optical isomers) based on the asymmetric carbon atom, and the present invention encompasses any one of these stereoisomers and a mixture containing these plurality of stereoisomers in any ratio. In addition, isomers may be produced due to conformation or tautomerism, and such isomers or mixtures thereof are also encompassed by the compound (I) of the present invention.

[0292] Compound (I) of the present invention may contain an isotope (e.g., 2 H. 3 H. 13 C. 14 C. 15 N. 18 F. 32 P. 35 S. 123 I, 125 I, 131 The compound may be a compound labeled or substituted with an isotope (e.g., I), and a compound labeled or substituted with an isotope can be used as a tracer (PET tracer) used in, for example, Single Photon Emission Computed Tomography (SPECT) or Positron Emission Tomography (PET), and is useful in fields such as medical diagnosis.

[0293] The compound (I) of the present invention or a pharmaceutically acceptable salt thereof may be crystalline, and may be in a single crystalline form or a mixture of multiple crystalline forms.

[0294] The compound (I) or a pharmaceutically acceptable salt thereof of the present invention may also include its internal salts, adducts, and solvates thereof. These solvates are compounds in which solvent molecules are coordinated to compound (I) or a salt thereof, and also include hydrates. Examples of the solvates include hydrates, ethanol solvates, and dimethyl sulfoxide solvates of compound (I) or a salt thereof.

[0295] Compound (I) of the present invention may be a prodrug.

[0296] The prodrug of compound (I) of the present invention refers to a compound that is converted to compound (I) in vivo by a reaction with an enzyme, gastric acid, or the like. The prodrug of compound (I) is a monoester or diester of a phosphate group, and the ester functional group preferably has a structure that is easily hydrolyzed or metabolized after administration to a patient. Specific examples of the ester functional group of such a prodrug include C-(C-amino)-1, which may be substituted with an acyloxy group. 1-6Examples of prodrugs other than the monoesters and diesters of the phosphate group include alkyl esters, phenyl esters, and benzyl esters (see Bioorganic Chemistry, 1984; 12: pp. 118-129). Examples of prodrugs other than the monoesters and diesters of the phosphate group include compounds having a group derived from a phosphate group, such as those described in Current Opinion in Investigational Drugs, 2006; 7: pp. 109-117, J. Med. Chem. 1994; 37: pp. 1857-1864, and J. Med. Chem. 2000; 43: pp. 4570-4574. Other embodiments of the prodrug of compound (I) include, for example, when compound (I) has an amino group, a compound in which the amino group is acylated, alkylated or phosphorylated (for example, a compound in which the amino group of compound (I) is eicosanoylated, alanylated, pentylaminocarbonylated, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonylated, tetrahydrofurylated, pyrrolidylmethylated, pivaloyloxymethylated, acetoxymethylated or tert-butylated); when compound (I) has a hydroxyl group, a compound in which the hydroxyl group is acylated, alkylated, phosphorylated or borated (for example, a compound in which the hydroxyl group of compound (I) is acetylated, palmitoylated, propanoylated or pivaloylated). , succinylated, fumarylated, alanylated, dimethylaminomethylcarbonylated compounds, etc.); when compound (I) has a carboxy group, compounds in which the carboxy group is esterified or amidated (for example, compounds in which the carboxy group of compound (I) is ethyl esterified, phenyl esterified, carboxymethyl esterified, dimethylaminomethyl esterified, pivaloyloxymethyl esterified, 1-{(ethoxycarbonyl)oxy}ethyl esterified, phthalidyl esterified, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl esterified, 1-{[(cyclohexyloxy)carbonyl]oxy}ethyl esterified, methylamidated compounds, etc.). These compounds can be produced by methods known per se. Furthermore, the prodrug of compound (I) may be either a hydrate or a non-hydrate.Furthermore, the prodrug of compound (I) may be one that is converted into a compound represented by compound (I) under physiological conditions, as described in "Drug Development," Vol. 7, "Molecular Design," pp. 163-198, Hirokawa Publishing, 1990.

[0297] (Method for producing compound (I) of the present invention) Hereinafter, a method for producing compound (I) of the present invention or a pharmaceutically acceptable salt thereof will be described. As examples of methods for producing compound (I), representative production methods (A) to (F) will be described below, but the production methods are not limited to these. In addition, the following production methods and steps may be combined with each other. Compound (I) (for example, compounds (I-1) to (I-403) described in the Examples below) can be produced by the following production methods (A) to (F), the Reference Examples and Examples below, or methods similar thereto.

[0298] Each starting compound may form a salt as long as it does not inhibit the reaction, and examples of such salts include the same as the salts of compound (I). Unless a specific production method is described, the starting compound may be a commercially available compound that is easily obtained and used, or may be produced according to a method known per se or a method similar thereto. In addition, intermediates produced in the following production methods may be isolated and purified by methods such as column chromatography, recrystallization, distillation, etc., or may be used in the next step without isolation.

[0299] The contents of all patent, non-patent, or literature references explicitly cited in this specification are hereby incorporated by reference in their entirety.

[0300] [Production Method (A)] In this production method, compound (1-1) is condensed with compound (2-1) to obtain compound (3-1), and then a protecting group (P 1 Compound (1-1) can be preferably synthesized by a method known per se (see, for example, the specification of U.S. Pat. No. 10,836,736, etc.).

[0301]

[0302] (In the formula, R1a -P 1 is a protected R 1 and the other symbols have the same meanings as above.)

[0303] (Step A-1) This step is a step of producing a compound (3-1) by condensing a compound (1-1) with a compound (2-1) in the presence of a condensing agent.

[0304] The amount of the compound (2-1) used is 0.8 to 5 moles, preferably 0.8 to 3 moles, per mole of the compound (1-1).

[0305] Condensing agents include O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (EDC.HCl) (WSC hydrochloride), dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBop), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), 1-[bis(dimethylamino)methylene]-5-chloro-1H-benzotriazolium 3-oxide hexafluorophosphate (HCTU), and O-benzotriazole-N,N,N',N'-tetramethyluronium Examples of the condensing agent include a solution of hexafluoroborate (HBTU) or propylphosphonic anhydride (T3P), and preferably HATU or WSC hydrochloride. The amount of the condensing agent used is usually 1 mol to 10 mol, and preferably 1 mol to 5 mol, per 1 mol of compound (1-1).

[0306] The reaction may be carried out in the presence of an additive such as 1-hydroxybenzotriazole (HOBt), 1-hydroxy-1H-1,2,3-triazole-5-carboxylic acid ethyl ester (HOCt), 1-hydroxy-7-azabenzotriazole (HOAt), etc. The amount of the additive used is usually 0 to 1.5 moles per mole of compound (1-1).

[0307] Examples of the base include organic bases such as triethylamine, pyridine, and N,N-diisopropylethylamine, and among these, triethylamine or N,N-diisopropylethylamine is preferred. The amount of the base used is usually 1 mol to 5 mol, preferably 1.5 mol, per 1 mol of compound (1-1).

[0308] This reaction can be carried out in a solvent that does not affect the reaction. The reaction solvent is not particularly limited, but examples thereof include aromatic hydrocarbons such as toluene and xylene; amide solvents such as N,N-dimethylformamide and N,N-dimethylacetamide; ethers such as diethyl ether, tetrahydrofuran and dioxane; halogenated hydrocarbons such as chloroform and dichloromethane; nitriles such as acetonitrile; and mixtures thereof.

[0309] The reaction temperature is usually −78° C. to room temperature, preferably 0° C. to room temperature, and the reaction time is usually 1 to 48 hours.

[0310] (Step A-2) This step is to remove the protecting group (P 1 ) to obtain compound (Ia).

[0311] The deprotection step of step A-2 is to remove the protecting group (P 1 The deprotection reaction conditions can be selected depending on the type of the protecting group. The deprotection reaction is carried out according to a method known per se, for example, a method described in "Protective Groups in Organic Synthesis, 4th Ed." (Theodora W. Greene, Peter GM Wuts), published by Wiley-Interscience in 2007; "Protective Groups, 3rd Ed." (PJ Kocienski), published by Thieme in 2004, or a method described in the Examples below.

[0312] [Production Method (B)] In this production method, compound (1-1) is condensed with compound (4-1) to obtain compound (5-1), which is then converted into compound (7-1) by a coupling reaction with compound (6-1), and a protecting group (P 2Compound (Ib) can be obtained by removing the 2-amino-2-methyl-2-propanol group from the compound (1-1). Compound (1-1) synthesized by a method known per se (see, for example, the specification of U.S. Pat. No. 10,836,736) can be suitably used.

[0313]

[0314] (wherein X represents a leaving group, P 2 and P 3 each independently represents a protecting group, and the other symbols have the same meanings as defined above.

[0315] Protecting group P in compound (6-1) 3 As the protecting group P, a tri-substituted silyl group such as a trimethylsilyl group, a triethylsilyl group, a tert-butyldimethylsilyl group, a tert-butyldiphenylsilyl group, or a triisopropylsilyl group is used. 3 is removed during the reaction in step B-2.

[0316] (Step B-1) This step is a step of producing a compound (5-1) by condensing a compound (1-1) with a compound (4-1) in the presence of a condensing agent.

[0317] The amount of the compound (4-1) used is 0.8 to 5 moles, preferably 0.8 to 3 moles, per mole of the compound (1-1).

[0318] In step B-1, the reaction can be carried out under the same conditions as in step A-1, except that compound (4-1) is used instead of compound (2-1).

[0319] (Step B-2) This step can be carried out by a cross-coupling reaction (Heck reaction) between compound (5-1) and compound (6-1) in a solvent that does not influence the reaction, in the presence of a metal catalyst (e.g., a palladium catalyst) and, if necessary, a base.

[0320] The amount of the compound (6-1) used is 0.8 to 5 moles, preferably 0.8 to 3 moles, per mole of the compound (5-1).

[0321] Metal catalysts include palladium(II) acetate, palladium(II) chloride, dichlorobis(tricyclohexylphosphine)palladium(II), tris(dibenzylideneacetone)dipalladium(0), and bis(dibenzylideneacetone)palladium(0) (Pd 2 (dba) 3 ), tetrakis(triphenylphosphine)palladium(0), bis(tri-tert-butylphosphine)palladium(0), palladium(II) chloride.diphenylphosphinoferrocene (PdCl 2 (dppf)), PdCl 2palladium catalysts such as (dppf) dichloromethane complex, palladium on carbon(0), bis(triphenylphosphine)palladium dichloride(II), dichlorobis(tri-o-tolylphosphine)palladium(II), bis(tris(2-tolyl)phosphine)palladium(0); copper catalysts such as copper iodide(I), copper bromide(I), copper chloride(I), copper chloride(II); iron catalysts such as iron(III) acetylacetonate; nickel catalysts such as bis(1,5-cyclooctadiene)nickel(0) and bis(acetylacetonate)nickel(II); ruthenium catalysts such as dichloro(p-cymene)ruthenium(II) dimer and ruthenium alumina, among which palladium catalysts are preferred, and particularly dichlorobis(tricyclohexylphosphine)palladium(II), dichlorobis(tri-o-tolylphosphine)palladium(II), or bis(tri-tert-butylphosphine)palladium(0). Furthermore, if necessary, 1,1'-bis(diphenylphosphino)ferrocene (dppf), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (SPhos), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (XPhos), 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl (RuPhos), 3,6-dimethoxy-2-dicyclohexylphosphino-2' Phosphine ligands such as 4',6'-triisopropylbiphenyl (BrettPhos), tri-t-butylphosphine, tricyclohexylphosphine, [4-(N,N-dimethylamino)phenyl]di-tert-butylphosphine (AmPhos), and (S)-1-[(RP)-2-(dicyclohexylphosphino)ferrocenyl]ethyldi-tert-butylphosphine (JosiPhos); phenanthroline, etc. may also be added. The amount of the metal catalyst used is usually 0.01 mol to 1 mol, preferably 0.05 mol to 0.3 mol, relative to 1 mol of compound (5-1). The amount of the ligand used is usually 0.05 mol to 1 mol, preferably 0.1 mol to 0.4 mol, relative to 1 mol of compound (5-1).

[0322] As an additive, zinc fluoride (ZnF 2 ), copper fluoride (CuF2 The reaction may be carried out in the coexistence of lithium fluoride (LiF), etc. The amount of the additive used is usually 0 to 1.5 moles per mole of compound (5-1).

[0323] Examples of the base include alkali metal amides such as lithium diisopropylamide, sodium amide, lithium bistrimethylsilylamide, etc.; alkali metal carbonates such as sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, etc.; alkali metal phosphates such as sodium phosphate, potassium phosphate, etc.; and amines such as triethylamine, N,N-diisopropylethylamine, pyridine, N-methylmorpholine, etc. The amount of the base used is usually 1 mol to 5 mol, preferably 1 mol to 2.5 mol, per 1 mol of compound (5-1).

[0324] The reaction solvent is not particularly limited, but examples thereof include amides such as N,N-dimethylformamide, N-methylpyrrolidone, etc.; ethers such as tetrahydrofuran, 1,4-dioxane, etc.; halogenated hydrocarbons such as chloroform, dichloromethane, etc.; aromatic hydrocarbons such as toluene, xylene, etc.; nitriles such as acetonitrile, etc.; and mixtures thereof.

[0325] The reaction temperature is usually −78° C. to 200° C., preferably −78° C. to 120° C. The reaction time is usually 0.5 to 12 hours.

[0326] (Step B-3) This step is to remove the protecting group (P 2 ) to obtain compound (Ib).

[0327] The deprotection step of step B-3 is to remove the protecting group (P 2The deprotection reaction conditions can be selected depending on the type of the protecting group. The deprotection reaction is carried out according to a method known per se, for example, a method described in "Protective Groups in Organic Synthesis, 4th Ed." (Theodora W. Greene, Peter GM Wuts), published by Wiley-Interscience in 2007; "Protective Groups, 3rd Ed." (PJ Kocienski), published by Thieme in 2004, or a method described in the Examples below.

[0328] [Production Method (C)] In this production method, compound (1-1) is condensed with compound (8-1) to obtain compound (9-1), and then a protecting group (P 4 ) is deprotected to obtain compound (10-1), which is then reacted with compound (11-1) to convert it to compound (12-1), and then the protecting group (P 5 ) to obtain compound (Ic).

[0329]

[0330] (In the formula, R 1b -P 5 is a protected R 1 represents X 1 represents a leaving group, P 4 and P 5 each independently represents a protecting group, and the other symbols have the same meanings as defined above.

[0331] (Step C-1) This step is a step of producing a compound (9-1) by condensing a compound (1-1) with a compound (8-1) in the presence of a condensing agent.

[0332] The amount of the compound (8-1) used is 0.8 to 5 moles, preferably 0.8 to 3 moles, per mole of the compound (1-1).

[0333] In step C-1, the reaction can be carried out under the same conditions as in step A-1, except that compound (8-1) is used instead of compound (2-1).

[0334] (Step C-2) This step is to remove the protecting group (P4 ) to obtain compound (10-1).

[0335] The deprotection step of step C-2 is to remove the protecting group (P 4 The deprotection reaction conditions can be selected depending on the type of the group. The deprotection reaction is carried out according to a method known per se, for example, the method described in "Protective Groups in Organic Synthesis, 4th Ed." (Theodora W. Greene, Peter GM Wuts), published by Wiley-Interscience in 2007; "Protective Groups, 3rd Ed." (PJ Kocienski), published by Thieme in 2004, or the method described in the Examples below.

[0336] (Step C-3) This step is a step of producing a compound (12-1) by reacting a compound (10-1) with a compound (11-1) in the presence of a base.

[0337] The amount of the compound (11-1) used is 1 to 5 moles, preferably 1 to 3 moles, per mole of the compound (10-1).

[0338] Examples of the base include organic bases such as triethylamine, pyridine, and N,N-diisopropylethylamine; and inorganic bases such as sodium carbonate, potassium carbonate, and cesium carbonate. Among these, triethylamine or N,N-diisopropylethylamine is preferred. The amount of the base used is usually 1 mol to 5 mol, preferably 1.5 mol, per 1 mol of compound (10-1).

[0339] The reaction may be carried out in the presence of an additive such as tetrabutylammonium iodide (TBAI), sodium iodide, silver trifluoromethanesulfonate, etc. The amount of the additive used is usually 0 to 1.5 moles per mole of compound (10-1).

[0340] This reaction can be carried out in a solvent that does not affect the reaction. The reaction solvent is not particularly limited, but examples thereof include aromatic hydrocarbons such as toluene and xylene; amide solvents such as N,N-dimethylformamide and N,N-dimethylacetamide; ethers such as diethyl ether, tetrahydrofuran and dioxane; halogenated hydrocarbons such as chloroform and dichloromethane; nitriles such as acetonitrile; and mixtures thereof.

[0341] The reaction temperature is usually 0° C. to 100° C., preferably 0° C. to 50° C., and the reaction time is usually 1 hour to 48 hours.

[0342] When the product obtained in this reaction contains a halogen, the halo group can be converted to an alkyl group or a cycloalkyl group by a subsequent coupling reaction.

[0343] (Step C-4) This step is to remove the protecting group (P 5 ) to obtain compound (Ic).

[0344] The deprotection step of step C-4 is to remove the protecting group (P 5 The deprotection reaction conditions can be selected depending on the type of the group. The deprotection reaction is carried out according to a method known per se, for example, the method described in "Protective Groups in Organic Synthesis, 4th Ed." (Theodora W. Greene, Peter GM Wuts), published by Wiley-Interscience in 2007; "Protective Groups, 3rd Ed." (PJ Kocienski), published by Thieme in 2004, or the method described in the Examples below.

[0345] When the product obtained in this reaction contains a halogen, the halo group can be converted to an alkyl group or a cycloalkyl group by a subsequent coupling reaction.

[0346] [Production Method (D)] In this production method, compound (10-1) and compound (13-1) are subjected to a reductive alkylation reaction to obtain compound (14-1), and then a protecting group (P 6) to obtain compound (Id).

[0347]

[0348] (In the formula, R 1c -P 6 is a protected R 1 represents P 6 represents a protecting group, L a represents a divalent organic group, and the other symbols are as defined above.

[0349] (Step D-1) This step is a step of reacting compound (10-1) with a reducing agent and compound (13-1) in a solvent that does not affect the reaction (reductive alkylation reaction) to obtain compound (14-1).

[0350] The amount of the compound (13-1) used is 1 to 3 moles, preferably 1 to 2 moles, per mole of the compound (10-1).

[0351] The reducing agent is not particularly limited, but examples thereof include sodium triacetoxyborohydride, sodium borohydride, etc. The amount of the reducing agent used is 1 mol to 10 mol, preferably 1 mol to 3 mol, per 1 mol of compound (10-1).

[0352] The reaction may be carried out in the presence of an additive such as an organic acid such as acetic acid, or a Lewis acid such as titanium(IV) tetrachloride or tetraisopropyl titanate. The amount of the additive used is 1 to 10 moles, preferably 1 to 3 moles, per mole of compound (10-1).

[0353] The reaction solvent is not particularly limited, but examples thereof include aromatic hydrocarbons such as benzene, toluene, and xylene; alcohols such as methanol and ethanol; ethers such as tetrahydrofuran; halogenated hydrocarbons such as chloroform and dichloromethane; and mixtures thereof.

[0354] The reaction temperature is usually from −10° C. to 100° C., preferably from 10° C. to 50° C., and the reaction time is usually from 1 hour to 48 hours.

[0355] (Step D-2) This step is to convert the protecting group (P 6 ) to obtain compound (Id).

[0356] The deprotection step of step D-2 is to remove the protecting group (P 6 The deprotection reaction conditions can be selected depending on the type of the group. The deprotection reaction is carried out according to a method known per se, for example, the method described in "Protective Groups in Organic Synthesis, 4th Ed." (Theodora W. Greene, Peter GM Wuts), published by Wiley-Interscience in 2007; "Protective Groups, 3rd Ed." (PJ Kocienski), published by Thieme in 2004, or the method described in the Examples below.

[0357] [Production Method (E)] In this production method, compound (8-1) is reacted with compound (11-1) to obtain compound (15-1), and then a protecting group (P 4 ) is deprotected to obtain compound (16-1), which is then condensed with compound (1-1) to obtain compound (12-1), and then the protecting group (P 5 Compound (1-1) can be preferably synthesized by a method known per se (see, for example, the specification of U.S. Pat. No. 10,836,736, etc.).

[0358]

[0359] (The symbols in the formula have the same meanings as defined above.)

[0360] (Step E-1) This step is a step of producing compound (15-1) by reacting compound (8-1) with compound (11-1) in the presence of a base. The amount of compound (11-1) used is 1 mol to 5 mol, preferably 1 mol to 3 mol, per 1 mol of compound (8-1).

[0361] Step E-1 can be carried out under the same conditions as in the above step C-3, except that compound (8-1) is used instead of compound (10-1).

[0362] (Step E-2) This step is to remove the protecting group (P 4 ) to obtain compound (16-1).

[0363] The deprotection step of step E-2 is to remove the protecting group (P 4 The deprotection reaction conditions can be selected depending on the type of the group. The deprotection reaction is carried out according to a method known per se, for example, the method described in "Protective Groups in Organic Synthesis, 4th Ed." (Theodora W. Greene, Peter GM Wuts), published by Wiley-Interscience in 2007; "Protective Groups, 3rd Ed." (PJ Kocienski), published by Thieme in 2004, or the method described in the Examples below.

[0364] (Step E-3) This step is a step of producing a compound (12-1) by condensing the compound (16-1) with the compound (1-1) in the presence of a condensing agent.

[0365] The amount of the compound (16-1) used is 0.8 to 5 moles, preferably 0.8 to 3 moles, per mole of the compound (1-1).

[0366] In step E-3, the reaction can be carried out under the same conditions as in step A-1, except that compound (16-1) is used instead of compound (2-1).

[0367] When the product obtained in this reaction contains a halogen, the halo group can be converted to an alkyl group or a cycloalkyl group by a subsequent coupling reaction.

[0368] (Step E-4) This step is to remove the protecting group (P 5 ) to obtain compound (Ic).

[0369] The deprotection step of step E-4 is to remove the protecting group (P 5The deprotection reaction conditions can be selected depending on the type of the group. The deprotection reaction is carried out according to a method known per se, for example, the method described in "Protective Groups in Organic Synthesis, 4th Ed." (Theodora W. Greene, Peter GM Wuts), published by Wiley-Interscience in 2007; "Protective Groups, 3rd Ed." (PJ Kocienski), published by Thieme in 2004, or the method described in the Examples below.

[0370] When the product obtained in this reaction contains a halogen, the halo group can be converted to an alkyl group or a cycloalkyl group by a subsequent coupling reaction.

[0371] [Production Method (F)] In this production method, compound (8-1) is reacted with compound (13-1) to obtain compound (17-1), and then a protecting group (P 4 ) is deprotected to obtain compound (18-1), which is then reacted with compound (1-1) to convert it to compound (14-1), and then the protecting group (P 6 ) to obtain compound (Id).

[0372]

[0373] (The symbols in the formula have the same meanings as defined above.)

[0374] (Step F-1) This step is a step of reacting compound (8-1) with a reducing agent and compound (13-1) in a solvent that does not affect the reaction (reductive alkylation reaction) to obtain compound (17-1).

[0375] The amount of the compound (13-1) used is 1 to 3 moles, preferably 1 to 2 moles, per mole of the compound (8-1).

[0376] In step F-1, the reaction can be carried out under the same conditions as in step D-1, except that compound (8-1) is used instead of compound (10-1).

[0377] (Step F-2) This step is to remove the protecting group (P 4) to obtain compound (18-1).

[0378] The deprotection step of step F-2 is to remove the protecting group (P 4 The deprotection reaction conditions can be selected depending on the type of the protecting group. The deprotection reaction is carried out according to a method known per se, for example, a method described in "Protective Groups in Organic Synthesis, 4th Ed." (Theodora W. Greene, Peter GM Wuts), published by Wiley-Interscience in 2007; "Protective Groups, 3rd Ed." (PJ Kocienski), published by Thieme in 2004, or a method described in the Examples below.

[0379] (Step F-3) This step is a step of producing a compound (14-1) by condensing the compound (18-1) with the compound (1-1) in the presence of a condensing agent.

[0380] The amount of the compound (18-1) used is 0.8 to 5 moles, preferably 0.8 to 3 moles, per mole of the compound (1-1).

[0381] In step F-3, the reaction can be carried out under the same conditions as in step A-1, except that compound (18-1) is used instead of compound (2-1).

[0382] When the product obtained in this reaction contains a halogen, the halo group can be converted to an alkyl group or a cycloalkyl group by a subsequent coupling reaction.

[0383] (Step F-4) This step is to remove the protecting group (P 6 ) to obtain compound (Id).

[0384] The deprotection step of step F-4 is to remove the protecting group (P 6The deprotection reaction conditions can be selected depending on the type of the group. The deprotection reaction is carried out according to a method known per se, for example, the method described in "Protective Groups in Organic Synthesis, 4th Ed." (Theodora W. Greene, Peter GM Wuts), published by Wiley-Interscience in 2007; "Protective Groups, 3rd Ed." (PJ Kocienski), published by Thieme in 2004, or the method described in the Examples below.

[0385] When the product obtained in this reaction contains a halogen, the halo group can be converted to an alkyl group or a cycloalkyl group by a subsequent coupling reaction.

[0386] [Production Method (G)] In this production method, compound (8-1) is reacted with compound (19-1) to obtain compound (20-1), and then a protecting group (P 4 ) to obtain compound (21-1), which is then reacted with compound (11-1) to convert it to compound (22-1), and then the protecting group (P 7 ) is removed to give compound (23-1), which is then reacted with compound (24-1) to give compound (12-1), and the protecting group (P 5 ) to obtain compound (Ic).

[0387]

[0388] (The symbols in the formula have the same meanings as defined above.)

[0389] (Step G-1) This step is a step in which compound (19-1) is reacted with a halogenating agent in a solvent that does not influence the reaction to generate an acid halide, and then the acid halide is reacted with compound (8-1) to obtain compound (20-1).

[0390] The amount of the compound (19-1) used is 1 to 3 moles, preferably 1 to 2 moles, per mole of the compound (8-1).

[0391] The halogenating agent is not particularly limited, but examples thereof include thionyl chloride, sulfuryl chloride, phosphorus trichloride, phosphorus pentachloride, phosphorus oxychloride, oxalyl chloride, etc. The amount of the halogenating agent used is 1 mol to 10 mol, preferably 1 mol to 3 mol, per 1 mol of compound (19-1).

[0392] The reaction may be carried out in the presence of an additive such as DMF. The amount of the additive used is 0.05 mol to 1 mol, preferably 10.05 mol to 0.1 mol, per 1 mol of compound (19-1).

[0393] The reaction solvent is not particularly limited, but examples thereof include aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as tetrahydrofuran; halogenated hydrocarbons such as chloroform and dichloromethane; and mixtures thereof.

[0394] The reaction temperature is usually from −10° C. to 100° C., preferably from 10° C. to 50° C., and the reaction time is usually from 1 hour to 48 hours.

[0395] (Step G-2) This step is to convert the protecting group (P 4 ) to obtain compound (21-1).

[0396] The deprotection step of step G-2 is to remove the protecting group (P 4 The deprotection reaction conditions can be selected depending on the type of the group. The deprotection reaction is carried out according to a method known per se, for example, the method described in "Protective Groups in Organic Synthesis, 4th Ed." (Theodora W. Greene, Peter GM Wuts), published by Wiley-Interscience in 2007; "Protective Groups, 3rd Ed." (PJ Kocienski), published by Thieme in 2004, or the method described in the Examples below.

[0397] (Step G-3) This step is a step of producing compound (22-1) by reacting compound (21-1) with compound (11-1) in the presence of a base. The amount of compound (11-1) used is 1 mol to 5 mol, preferably 1 mol to 3 mol, per 1 mol of compound (21-1).

[0398] Step G-3 can be carried out under the same conditions as in the above step C-3, except that compound (21-1) is used instead of compound (10-1).

[0399] (Step G-4) This step is to remove the protecting group (P 7 ) to obtain compound (23-1).

[0400] The deprotection step of step G-4 is to remove the protecting group (P 7 The deprotection reaction conditions can be selected depending on the type of the protecting group. The deprotection reaction is carried out according to a method known per se, for example, a method described in "Protective Groups in Organic Synthesis, 4th Ed." (Theodora W. Greene, Peter GM Wuts), published by Wiley-Interscience in 2007; "Protective Groups, 3rd Ed." (PJ Kocienski), published by Thieme in 2004, or a method described in the Examples below.

[0401] (Step G-5) This step is a step of producing a compound (12-1) by condensing the compound (23-1) with the compound (24-1) in the presence of a condensing agent.

[0402] The amount of the compound (23-1) used is 0.8 to 5 moles, preferably 0.8 to 3 moles, per mole of the compound (24-1).

[0403] In step G-5, the reaction can be carried out under the same conditions as in step A-1, except that compound (23-1) is used instead of compound (2-1).

[0404] (Step G-6) This step is to remove the protecting group (P 5 ) to obtain compound (Ic).

[0405] The deprotection step of step G-6 is to remove the protecting group (P 5 The deprotection reaction conditions can be selected depending on the type of the protecting group. The deprotection reaction is carried out according to a method known per se, for example, a method described in "Protective Groups in Organic Synthesis, 4th Ed." (Theodora W. Greene, Peter GM Wuts), published by Wiley-Interscience in 2007; "Protective Groups, 3rd Ed." (PJ Kocienski), published by Thieme in 2004, or a method described in the Examples below.

[0406] The compound (I) or a pharmaceutically acceptable salt thereof obtained by the above-mentioned production method can be isolated and purified by ordinary separation means such as recrystallization, distillation, chromatography, etc.

[0407] When compound (I) of the present invention or a pharmaceutically acceptable salt thereof exists as an optical isomer based on an asymmetric carbon, it can be separated into individual optical isomers by conventional optical resolution means (e.g., fractional crystallization, resolution using a chiral column). Alternatively, optical isomers can be synthesized using optically pure starting materials. Furthermore, optical isomers can also be synthesized by stereoselectively carrying out each reaction using an asymmetric auxiliary group or an asymmetric catalyst.

[0408] (Medicine (Pharmaceutical Composition) of the Present Invention) The medicament of the present invention is a medicament for preventing and / or treating a disease whose symptoms can be alleviated by B0AT1 inhibitory action, which contains compound (I) or a pharmaceutically acceptable salt thereof as an active ingredient. Specifically, the medicament of the present invention is at least one of a medicament for preventing the onset of a disease whose symptoms can be alleviated by B0AT1 inhibitory action, and a medicament for ameliorating the symptoms of the disease, which contains the active ingredient.

[0409] The pharmaceutical of the present invention may be either a pharmaceutical consisting of compound (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising compound (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, etc. The pharmaceutical of the present invention can be administered to a subject (e.g., mouse, rat, hamster, rabbit, cat, dog, cow, sheep, monkey, human, etc.) in a prophylactically effective amount or a therapeutically effective amount.

[0410] Examples of pharmaceutically acceptable carriers include excipients (e.g., starch, lactose, sugar, calcium carbonate, calcium phosphate, etc.), binders (e.g., starch, gum arabic, carboxymethylcellulose, hydroxypropylcellulose, crystalline cellulose, etc.), lubricants (e.g., magnesium stearate, talc, etc.), disintegrants (e.g., carboxymethylcellulose, talc, etc.), solvents (e.g., water for injection, physiological saline, Ringer's solution, alcohol, propylene glycol, polyethylene glycol, sesame oil, corn oil, olive oil, cottonseed oil, etc.), solubilizing agents (e.g., polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, sodium salicylate, sodium acetate, etc.), suspending agents (e.g., surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glycerin monostearate; polyvinyl alcohol hydrophilic polymers such as cellulose acetate, polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylcellulose; polysorbates, polyoxyethylene hydrogenated castor oil, and the like), isotonic agents (for example, sodium chloride, glycerin, D-mannitol, D-sorbitol, glucose, and the like), buffers (for example, buffer solutions such as phosphates, acetates, carbonates, and citrates, and the like), soothing agents (for example, benzyl alcohol, and the like), preservatives (for example, parahydroxybenzoates, , chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid, etc.), antioxidants (e.g., sulfites, ascorbates, etc.), coloring agents (e.g., water-soluble food tar dyes (e.g., food dyes such as Food Red No. 2 and No. 3, Food Yellow No. 4 and No. 5, Food Blue No. 1 and No. 2), water-insoluble lake dyes (e.g., aluminum salts of the above-mentioned water-soluble food tar dyes), natural dyes (e.g., β-carotene, chlorophyll, red iron oxide), etc.), sweeteners (e.g., saccharin sodium, dipotassium glycyrrhizinate, stevia, etc.), and the like.

[0411] The medicament (pharmaceutical composition) of the present invention can be prepared by mixing the above-mentioned components and then processing the mixture according to known means into preparations for oral administration such as tablets, fine granules, granules, capsules, dry syrup, etc., or for parenteral administration such as injections (e.g., subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, drip infusions, etc.), topical preparations (e.g., transdermal preparations, ointments, lotions, patches), suppositories (e.g., rectal suppositories, vaginal suppositories), pellets, nasal preparations, pulmonary preparations (inhalants), eye drops, implants, microcapsules, liposome preparations, etc. Among these, oral preparations such as tablets are preferred as the medicament of the present invention.

[0412] The content of compound (I) of the present invention or a pharmaceutically acceptable salt thereof in the medicament (pharmaceutical composition) of the present invention varies depending on the form of the preparation, but is usually in the range of about 0.01 to 100% by weight, preferably about 0.1 to 50% by weight, and more preferably about 0.5 to 20% by weight, based on the total weight of the preparation.

[0413] The dosage of compound (I) of the present invention, or a pharmaceutically acceptable salt thereof, can be appropriately selected depending on the subject of administration (such as the subject's age, body weight, general health condition, sex, and severity of the condition), the administration route, the type of disease, and the type of concomitant medication. For example, in the case of humans, when orally administered to an adult patient (body weight approximately 60 kg), the daily dosage of compound (I) or a pharmaceutically acceptable salt thereof is generally 0.001 mg to 1000 mg, preferably 0.01 mg to 100 mg, calculated as the active ingredient, of compound (I), and can be administered once or several times a day, regardless of whether it is before, after, or between meals. The administration period is not particularly limited.

[0414] Compound (I) of the present invention, or a pharmaceutically acceptable salt thereof, is useful for preventing the onset of or treating diseases whose symptoms can be alleviated by B0AT1 inhibitory activity, particularly amino acid metabolism disorders such as phenylketonuria, urea cycle disorders, hypertyrosinemia (type 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemia, and isovaleric acidemia.

[0415] Compound (I) of the present invention, or a pharmaceutically acceptable salt thereof, can be administered (concomitantly used) in combination with other drugs (concomitant drugs) as long as the efficacy of the compound (I) is not impaired. The concomitant drugs are not particularly limited, and for example, one or more known drugs conventionally used in the treatment of the above-mentioned "diseases whose symptoms can be alleviated by B0AT1 inhibitory action" can be suitably used.

[0416] Specifically, when compound (I) of the present invention or a pharmaceutically acceptable salt thereof is used for the treatment and / or prevention of amino acid metabolism disorders such as phenylketonuria, urea cycle disorders, hypertyrosinemia (type 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemia, and isovaleric acidemia, examples of concomitant drugs include vitamin preparations (e.g., folic acid (vitamin B9), nicotinamide (vitamin B3), thiamine (vitamin B1), pyridoxine (vitamin B6), etc.) and drugs for alleviating various symptoms of amino acid metabolism disorders (for example, LNAAs such as L-dopa and 5-hydroxytryptophan, sapropterin hydrochloride, pegvaliase, nicotinic acid, nitisinone, S-adenosylmethionine, betaine, aspirin, dipyridamole, sodium benzoate, sodium phenylbutyrate, dextromethorphan, ketamine, antidepressants, anti-anxiety drugs, drugs for treating ADHD, etc.).

[0417] When a concomitant drug is used, the administration timing is not limited, and they may be administered to the subject simultaneously or at staggered times. Staggered administration may involve administering the medicament of the present invention first and the concomitant drug later, or the concomitant drug first and the medicament of the present invention later. The respective administration methods may be the same or different. Furthermore, compound (I) of the present invention or a pharmaceutically acceptable salt thereof may be administered in combination with the concomitant drug as a single formulation.

[0418] The dosage of the concomitant drug can be appropriately selected based on the clinically used dosage. The compounding ratio of the compound of the present invention or a pharmaceutically acceptable salt thereof to the concomitant drug can be appropriately selected depending on the subject (the subject's age, body weight, general health condition, sex, severity of disease, etc.), administration route, type of disease, type of concomitant drug, etc.

[0419] The mass ratio of compound (I) or a pharmaceutically acceptable salt thereof to the concomitant drug is not particularly limited.

[0420] Furthermore, concomitant drugs that complement and / or enhance the therapeutic effect of compound (I) or a pharmaceutically acceptable salt thereof also include those that have not been discovered so far but will be discovered in the future, based on the above-mentioned mechanism.

[0421] Furthermore, in order to complement and / or enhance the therapeutic effect of compound (I) or a pharmaceutically acceptable salt thereof, it is also effective to use it in combination with a dietary therapy that avoids the intake of specific amino acids or enzyme replacement therapy.

[0422] The medicament or pharmaceutical composition of the present invention may be provided in the form of a kit together with instructions for administration and the like. The drugs contained in the kit are supplied in a container made of a material that maintains the activity of the components of the medicament or pharmaceutical composition for a long period of time, does not adsorb to the inside of the container, and does not alter the components. For example, a sealed glass ampoule may contain a buffer or the like sealed in the presence of a neutral, non-reactive gas such as nitrogen gas. The kit may also include instructions for use. The instructions for use of the kit may be printed on paper or stored on an electromagnetically readable medium such as a CD-ROM or DVD-ROM and provided to the user.

[0423] The present invention will be described in detail below based on Reference Examples, Examples, and Test Examples, but the present invention is not limited to the Examples and Test Examples and may be modified within the scope of the present invention. Furthermore, reagents, devices, and materials used in the present invention are commercially available unless otherwise specified.

[0424] % indicates mol / mol% for yield, and % by weight for other values ​​unless otherwise specified. Furthermore, unless otherwise specified, room temperature indicates a temperature between 15°C and 30°C. Below, * in the structural formulas indicates racemic carbon. Other abbreviations used in the text have the following meanings. THF: tetrahydrofuran DMSO: dimethyl sulfoxide DMF: N,N-dimethylformamide HATU: O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate WSC: 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide HOBt: 1-hydroxybenzotriazole

[0425] Unless otherwise specified, the raw material compounds used in the following Reference Examples and Examples are known compounds, and were synthesized and identified according to methods known per se (e.g., U.S. Pat. No. 10,836,736; Bioorganic & Medicinal Chemistry Letters, 2017, 27(21), 4805-4811; J. Med. Chem., 2014, 57, 3687-3706; WO 2013 / 067274), or methods equivalent thereto.

[0426] Reference Example 1: Preparation of 6-bromo-4-methoxy-1,2,3,4-tetrahydroisoquinoline

[0427]

[0428] (1) To a solution of 6-bromo-2-(2-nitrophenyl)sulfonyl-3,4-dihydro-1H-isoquinolin-4-ol (300 mg) in toluene (2 ml), tetrabutylammonium hydrogen sulfate (25 mg), iodomethane (206 mg), and potassium hydroxide (50% w / v, 2 ml) were added, and the reaction mixture was stirred at 50°C for 1 hour. Water was added to the reaction mixture, and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 50 / 50) to give 6-bromo-4-methoxy-2-(2-nitrophenyl)sulfonyl-3,4-dihydro-1H-isoquinoline (295 mg; yield 95%) as a colorless viscous oil. MS (ESI) m / z: 397.1 / 399.1 [M-ОMe+H] +

[0429] (2) To a solution of 6-bromo-4-methoxy-2-(2-nitrophenyl)sulfonyl-3,4-dihydro-1H-isoquinoline (295 mg) obtained in (1) above in DMF (2 ml) were added potassium carbonate (191 mg) and phenylmethanethiol (172 mg), and the reaction mixture was stirred at room temperature for 3 hours. Water was added to the reaction mixture, and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and dried under reduced pressure to obtain the crude product of the title compound (167 mg; yield 99%) as a brown viscous oil.

[0430] Reference Example 2: Preparation of methyl 3-(1-methylpiperazin-2-yl)benzoate

[0431]

[0432] (1) Benzyl 3-(3-bromophenyl)piperazine-1-carboxylate (1.4 g) was dissolved in THF (12 ml), and acetic acid (2 ml), aqueous formalin (37%, 1.4 ml), and sodium triacetoxyborate (1.58 g) were added. The reaction mixture was stirred at room temperature for 30 minutes. Aqueous sodium hydroxide solution (1 mol / l) and chloroform were added to the reaction mixture, and the organic layer was separated. The aqueous layer was then extracted with chloroform. The combined organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was evaporated under reduced pressure to give crude benzyl 3-(3-bromophenyl)-4-methylpiperazine-1-carboxylate (1.47 g) as a yellow oil.

[0433] (2) The crude product (350 mg) of benzyl 3-(3-bromophenyl)-4-methylpiperazine-1-carboxylate obtained in (1) above was dissolved in acetonitrile (6 ml), and methanol (3 ml), molybdenum hexacarbonyl (239 mg), and DBU (0.28 ml) were added. The atmosphere was then purged with nitrogen. Bis(tri-tert-butylphosphine)palladium(0) (46 mg) was added to the reaction mixture, and the mixture was stirred at 140°C for 30 minutes under microwave irradiation. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 50 / 50 to 25 / 75) to give benzyl 3-(3-methoxycarbonylphenyl)-4-methylpiperazine-1-carboxylate (306 mg; yield 92.4%) as a yellow oil. MS (ESI) m / z: 369.2 [M+H] +

[0434] (3) Benzyl 3-(3-methoxycarbonylphenyl)-4-methylpiperazine-1-carboxylate (306 mg) obtained in (2) above was dissolved in methanol (2.8 ml), palladium hydroxide (30 mg) was added, and the atmosphere was replaced with hydrogen. The reaction mixture was stirred at 60°C for 4 hours and 30 minutes, then cooled to room temperature, filtered through Celite, and washed with methanol. The filtrate was concentrated under reduced pressure to obtain the title compound (265 mg; yield 136.2%) as a yellow amorphous substance. MS (ESI) m / z: 235.2 [M+H] +

[0435] Reference Example 3: Preparation of methyl 2-[2-(1,2,3,6-tetrahydropyridin-5-yl)phenyl]acetate hydrochloride

[0436]

[0437] (1) tert-Butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (1.0 g) was dissolved in 1,4-dioxane (40 ml), methyl 2-(2-bromophenyl)acetate (890 mg), tetrakis(triphenylphosphine)palladium (380 mg), cesium carbonate (2.1 g), and water (10 ml) were added, and the reaction mixture was stirred at 90° C. for 1 hour. The reaction mixture was cooled to room temperature, water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate=80 / 20 to 50 / 50) to give tert-butyl 5-[2-(2-methoxy-2-oxoethyl)phenyl]-3,6-dihydro-2H-pyridine-1-carboxylate (1.0 g; yield 93.3%) as a colorless oil.

[0438] (2) tert-Butyl 5-[2-(2-methoxy-2-oxoethyl)phenyl]-3,6-dihydro-2H-pyridine-1-carboxylate (300 mg) obtained in (1) above was dissolved in methanol (3 ml), and a hydrogen chloride-1,4-dioxane solution (4 mol / l, 3 ml) was added. The reaction mixture was stirred at room temperature for 1 hour and then concentrated under reduced pressure at 40°C to give the title compound (242 mg) as a crude product in the form of a colorless amorphous substance.

[0439] Reference Example 4: Preparation of methyl 2-(3-piperidin-3-ylphenyl)acetate hydrochloride

[0440]

[0441] (1) tert-butyl 5-[2-(2-methoxy-2-oxoethyl)phenyl]-3,6-dihydro-2H-pyridine-1-carboxylate (700 mg) obtained in Step (1) of Reference Example 3 was dissolved in methanol (10 ml), and palladium-carbon (10%, 200 mg) was added. The reaction mixture was purged with hydrogen and stirred at room temperature for 2 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 95 / 5 to 80 / 20) to give tert-butyl 3-[3-(2-methoxy-2-oxoethyl)phenyl]piperidine-1-carboxylate (580 mg; yield 82.3%) as a colorless oil. MS (ESI) m / z: 334.1 [M+H] +

[0442] (2) tert-Butyl 3-[3-(2-methoxy-2-oxoethyl)phenyl]piperidine-1-carboxylate (580 mg) obtained in (1) above was dissolved in methanol (6 ml), and a hydrogen chloride-1,4-dioxane solution (4 mol / l, 6 ml) was added. The reaction mixture was stirred at room temperature for 1 hour and then concentrated under reduced pressure at 40°C to give the title compound (469 mg) as a crude product in the form of a colorless amorphous substance.

[0443] Reference Example 5: Preparation of tert-butyl 3-(5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)propanoate

[0444]

[0445] (1) To a mixture of 2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine hydrochloride (400 mg), benzyloxycarbonyl chloride (0.48 ml), sodium bicarbonate (326 mg), and 1,4-dioxane (6.4 ml) was added water (1.8 ml) and stirred at room temperature for 18 hours. Water was added to the reaction mixture, and the organic layer was extracted with ethyl acetate. The combined organic layer was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 30 / 70) to give benzyl 2-chloro-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylate (535 mg; yield 80%) as a colorless viscous oil. MS (ESI) m / z: 304.1 / 306.1 [M+H] +

[0446] (2) To a mixture of benzyl 2-chloro-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylate (535 mg) obtained in (1), palladium(II) chloride.bis[4-(N,N-dimethylamino)phenyl]di-tert-butylphosphine (124 mg), tert-butyl (E)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-2-enoate (538 mg), cesium carbonate (1.15 g), and 1,4-dioxane (3 ml), water (0.8 ml) was added and the mixture was stirred under microwave irradiation at 140°C for 1 hour. Water was added to the reaction mixture, and the organic layer was extracted with ethyl acetate. The combined organic layer was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 30 / 70) to give benzyl 2-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylate (318 mg; yield 46%) as a yellow viscous oil. MS (ESI) m / z: 396.2 [M+H] +

[0447] (3) To a solution of benzyl 2-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylate (52 mg) obtained in (2) above in ethanol (1.4 ml) was added palladium(II) hydroxide (20 mg), and the mixture was stirred under a hydrogen atmosphere at room temperature for 3 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to give the title compound (35 mg) as a crude product as a colorless viscous oil.

[0448] Reference Example 6: Preparation of methyl 3-(indolin-4-yl)propanoate trifluoroacetate

[0449]

[0450] (1) tert-Butyl 4-bromoindoline-1-carboxylate (500 mg) was dissolved in 1,4-dioxane (4.5 ml), and water (1 ml), cesium carbonate (1.1 g), ethyl (E)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-2-enoate (570 mg), and bis(4-di-tert-butylphosphanyl-N,N-dimethylaniline)dichloropalladium(II) (100 mg) were added to the reaction mixture. The reaction mixture was stirred under microwave irradiation at 110°C for 2 hours and 30 minutes. The reaction mixture was cooled to room temperature and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure to give crude tert-butyl 4-[(E)-3-ethoxy-3-oxoprop-1-enyl]indoline-1-carboxylate (560 mg) as a brown solid.

[0451] (2) The crude product (560 mg) of tert-butyl 4-[(E)-3-ethoxy-3-oxoprop-1-enyl]indoline-1-carboxylate obtained in (1) above was dissolved in methanol (25 ml), magnesium (500 mg) was added, and the mixture was stirred at room temperature for 14 hours. The reaction mixture was diluted with ethyl acetate and washed with hydrochloric acid (1 mol / l). The organic layer was dried over sodium sulfate and then extracted with NH 2Silica gel was added and the mixture was filtered, and the filtrate was concentrated under reduced pressure to give crude tert-butyl 4-(3-methoxy-3-oxopropyl)indoline-1-carboxylate (550 mg) as a yellow oil.

[0452] (3) The crude product (247 mg) of tert-butyl 4-(3-methoxy-3-oxopropyl)indoline-1-carboxylate obtained in (2) above was dissolved in dichloromethane (1 ml), trifluoroacetic acid (1.3 ml) was added, and the mixture was stirred at room temperature for 1 hour. The solvent was evaporated under reduced pressure, toluene was added to the residue, and the mixture was again concentrated under reduced pressure to give the crude product (258.2 mg) of the title compound.

[0453] Reference Example 7: Preparation of tert-butyl 2-(5-cyano-1,2,3,4-tetrahydroisoquinolin-6-yl)acetate

[0454]

[0455] (1) 1-Chloropyrrolidine-2,5-dione (1.3 g) was added to a solution of 6-bromoisoquinoline (1 g) in sulfuric acid (10 ml), and the mixture was stirred at 50°C for 3 hours. 1-Chloropyrrolidine-2,5-dione (1.3 g) was added, and the mixture was stirred at 50°C for an additional 15 hours. Water and sodium hydroxide were added to the reaction mixture, and the organic layer was extracted with ethyl acetate. The combined organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 30 / 70) to give 6-bromo-5-chloroisoquinoline (824 mg; yield 71%) as a white solid. MS (ESI) m / z: 242.0 / 244.0 [M+H] +

[0456] (2) To a solution of 6-bromo-5-chloroisoquinoline (824 mg) obtained in (1) above in acetic acid (10 ml) was added sodium borohydride (141 mg) under ice-cooling, and the mixture was stirred at room temperature for 1 hour. Sodium borohydride (71 mg) was added under ice-cooling, and the mixture was stirred at room temperature for an additional 2 hours. The reaction mixture was neutralized with aqueous sodium hydroxide, and the organic layer was extracted with ethyl acetate. The combined organic layers were washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain crude 6-bromo-5-chloro-1,2,3,4-tetrahydroisoquinoline (837 mg) as a white solid.

[0457] (3) Ethyl acetate (4 ml) and hydrogen chloride (4 mol / l 1,4-dioxane solution) (0.93 ml) were added to the crude 6-bromo-5-chloro-1,2,3,4-tetrahydroisoquinoline (837 mg) obtained in (2), and the precipitated solid was collected by filtration to obtain 6-bromo-5-chloro-1,2,3,4-tetrahydroisoquinoline hydrochloride (766 mg; yield 80%) as a white solid. MS (ESI) m / z: 246.0 / 248.0 [M+H] +

[0458] (4) To a mixture of 6-bromo-5-chloro-1,2,3,4-tetrahydroisoquinoline hydrochloride (1 g) obtained in (3), pyridine (7 ml), and N,N-dimethylpyridin-4-amine (43 mg), trifluoroacetic anhydride (1.5 g) was added under ice cooling, and the mixture was stirred at room temperature for 2 hours. Water and 1 mol / L hydrochloric acid were added to the reaction mixture, and the organic layer was extracted with ethyl acetate. The combined organic layer was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 80 / 20) to give 1-(6-bromo-5-chloro-3,4-dihydro-1H-isoquinolin-2-yl)-2,2,2-trifluoroethanone (1.05 g; yield 87%) as a white solid. 1 H-NMR (400MHz, CDCl 3) δppm: 3.05 (2H, t), 3.87 (2H, t), 4.76 (2H, s), 6.96 (1H, d), 7.53 (1H, d) ( * Rotamers were observed with an NMR integration ratio of approximately 2:1.

[0459] (5) 1-(6-bromo-5-chloro-3,4-dihydro-1H-isoquinolin-2-yl)-2,2,2-trifluoroethanone (1.05 g) obtained in (4) above, 1-tert-butoxyvinyloxy-tert-butyl-dimethylsilane (285 mg), potassium carbonate (114 mg), and bis(tri-tert-butylphosphine)palladium(0) (63 mg) were dissolved in DMF (7 ml) and stirred at 120°C for 1 hour under microwave irradiation. Water was added to the reaction mixture, and the organic layer was extracted with ethyl acetate. The combined organic layer was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 30 / 70) to give tert-butyl 2-[5-chloro-2-(2,2,2-trifluoroacetyl)-3,4-dihydro-1H-isoquinolin-6-yl]acetate (1.02 g; yield 76%) as a colorless viscous oil. MS (ESI) m / z: 322.1 [M-C 4 H 8 + H] +

[0460] (6) tert-Butyl 2-[5-chloro-2-(2,2,2-trifluoroacetyl)-3,4-dihydro-1H-isoquinolin-6-yl]acetate (1.02 g) obtained in (5) above, potassium hexacyanoferrate(II) trihydrate (1.65 g), [2-(2-aminophenyl)phenyl]chloropalladium; 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (212 mg), and potassium acetate (530 mg) were dissolved in 1,4-dioxane (50 ml), water (15 ml) was added, and the mixture was stirred at 100°C for 2 hours. After filtering the reaction mixture, water was added to the filtrate, and the organic layer was extracted with ethyl acetate. The combined organic layer was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate=100 / 0 to 80 / 20) to obtain tert-butyl 2-[5-cyano-2-(2,2,2-trifluoroacetyl)-3,4-dihydro-1H-isoquinolin-6-yl]acetate (551 mg; yield 55%) as a brown viscous oil. 1 H-NMR (400MHz, CDCl 3 ) δppm: 1.47 (9H, s), 3.18 (2H, t), 3.79 (2H, s), 3.91 (2H, t), 4.81 (2H, s), 7.29 (1H, d), 7.34 (1H, d). ( * Rotamers were observed with an NMR integration ratio of approximately 2:1.

[0461] (7) tert-Butyl 2-[5-cyano-2-(2,2,2-trifluoroacetyl)-3,4-dihydro-1H-isoquinolin-6-yl]acetate (551 mg) obtained in (6) above was dissolved in ethanol (9 ml), and 1 mol / l aqueous sodium hydroxide solution (5.4 ml) was added and stirred at room temperature for 1 hour. Water was added to the reaction mixture, and the organic layer was extracted with ethyl acetate. The combined organic layer was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 0 / 100) to obtain the title compound (172 mg; yield 42%) as a white solid. MS (ESI) m / z: 273.3 [M+H] +

[0462] Reference Example 8: Preparation of tert-butyl 2-(1,2,3,4-tetrahydroisoquinolin-6-yl)acetate

[0463]

[0464] (1) Benzyl 6-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylate (2 g), tert-butyl-(1-methoxyvinyloxy)-dimethylsilane (2.5 ml), potassium carbonate (1.6 g), and bis(tri-tert-butylphosphine)palladium(0) (886 mg) were dissolved in DMF (19 ml) and stirred at 120°C for 2 hours under microwave irradiation. Water was added to the reaction mixture, and the organic layer was extracted with ethyl acetate. The combined organic layer was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 70 / 30) to give benzyl 6-(2-methoxy-2-oxoethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (978 mg; yield 48%) as a yellow viscous oil. 1 H-NMR (400MHz, CDCl 3) δppm: 2.84 (2H, br-s), 3.58 (2H, s), 3.69 (3H, s), 3.72 (2H, s), 4.63 (2H, s), 5.18 (2H, s), 7.01-7.12 (3H, m), 7.29-7.42 (5H, m).

[0465] (2) Benzyl 6-(2-methoxy-2-oxoethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (1.41 g) obtained in (1) above was dissolved in methanol (31 ml), and a 4 mol / l aqueous solution of lithium hydroxide (9.2 ml) was added, followed by stirring at room temperature for 3 hours. The reaction mixture was neutralized, and the organic layer was extracted with ethyl acetate. The combined organic layers were washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain crude 2-(2-phenylmethoxycarbonyl-3,4-dihydro-1H-isoquinolin-6-yl)acetic acid (1.33 g) as a yellow viscous oil.

[0466] (3) The crude product (1.33 g) of 2-(2-phenylmethoxycarbonyl-3,4-dihydro-1H-isoquinolin-6-yl)acetic acid obtained in (2) above was dissolved in toluene (13.6 ml), and 1,1-di-tert-butoxy-N,N-dimethylmethanamine (4 ml) was added and stirred at 120°C for 3 hours. The reaction mixture was cooled and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 70 / 30) to obtain benzyl 6-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (428 mg; yield 26%) as a colorless viscous oil. MS (ESI) m / z: 380.4 [M-H] -

[0467] (4) Palladium(II) hydroxide (40 mg) was added to a solution of benzyl 6-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (400 mg) obtained in (3) above in ethanol (3.3 ml), and the mixture was stirred at room temperature under a hydrogen atmosphere for 3 hours. The reaction mixture was filtered through a membrane filter, and the filtrate was concentrated under reduced pressure to give the title compound (244 mg) as a crude product in the form of a white solid.

[0468] Reference Examples 9 to 21: The corresponding starting compounds were treated in the same manner as in Reference Example 8 to obtain crude products of the compounds listed in Tables 1-1 and 1-2 below.

[0469]

[0470]

[0471] Reference Example 22: Preparation of tert-butyl (2S)-1-(1,2,3,4-tetrahydroisoquinolin-6-yl)piperidine-2-carboxylate

[0472]

[0473] (1) To a mixture of benzyl 6-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylate (1.00 g), tert-butyl (2S)-piperidine-2-carboxylate (800 mg), bis(dibenzylideneacetone)palladium(0) (270 mg), 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl (135 mg), and toluene (30 ml), sodium tert-butoxide (1.10 g) was added and the mixture was stirred at 120°C for 1 hour. After allowing the reaction mixture to cool, water was added, and the organic layer was extracted with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 90 / 10 to 60 / 40) to give benzyl 6-[(2S)-2-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-1-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (113 mg; yield 9%) as a brown viscous oil. MS (ESI) m / z: 451.4 [M+H] +

[0474] (2) Benzyl 6-[(2S)-2-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-1-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (113 mg) obtained in (1) above was dissolved in methanol (5 ml), and then 10% palladium-carbon (100 mg) was added and the mixture was stirred at room temperature under a hydrogen atmosphere for 3 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to obtain the title compound as a crude product in the form of a brown solid.

[0475] Reference Example 23: Preparation of tert-butyl 1-(1,2,3,4-tetrahydroisoquinolin-6-yl)pyrrolidine-3-carboxylate

[0476]

[0477] (1) To a mixture of benzyl 6-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylate (1.00 g), tert-butyl pyrrolidine-3-carboxylate (600 mg), bis(dibenzylideneacetone)palladium(0) (270 mg), 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl (135 mg), and toluene (30 ml), sodium tert-butoxide (1.10 g) was added and the mixture was stirred at 120°C for 1 hour. After allowing the reaction mixture to cool, water was added, and the organic layer was extracted with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 90 / 10 to 60 / 40) to give benzyl 6-[3-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-1-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (517 mg; yield 41%) as a brown viscous oil. MS (ESI) m / z: 436.9 [M+H] +

[0478] (2) Benzyl 6-[3-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-1-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (517 mg) obtained in (1) above was dissolved in methanol (30 ml), and then 10% palladium-carbon (200 mg) was added and the mixture was stirred at room temperature under a hydrogen atmosphere for 3 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to obtain the title compound (311 mg; yield 87%) as a yellow solid. MS (ESI) m / z: 303.3 [M+H] +

[0479] Reference Example 24: Preparation of tert-butyl 1-(1,2,3,4-tetrahydroisoquinolin-6-yl)piperidine-4-carboxylate

[0480]

[0481] (1) To a mixture of benzyl 6-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylate (1.00 g), tert-butyl piperidine-4-carboxylate hydrochloride (770 mg), bis(dibenzylideneacetone)palladium(0) (270 mg), 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl (135 mg), and toluene (30 ml), N,N-diisopropylethylamine (0.6 ml) and sodium tert-butoxide (840 mg) were added, and the mixture was stirred at 120°C for 1 hour. After allowing the reaction mixture to cool, water was added, and the organic layer was extracted with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 90 / 10 to 60 / 40) to give benzyl 6-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-1-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (1.11 g; yield 85%) as a brown viscous oil. MS (ESI) m / z: 450.9 [M+H] +

[0482] (2) Benzyl 6-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-1-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (1.11 g) obtained in (1) above was dissolved in methanol (10 ml), and then 10% palladium-carbon (200 mg) was added and the mixture was stirred at room temperature under a hydrogen atmosphere for 3 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to obtain the title compound (707 mg; yield 91%) as a brown solid. MS (ESI) m / z: 317.3 [M+H] +

[0483] Reference Example 25: Preparation of tert-butyl 2-methyl-3-(1,2,3,4-tetrahydroisoquinolin-6-yl)propanoate

[0484]

[0485] (1) Benzyl 6-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylate (1 g), tert-butyl 2-methylprop-2-enoate (821 mg), potassium carbonate (567 mg), and [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(II) dichloride (394 mg) were dissolved in DMF (6 ml) and stirred at 120°C for 2 hours under microwave irradiation. Water was added to the reaction mixture, and the organic layer was extracted with ethyl acetate. The combined organic layer was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 30 / 70) to give benzyl 6-[2-methyl-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (1.06 g; yield 32%) as a colorless viscous oil. MS (ESI) m / z: 352.2 [M-C 4 H 8 +H] +

[0486] (2) Palladium(II) hydroxide (48 mg) was added to a solution of benzyl 6-[2-methyl-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (1.06 g) obtained in (1) above in ethanol (4 ml), and the mixture was stirred at room temperature under a hydrogen atmosphere for 3 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to give the title compound (1.04 g) as a crude product in the form of a colorless viscous oil.

[0487] Reference Example 26: Preparation of tert-butyl 3-(1,2,3,4-tetrahydroisoquinolin-6-yl)butanoate

[0488]

[0489] (1) Benzyl 6-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylate (1 g), tributyl(1-ethoxyvinyl)tin (1.27 ml), and bis(tri-tert-butylphosphine)palladium(0) (74 mg) were dissolved in DMF (9 ml) and stirred at 100°C for 1 hour under microwave irradiation. 1 mol / L hydrochloric acid was added to the reaction mixture, and the mixture was stirred at room temperature for 1 hour. Water was added to the reaction mixture, and the organic layer was extracted with ethyl acetate. The combined organic layers were washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 60 / 40) to give benzyl 6-acetyl-3,4-dihydro-1H-isoquinoline-2-carboxylate (67.1 mg; yield 8%) as a colorless viscous oil. 1 H-NMR (400MHz, CDCl 3 ) δppm: 2.58 (3H, s), 2.91 (2H, br-s), 3.75 (2H, t), 4.70 (2H, s), 5.19 (2H, s), 7.20 (1H, br-s), 7.29-7.45 (5H, m), 7.74 (1H, s), 7.77 (1H, d).

[0490] (2) Sodium hydride (60%, 17 mg) was added to a solution of tert-butyl 2-diethoxyphosphoryl acetate (109 mg) in THF (1.4 ml). To the reaction mixture was added a THF solution of benzyl 6-acetyl-3,4-dihydro-1H-isoquinoline-2-carboxylate (67.1 mg) obtained in (1) above, and the mixture was stirred at room temperature for 18 hours. Water was added to the reaction mixture, and the organic layer was extracted with ethyl acetate. The combined organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate=100 / 0 to 70 / 30) to obtain benzyl 6-[4-[(2-methylpropan-2-yl)oxy]-4-oxobut-2-en-2-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (68.5 mg; yield 78%) as a colorless viscous oil. 1H-NMR (400MHz, CDCl 3 ) δppm: 1.52 (9H, s), 2.51 (3H, d), 2.86 (2H, br-s), 3.73 (2H, br-s), 4.66 (2H, s), 5.18 (2H, s), 6.03 (1H, d), 6.94-7.16 (2H, m), 7.20-7.43 (6H, m). ( * A mixture of geometric isomers with an NMR integral ratio of approximately 3:1

[0491] (3) Palladium(II) hydroxide (8 mg) was added to a solution of benzyl 6-[4-[(2-methylpropan-2-yl)oxy]-4-oxobut-2-en-2-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (68.5 mg) obtained in (2) above in ethanol (1 ml), and the mixture was stirred at room temperature under a hydrogen atmosphere for 3 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to give the title compound (46.3 mg) as a crude product in the form of a colorless viscous oil.

[0492] Reference Example 27: Preparation of tert-butyl 1-(1,2,3,4-tetrahydroisoquinolin-6-yl)cyclopropane-1-carboxylate

[0493]

[0494] (1) A mixture of benzyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (2.2 g), tert-butyl 2-bromoacrylate (1.1 g), bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (190 mg), cesium carbonate (3.5 g), 1,4-dioxane (20 ml), and water (4 ml) was stirred in a microwave reactor at 140° C. for 1 hour. After cooling to room temperature, the reaction mixture was filtered and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 70 / 30) to give benzyl 6-[3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-en-2-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (725 mg; yield 31%) as a brown oil. MS (ESI) m / z: 338.1 [M-C 4 H 8 +H] +

[0495] (2) To a DMSO solution (6 ml) of trimethylsulfoxonium iodide (810 mg), 60% sodium hydride (148 mg) was added at 0°C, and the mixture was stirred for 10 minutes. A DMSO solution of benzyl 6-[3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-en-2-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (725 mg; 89 mass%) obtained in (1) above was added, and the mixture was stirred at room temperature for 18 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate=100 / 0 to 70 / 30) to obtain benzyl 6-[1-[(2-methylpropan-2-yl)oxycarbonyl]cyclopropyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (454 mg; yield 55%) as a yellow oil. 1 H-NMR (400MHz, CDCl 3) δppm: 1.08-1.10 (2H, m), 1.38 (9H, s), 1.47-1.51 (2H, m), 3.71 (2H, br), 2. 83 (2H, br), 4.62 (2H, s), 5.17 (2H, s), 7.00-7.15 (3H, m), 7.30-7.39 (5H, m).

[0496] (3) To the benzyl 6-[1-[(2-methylpropan-2-yl)oxycarbonyl]cyclopropyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (454 mg) obtained in (2) above, ethanol (4 ml) and 20% palladium hydroxide (45 mg) were added, and the mixture was stirred under a hydrogen atmosphere at room temperature for 3 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to give the title compound (277 mg) as a crude product as a colorless oil.

[0497] Reference Example 28: Preparation of tert-butyl 2-methyl-2-(1,2,3,4-tetrahydroisoquinolin-6-yl)propanoate

[0498]

[0499] (1) 60% sodium hydride (25.6 mg) was added to DMSO (1.6 ml). To the reaction mixture, a solution of methyl iodide (90 mg) and benzyl 6-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (130 mg) in THF (1.6 ml) was added at 0°C, and the reaction mixture was stirred at room temperature for 4 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 50 / 50) to obtain benzyl 6-[1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (79.7 mg; yield 52%) as a colorless oil. MS (ESI) m / z: 340.1 [M-C 4 H 8 +H] +

[0500] (2) 60% sodium hydride (26 mg) was added to DMSO (1.2 ml). To the reaction mixture, methyl iodide (91 mg) and a solution of benzyl 6-[1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (79.7 mg) obtained in (1) above in THF (1.2 ml) were added at 0°C, and the reaction mixture was stirred at room temperature for 18 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 85 / 15) to give benzyl 6-[2-methyl-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (22.4 mg; yield 33%) as a colorless oil. MS (ESI) m / z: 354.2 [M-C 4 H 8 +H] +

[0501] (3) To the benzyl 6-[2-methyl-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (22.4 mg) obtained in (2) above, ethanol (0.6 ml) and 20% palladium hydroxide (4 mg) were added, and the mixture was stirred under a hydrogen atmosphere at room temperature for 3 hours. The reaction mixture was filtered through Celite and concentrated under reduced pressure to give the title compound (15.1 mg) as a crude product as a colorless oil.

[0502] Reference Example 29: Preparation of tert-butyl 4-(1,2,3,4-tetrahydroisoquinolin-6-yl)butanoate

[0503]

[0504] (1) To a solution of benzyl 6-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylate (1 g) in 1,4-dioxane (10 ml), [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(II) dichloride (197 mg) and 4-ethoxy-4-oxobutylzinc bromide (1 mol / l, 3.5 ml) were added, and the mixture was stirred at room temperature for 3 hours under a nitrogen atmosphere. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate=100 / 0 to 0 / 100) to obtain benzyl 6-(4-ethoxy-4-oxobutyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (183 mg; yield 17%) as a yellow oil. 1 H-NMR (400MHz, CDCl 3 ) δppm: 1.25 (3H, t), 1.89-1.94 (2H, m), 2.29-2.33 (2H, m), 2.60-2.61 (2H, m), 2.82 (2H, br), 3.72 (2H, br), 4.13 (2H, q), 4.62 (2H, s), 5.18 (2H, s), 6.95-7.00 (3H, m), 7.30-7.40 (5H, m).

[0505] (2) To a reaction mixture of benzyl 6-(4-ethoxy-4-oxobutyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (183 mg) obtained in (1) above and methanol (1.6 ml) was added 4N aqueous lithium hydroxide solution (0.48 ml), and the mixture was stirred at room temperature for 12 hours. The reaction solution was neutralized with 1N hydrochloric acid and then extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain crude 4-(2-phenylmethoxycarbonyl-3,4-dihydro-1H-isoquinolin-6-yl)butanoic acid (159 mg) as a yellow oil.

[0506] (3) To a mixed solution of the crude 4-(2-phenylmethoxycarbonyl-3,4-dihydro-1H-isoquinolin-6-yl)butanoic acid (159 mg) obtained in (2) above and toluene (1.5 ml), N,N-dimethylformamide di-tert-butyl acetal (0.3 ml) was added and stirred at 120°C for 1 hour. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 70 / 30) to obtain benzyl 6-[4-[(2-methylpropan-2-yl)oxy]-4-oxobutyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (57 mg; yield 31%) as a colorless oil. 1 H-NMR (400MHz, CDCl 3 ) δppm: 1.44 (9H, s), 1.84-1.92 (2H, m), 2.21-2.24 (2H, m), 2.56-1.61 (2H, m), 2.82 (2 H, br), 3.71 (2H, br), 4.62 (2H, s), 5.18 (2H, s), 6.95-7.03 (3H, m), 7.36-7.40 (5H, m).

[0507] (4) To the benzyl 6-[4-[(2-methylpropan-2-yl)oxy]-4-oxobutyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (57 mg) obtained in (3) above, ethanol (0.9 ml) and 20% palladium hydroxide (4 mg) were added, and the mixture was stirred under a hydrogen atmosphere at room temperature for 3 hours. The reaction mixture was filtered through Celite and concentrated under reduced pressure to give the title compound (39 mg) as a crude product as a colorless oil.

[0508] Reference Example 30: Preparation of tert-butyl 2-(1,2,3,4-tetrahydroisoquinolin-6-yl)propanoate

[0509]

[0510] Ethanol (1.4 ml) and 20% palladium hydroxide (10 mg) were added to benzyl 6-[1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (85.4 mg) obtained in Reference Example 28(1), and the mixture was stirred at room temperature under a hydrogen atmosphere for 3 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to give the title compound (56.4 mg) as a crude yellow oil.

[0511] Reference Example 31: Preparation of tert-butyl rac-(1R,2R)-2-(1,2,3,4-tetrahydroisoquinolin-6-yl)cyclopropane-1-carboxylate

[0512]

[0513] (1) A mixture of benzyl 6-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylate (1.5 g), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (800 mg), bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (155 mg), cesium carbonate (2.8 g), 1,4-dioxane (14 ml), and water (2 ml) was stirred at 140°C for 1 hour in a microwave reactor. After cooling to room temperature, the reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 80 / 20) to give benzyl 6-ethenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate (734 mg; yield 55%) as a colorless oil. MS (ESI) m / z: 294.1 [M+H] +

[0514] (2) Benzyl 6-ethenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate (734 mg) obtained in (1) above was dissolved in 1,4-dioxane (8 ml), and sodium periodate (1 g), 2,6-lutidine (0.56 ml), and a 2.5 wt % osmium tetroxide tert-butanol solution (2.4 ml) were added and stirred at room temperature for 18 hours. The reaction solution was filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 70 / 30) to obtain benzyl 6-formyl-3,4-dihydro-1H-isoquinoline-2-carboxylate (565 mg; yield 74%) as a colorless oil. MS (ESI) m / z: 296.2 [M+H] +

[0515] (3) A reaction mixture of benzyl 6-formyl-3,4-dihydro-1H-isoquinoline-2-carboxylate (1.06 g) obtained in (2), tert-butyl diethoxyphosphoryl acetate (1.8 g), 1,1,3,3-tetramethylguanidine (830 mg), and THF (11 ml) was stirred at room temperature for 12 hours. The reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 70 / 30) to obtain benzyl 6-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (698 mg; yield 46%) as a white solid. MS (ESI) m / z: 392.4 [M-H] -

[0516] (4) To a DMSO solution (12 ml) of trimethylsulfoxonium iodide (1.6 g) was added 60% sodium hydride (288 mg) at 0°C, and the mixture was stirred for 10 minutes. To the reaction mixture was added a DMSO solution of benzyl 6-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (698 mg) obtained in (3) above, and the mixture was stirred at room temperature for 18 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate=100 / 0 to 70 / 30) to obtain benzyl 6-[rac-(1R,2R)-2-[(2-methylpropan-2-yl)oxycarbonyl]cyclopropyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (129 mg; yield 19%) as a colorless oil. 1 H-NMR (400MHz, CDCl 3 ) δppm: 1.18-1.21 (1H, m), 1.46 (9H.s), 1.47-1.50 (1H, m), 1.80-1.82 (1H. , m), 2.38-2.41 (1H, m), 2.81 (br, 1H), 3.70 (1H, br), 4.61 (2H, s), 5.17 (2H, s), 6.87-7.02 (3H, m), 7.33-7.39 (5H, m).

[0517] (5) To the benzyl 6-[rac-(1R,2R)-2-[(2-methylpropan-2-yl)oxycarbonyl]cyclopropyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (129 mg) obtained in (4) above, ethanol (1 ml) and 20% palladium hydroxide (12 mg) were added, and the mixture was stirred at room temperature under a hydrogen atmosphere for 3 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to obtain the title compound (107 mg; yield 97%) as a gray oil. MS (ESI) m / z: 274.3 [M+H] +

[0518] Reference Example 32: Preparation of tert-butyl 1-(5,6,7,8-tetrahydro-2,7-naphthyridin-3-yl)piperidine-4-carboxylate

[0519]

[0520] (1) A mixture of benzyl 6-chloro-3,4-dihydro-1H-2,7-naphthyridine-2-carboxylate (300 mg), DMSO (3 ml), diisopropylethylamine (0.33 ml), and tert-butyl piperidine-4-carboxylate hydrochloride (250 mg) was stirred at 180°C for 1 hour in a microwave reactor. After cooling to room temperature, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 40 / 60) to give benzyl 6-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-1-yl]-3,4-dihydro-1H-2,7-naphthyridine-2-carboxylate (117 mg; yield 22%) as a yellow oil. MS (ESI) m / z: 452.3 [M+H] +

[0521] (2) To the benzyl 6-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-1-yl]-3,4-dihydro-1H-2,7-naphthyridine-2-carboxylate (117 mg) obtained in (1) above, ethanol (1 ml) and 20% palladium hydroxide (12 mg) were added, and the mixture was stirred under a hydrogen atmosphere at room temperature for 3 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to give the title compound (65 mg) as a crude product in the form of a yellow solid.

[0522] Reference Example 33: Preparation of tert-butyl 3-(1,2,3,4-tetrahydroisoquinolin-6-yl)propanoate

[0523]

[0524] (1) 6-Bromo-1,2,3,4-tetrahydroisoquinoline (12 g) was dissolved in pyridine (47 ml), and N,N-dimethylpyridin-4-amine (172 mg) and trifluoroacetic anhydride (6 g) were added. The mixture was stirred at room temperature for 18 hours. The reaction mixture was concentrated, and ethyl acetate was added to the residue, which was then washed with 1N hydrochloric acid. The organic layer was dried and concentrated, and the residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 70 / 30) to obtain 1-(6-bromo-3,4-dihydro-1H-isoquinolin-2-yl)-2,2,2-trifluoroethanone (11.8 g; yield 68%) as a white solid. MS (ESI) m / z: 308.0 / 310.0 [M+H] +

[0525] (2) 1-(6-bromo-3,4-dihydro-1H-isoquinolin-2-yl)-2,2,2-trifluoroethanone (2.4 g) obtained in (1) above was dissolved in 1,4-dioxane (16 ml), and water (4 ml), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (1.16 g), bis[di-tert-butyl(4-dimethylaminophenyl)phosphine]dichloropalladium(II) (178 mg), and cesium carbonate (3.3 g) were added, followed by stirring at 140° C. for 1 hour using a microwave reaction apparatus. The reaction solution was filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 80 / 20) to give 1-(6-ethenyl-3,4-dihydro-1H-isoquinolin-2-yl)-2,2,2-trifluoroethanone (903 mg; 44%) as a white solid. MS (ESI) m / z: 256.2 [M+H] +

[0526] (3) 1-(6-ethenyl-3,4-dihydro-1H-isoquinolin-2-yl)-2,2,2-trifluoroethanone (903 mg) obtained in (2) above was dissolved in 1,4-dioxane (12 ml), and water (3 ml), 2,6-lutidine (0.78 ml), 2.5 wt % osmium tetroxide-tert-butanol solution (3.5 ml), and sodium periodate (1.4 g) were added, followed by stirring at room temperature for 18 hours. The reaction solution was filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 80 / 20 to 50 / 50) to obtain 2-(2,2,2-trifluoroacetyl)-3,4-dihydro-1H-isoquinoline-6-carbaldehyde (573 mg; 66%) as a white solid. MS (ESI) m / z: 258.0 [M+H] +

[0527] (4) 2-(2,2,2-trifluoroacetyl)-3,4-dihydro-1H-isoquinoline-6-carbaldehyde (573 mg) obtained in (3) above was dissolved in THF (7 ml), and 1,1,3,3-tetramethylguanidine (513 mg) and tert-butyl 2-diethoxyphosphoryl acetate (843 mg) were added thereto and stirred at room temperature for 3 hours. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 100 / 0 to 70 / 30) to obtain tert-butyl (E)-3-[2-(2,2,2-trifluoroacetyl)-3,4-dihydro-1H-isoquinolin-6-yl]prop-2-enoate (544 mg; 63%) as a colorless oil. 1 H-NMR (400MHz, CDCl 3 ) δppm: 1.56 (9H, s), 2.99 (2H, t), 3.88 (2H, t), 4.82 (2H, s), 6.38 (1H, d), 7.19 (1H, d), 7.32 (1H, s), 7.41 (1H, d), 7.56 (1H, d). ( * A mixture of rotamers with an NMR integral ratio of approximately 2:1

[0528] (5) tert-butyl (E)-3-[2-(2,2,2-trifluoroacetyl)-3,4-dihydro-1H-isoquinolin-6-yl]prop-2-enoate (544 mg) obtained in (4) above was dissolved in ethanol (6 ml), palladium hydroxide on activated carbon (55 mg) was added, and the mixture was stirred at room temperature under a hydrogen atmosphere for 3 hours. The reaction solution was filtered through a membrane filter, and the filtrate was concentrated under reduced pressure to give crude tert-butyl 3-[2-(2,2,2-trifluoroacetyl)-3,4-dihydro-1H-isoquinolin-6-yl]propanoate (527 mg) as a colorless oil. 1 H-NMR (400MHz, CDCl 3 ) δppm: 1.35 (9H, s), 2.45 (2H, t), 2.80 (2H, t), 2.85 (2H, t), 3.76 (2H, t), 4.69 (2H, s), 7.01-6.92 (3H, m). ( * A mixture of rotamers with an NMR integral ratio of approximately 2:1

[0529] (6) The crude product (527 mg) of tert-butyl 3-[2-(2,2,2-trifluoroacetyl)-3,4-dihydro-1H-isoquinolin-6-yl]propanoate obtained in (5) above was dissolved in ethanol (5 ml), and an aqueous sodium hydroxide solution (4 mol / l, 1.5 ml) was added and stirred at room temperature for 3 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated brine, dried, and concentrated to obtain the crude product (377 mg) of the title compound as a colorless oil.

[0530] Reference Example 34: Preparation of tert-butyl 2-[(8-bromo-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy]acetate

[0531]

[0532] (1) A mixture of 8-bromo-6-methoxy-1,2,3,4-tetrahydroisoquinoline (180 mg) and 50% hydrobromic acid (4 ml) was stirred at 130°C for 8 hours. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. To a mixture of the resulting residue, 1,4-dioxane (1 ml), and water (1 ml), 1N aqueous sodium hydroxide (2 ml) and benzyl chloroformate (0.15 ml) were added in an ice bath, and the mixture was stirred for 1 hour. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 90 / 10 to 50 / 50) to give benzyl 8-bromo-6-hydroxy-3,4-dihydro-1H-isoquinoline-2-carboxylate (53 mg; yield 23%) as a colorless oil. MS (ESI) m / z: 360.1 / 362.1 [M-H] -

[0533] (2) To a mixture of benzyl 8-bromo-6-hydroxy-3,4-dihydro-1H-isoquinoline-2-carboxylate (53 mg) obtained in (1) above, DMF (0.5 ml), and THF (0.1 ml), 60% sodium hydride (9 mg) was added in an ice bath, and the mixture was stirred for 5 minutes. After the temperature was raised to room temperature, tert-butyl bromoacetate (47 mg) was added and the mixture was stirred for 1 hour. A saturated aqueous solution of ammonium chloride was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 90 / 10 to 70 / 30) to give benzyl 8-bromo-6-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethoxy]-3,4-dihydro-1H-isoquinoline-2-carboxylate (64 mg; yield 92%) as a colorless oil. MS (ESI) m / z: 493.0 / 495.0 [M+NH 4 ] +

[0534] (3) To a mixture of palladium acetate (7 mg) and dichloromethane (1.0 ml) under a nitrogen atmosphere, triethylamine (0.02 ml), triethylsilane (0.032 ml), and benzyl 8-bromo-6-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethoxy]-3,4-dihydro-1H-isoquinoline-2-carboxylate (64 mg) obtained in (2) above were added, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to obtain crude tert-butyl 2-[(8-bromo-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy]acetate as a brown oil. MS (ESI) m / z: 342.1 / 344.1 [M+H] +

[0535] Reference Example 35: Preparation of tert-butyl 2-[(8-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy]-2-methylpropanoate

[0536]

[0537] (1) Benzyl 8-fluoro-6-hydroxy-3,4-dihydro-1H-isoquinoline-2-carboxylate (101 mg) was dissolved in DMF (1 ml), potassium carbonate (52 mg) and tert-butyl 2-bromo-2-methylpropanoate (0.064 ml) were added, and the reaction mixture was stirred at room temperature for 5 hours. Potassium carbonate (49 mg) and tert-butyl 2-bromo-2-methylpropanoate (0.064 ml) were added to the reaction mixture, and the mixture was stirred at room temperature for 15 hours and 30 minutes, at 50°C for 7 hours, and then at 80°C for 1 hour. Potassium carbonate (102 mg) and tert-butyl 2-bromo-2-methylpropanoate (0.128 ml) were added to the reaction mixture, and the mixture was stirred at 80°C for 15 hours and 30 minutes. The reaction mixture was cooled to room temperature, water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with 2-fold diluted saturated saline and filtered through a Phase-separator (Biotage). The filtrate was then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 91 / 9 to 70 / 30) to give benzyl 8-fluoro-6-[2-methyl-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]oxy-3,4-dihydro-1H-isoquinoline-2-carboxylate (97.2 mg; yield 69.8%) as a colorless oil. MS (ESI) m / z: 444.4 [M+H] +

[0538] (2) Benzyl 8-fluoro-6-[2-methyl-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]oxy-3,4-dihydro-1H-isoquinoline-2-carboxylate (97 mg) obtained in (1) above was dissolved in ethanol (1 ml), palladium-carbon (10%, 50 mg) was added, and the mixture was stirred at room temperature for 2 hours and 30 minutes under a hydrogen atmosphere. After purging with nitrogen, the reaction mixture was filtered through a membrane filter, and the filtrate was concentrated under reduced pressure and then dried in vacuo to obtain the title compound (65.2 mg; yield 96.2%) as a colorless oil. MS (ESI) m / z: 310.3 [M+H] +

[0539] Reference Example 36: The corresponding starting compounds were treated in the same manner as in Reference Example 35 to give crude products of the compounds listed in Table 2 below.

[0540]

[0541] Reference Example 37: Preparation of tert-butyl 3-[(8-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy]-2,2-dimethylpropanoate

[0542]

[0543] (1) Benzyl 8-fluoro-6-hydroxy-3,4-dihydro-1H-isoquinoline-2-carboxylate (108 mg) was dissolved in THF (1 ml), and triphenylphosphine (117 mg), tert-butyl 3-hydroxy-2,2-dimethyl-propanoate (115 mg), and diethyl azodicarboxylate (2.2 mol / l toluene solution, 0.31 ml) were added thereto, and the reaction mixture was stirred at 70°C for 21 hours. Thereafter, the mixture was stirred for 4 days while naturally cooling to room temperature. The reaction mixture was concentrated under reduced pressure, and the residue was diluted with diisopropyl ether. The precipitate was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 95 / 5 to 75 / 25) to give benzyl 6-[2,2-dimethyl-3-[(2-methylpropan-2-yl)oxy]-3-oxopropoxy]-8-fluoro-3,4-dihydro-1H-isoquinoline-2-carboxylate (85.8 mg; yield 44.4%) as a colorless oil. MS (ESI) m / z: 402.3 [M-C 4 H 8 +H] +

[0544] (2) Benzyl 6-[2,2-dimethyl-3-[(2-methylpropan-2-yl)oxy]-3-oxopropoxy]-8-fluoro-3,4-dihydro-1H-isoquinoline-2-carboxylate (85.8 mg) obtained in (1) above was dissolved in ethanol (2 ml), palladium-carbon (10%, 23 mg) was added, and the mixture was stirred at room temperature for 30 minutes under a hydrogen atmosphere. After purging with nitrogen, the reaction mixture was filtered through a membrane filter, and the filtrate was concentrated under reduced pressure and then dried in vacuo to obtain the title compound (57.1 mg; yield 104%) as a colorless oil. MS (ESI) m / z: 324.3 [M+H] +

[0545] Reference Example 38: Preparation of tert-butyl 3-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)propanoate

[0546]

[0547] (1) To a mixture of ethyl 3-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)propanoate (1.0 g) and dichloromethane (13 ml), triethylamine (1.8 ml) and benzyl chloroformate (0.6 ml) were added and stirred at room temperature for 3 hours. A saturated aqueous solution of ammonium chloride was added to the reaction mixture, followed by extraction with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give benzyl 2-(3-ethoxy-3-oxopropyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (1.4 g; yield 102%) as a white solid. MS (ESI) m / z: 358.2 [M+H] +

[0548] (2) To a mixture of benzyl 2-(3-ethoxy-3-oxopropyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (1.4 g) obtained in (1) above and ethanol (13 ml) was added 4N aqueous sodium hydroxide solution (1.6 ml), and the mixture was stirred at 50°C for 1 hour. The reaction mixture was neutralized with 1N hydrochloric acid and then extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain 3-(5-phenylmethoxycarbonyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)propanoic acid (940 mg; yield 73%) as a colorless oil. MS (ESI) m / z: 328.1 [M-H] -

[0549] (3) To a mixed solution of 3-(5-phenylmethoxycarbonyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)propanoic acid (940 mg) obtained in (2) above and toluene (10 ml), N,N-dimethylformamide di-tert-butyl acetal (2.2 ml) was added, and the mixture was stirred at 120°C under a nitrogen atmosphere for 30 minutes. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 60 / 40 to 40 / 60) to obtain benzyl 2-[3-[(2-methylpropan-2-yl)oxy]-3-oxopropyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (611 mg; yield 56%) as a colorless oil. MS (ESI) m / z: 386.1 [M+H] +

[0550] (4) To a mixture of benzyl 2-[3-[(2-methylpropan-2-yl)oxy]-3-oxopropyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate (95 mg) obtained in (3) above and methanol (1 ml), 20% palladium hydroxide (15 mg) was added, and the mixture was stirred under a hydrogen atmosphere at 60° C. for 2 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to give the title compound (62 mg) as a crude product as a gray oil.

[0551] Reference Example 39: Preparation of methyl 2-(4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridin-2-yl)acetate trifluoroacetate

[0552]

[0553] (1) Pyrrolidine (6.6 L) and p-toluenesulfonic acid monohydrate (5 mg) were added to a mixed solution of tert-butyl 4-oxopiperidine-1-carboxylate (15 g) and toluene (70 ml), and the mixture was heated to reflux for 8 hours using a Dean-Stark apparatus. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure. Methanol (30 ml) and sulfur (2.41 g) were added to the residue, and a solution of cyanamide (3.17 g) in methanol (10 ml) was added dropwise in an ice bath. After the addition was complete, the mixture was stirred in an ice bath for 5 hours. The precipitated solid was collected by filtration, washed with ethyl acetate, and dried under reduced pressure to obtain tert-butyl 2-amino-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-5-carboxylate (11.6 g; yield 60%) as a pale yellow solid. MS (APCI) m / z: 256.1 [M+H] +

[0554] (2) To a mixture of copper(II) bromide (11.9 g) and DMF (40 ml), hexyl nitrite (6.83 g) was added and stirred at 50°C for 5 minutes. To the reaction mixture, tert-butyl 2-amino-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-5-carboxylate (11.3 g) obtained in (1) above was added, and the mixture was stirred at 50°C for 2 hours. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent: n-hexane / ethyl acetate = 83 / 17) to obtain tert-butyl 2-bromo-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-5-carboxylate (4.1 g; yield 24%) as a pale yellow solid. MS (APCI) m / z: 319.0 / 321.0 [M+H] +

[0555] (3) A mixture of tert-butyl 2-bromo-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-5-carboxylate (150 mg) obtained in (2), 1-(tert-butyldimethylsilyloxy)-1-methoxyethene (266 mg), potassium carbonate (130 mg), bis(tri-tert-butylphosphine)palladium(0) (72 mg), and DMF (1 ml) was stirred at 120°C for 1 hour in a microwave reactor. After cooling the reaction mixture to room temperature, a saturated aqueous ammonium chloride solution was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by reverse-phase HPLC (10 mmol / L aqueous ammonium carbonate solution / acetonitrile=60 / 40 to 30 / 70) to give tert-butyl 2-(2-methoxy-2-oxoethyl)-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-5-carboxylate (36 mg; yield 25%) as a yellow amorphous solid. MS (ESI) m / z: 313.2 [M+H] +

[0556] (4) To a mixture of tert-butyl 2-(2-methoxy-2-oxoethyl)-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-5-carboxylate (34 mg) obtained in (3) above and dichloromethane (0.5 ml), trifluoroacetic acid (0.1 ml) was added and stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure to give the title compound (36 mg) as a crude product in the form of a colorless amorphous substance.

[0557] Reference Example 40: Preparation of methyl 2-(8-cyano-1,2,3,4-tetrahydroisoquinolin-6-yl)acetate trifluoroacetate

[0558]

[0559] (1) To a mixture of 6-bromo-8-chloro-1,2,3,4-tetrahydroisoquinoline (58 mg) and dichloromethane (1.5 ml), di-tert-butyl dicarbonate (77 mg) and triethylamine (0.05 ml) were added and stirred at room temperature for 3 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified by reverse-phase HPLC (10 mmol / l aqueous ammonium carbonate solution / acetonitrile = 30 / 70 to 0 / 100) to obtain tert-butyl 6-bromo-8-chloro-3,4-dihydro-1H-isoquinoline-2-carboxylate (63 mg; yield 77%) as a colorless amorphous substance. MS (ESI) m / z: 346.0 / 348.0 [M+H] +

[0560] (2) A mixture of tert-butyl 6-bromo-8-chloro-3,4-dihydro-1H-isoquinoline-2-carboxylate (60 mg) obtained in (1), 1-(tert-butyldimethylsilyloxy)-1-methoxyethene (98 mg), potassium carbonate (48 mg), bis(tri-tert-butylphosphine)palladium(0) (27 mg), and DMF (0.35 ml) was stirred at 120°C for 1 hour in a microwave reaction apparatus. After the reaction mixture was cooled to room temperature, water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by reverse-phase HPLC (10 mmol / L aqueous ammonium carbonate / acetonitrile = 50 / 50 to 20 / 80) to give tert-butyl 8-chloro-6-(2-methoxy-2-oxoethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (31 mg; yield 53%) as a pale yellow amorphous solid. MS (ESI) m / z: 240.1 / 242.1 [M-Boc+H] +

[0561] (3) To a solution of tert-butyl 8-chloro-6-(2-methoxy-2-oxoethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (30 mg) obtained in (2) above in water (1.5 ml) and dioxane (5 ml) were added potassium hexacyanoferrate(II) trihydrate (24 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (9 mg), and potassium acetate (9 mg), and the mixture was stirred for 2 hours at 100° C. After allowing the reaction mixture to cool, saturated aqueous ammonium chloride solution was added, the mixture was extracted with ethyl acetate, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by reverse-phase HPLC (10 mmol / L aqueous ammonium carbonate / acetonitrile = 80 / 20 to 50 / 50) to give 2-[8-cyano-2-[(2-methylpropan-2-yl)oxycarbonyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid (27 mg; yield 97%) as a colorless oil. MS (ESI) m / z: 217.2 [M-Boc+H] +

[0562] (4) To a solution of 2-[8-cyano-2-[(2-methylpropan-2-yl)oxycarbonyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid (24 mg) obtained in (3) above in methanol (0.3 ml) and toluene (1.2 ml) was added dropwise trimethylsilyldiazomethane (10% hexane solution) (0.3 ml), and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure to obtain tert-butyl 8-cyano-6-(2-methoxy-2-oxoethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (24 mg; yield 96%) as a colorless amorphous substance. MS (ESI) m / z: 331.3 [M+H] +

[0563] (5) To a mixture of tert-butyl 8-cyano-6-(2-methoxy-2-oxoethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (22 mg) obtained in (4) above and dichloromethane (1 ml), trifluoroacetic acid (0.1 ml) was added and stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure to give the title compound (23 mg) as a crude product in the form of a colorless amorphous substance.

[0564] Reference Example 41: Preparation of methyl 4-(3-phenylpiperazin-1-yl)butanoate hydrochloride

[0565]

[0566] (1) Diethyl oxalate (2.3 ml) was added to a solution of 2-phenylpiperazine (1.84 g) in THF (ml), and the reaction mixture was stirred overnight. Di-tert-butyl dicarbonate (3.25 g) was added to the reaction mixture, and the mixture was stirred overnight at room temperature. The solvent was evaporated, and methanol (23 ml) and water (23 ml) were added to the residue. 10 mol / l aqueous sodium hydroxide solution (11.3 ml) was added, and the mixture was stirred at 80°C for 12 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by NH silica gel column chromatography (hexane / ethyl acetate = 75 / 25 to 50 / 50), and the fractions containing the target product were concentrated under reduced pressure to give tert-butyl 2-phenylpiperazine-1-carboxylate (1.1958 g; yield 40%) as a pale yellow oil. MS (ESI) m / z: 263.3 [M+H] +

[0567] (2) The tert-butyl 2-phenylpiperazine-1-carboxylate (200 mg) obtained in (1) above was added to DMF (1.9 ml), and methyl 4-bromobutyrate (207 mg), potassium carbonate (316 mg), and potassium iodide (127 mg) were added sequentially, followed by stirring at 80°C for 5 hours and 5 minutes. Water was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was washed sequentially with water and saturated brine, dried over sodium sulfate, and concentrated under reduced pressure to obtain tert-butyl 4-(4-methoxy-4-oxobutyl)-2-phenylpiperazine-1-carboxylate (270 mg; yield 98%) as a pale yellow oil. MS (ESI) m / z: 363.3 [M+H] +

[0568] (3) The tert-butyl 4-(4-methoxy-4-oxobutyl)-2-phenylpiperazine-1-carboxylate (270 mg) obtained in (2) above was added to dioxane (1.86 ml), and a 4M hydrogen chloride-dioxane solution (1.86 ml) was added, followed by stirring at room temperature for 4 hours and 10 minutes. The reaction mixture was evaporated under reduced pressure, followed by adding dioxane and evaporating the solvent under reduced pressure to obtain a crude product of the title compound. MS (ESI) m / z: 263.3 [M+H] +

[0569] Reference Examples 42 to 46: The corresponding starting compounds were treated in the same manner as in Reference Example 41 to give the compounds listed in Table 3 below.

[0570]

[0571] Reference Example 47: Preparation of methyl 4-[(2R,5S)-2-methyl-5-phenylpiperazin-1-yl]butanoate

[0572]

[0573] (1) To a solution of methyl (2S)-2-(benzylamino)-2-phenylacetate (2.3 g) in DMF (20 ml), (2R)-2-(tert-butoxycarbonylamino)propanoic acid (5.0 g), HATU (12.3 g), and N,N-diisopropylethylamine (5.62 ml) were added, and the reaction mixture was stirred at room temperature for 4 days. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate = 80 / 20 to 40 / 60) to give methyl (2S)-2-[benzyl-[(2R)-2-(tert-butoxycarbonylamino)propanoyl]amino]-2-phenylacetate (1.74 g; yield 45.3%) as a colorless oil. MS (ESI) m / z: 425.3 [MH] ―

[0574] (2) Methyl (2S)-2-[benzyl-[(2R)-2-(tert-butoxycarbonylamino)propanoyl]amino]-2-phenylacetate (1.74 g) obtained in (1) above was dissolved in dichloromethane (10 ml), trifluoroacetic acid (10 ml) was added, and the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure at 40°C, and the resulting residue was purified by silica gel column chromatography (chloroform / methanol = 100 / 0 to 90 / 10) to obtain (3R,6S)-1-benzyl-3-methyl-6-phenylpiperazine-2,5-dione (1.0 g; yield 83.3%) as a colorless amorphous substance. MS (ESI) m / z: 295.1 [M+H] +

[0575] (3) (3R,6S)-1-benzyl-3-methyl-6-phenylpiperazine-2,5-dione (1.0 g) obtained in (2) above was dissolved in THF (7 ml), and borane dimethyl sulfide (6.59 ml) was added. The reaction mixture was stirred at 60°C for 15 hours. The reaction mixture was cooled to 0°C, and water was slowly added thereto. After that, hydrochloric acid (1 mol / L, 20 ml) was added and the mixture was stirred at room temperature for 10 minutes. The reaction mixture was neutralized with aqueous sodium hydroxide (1 mol / L) and extracted with chloroform. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then filtered. The filtrate was concentrated under reduced pressure, and methanol (20 ml) and aqueous sodium hydroxide (1 mol / L, 20 ml) were added thereto. The reaction mixture was stirred at 90°C for 15 hours. The reaction mixture was cooled to room temperature and extracted with chloroform. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate=80 / 20 to 50 / 50) to give (2S,5R)-1-benzyl-5-methyl-2-phenylpiperazine (231 mg; yield 25.5%) as a colorless solid. MS (ESI) m / z: 267.2 [M+H] +

[0576] (4) (231 mg) of (2S,5R)-1-benzyl-5-methyl-2-phenylpiperazine obtained in (3) above was dissolved in DMF (3 ml), and methyl 4-bromobutanoate (240 mg), potassium carbonate (160 mg), and potassium iodide (150 mg) were added. The reaction mixture was stirred at 80°C for 2 hours. The reaction mixture was cooled to room temperature, water was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate = 80 / 20 to 60 / 40) to give methyl 4-[(2R,5S)-4-benzyl-2-methyl-5-phenylpiperazin-1-yl]butanoate (272 mg; yield 85.6%) as a colorless oil. MS (ESI) m / z: 367.2 [M+H] +

[0577] (5) Methyl 4-[(2R,5S)-4-benzyl-2-methyl-5-phenylpiperazin-1-yl]butanoate (272 mg) obtained in (4) above was dissolved in methanol (6 ml), and palladium hydroxide on carbon (20%, 200 mg) was added. The reaction mixture was purged with hydrogen and stirred at room temperature for 15 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure at 40°C to give the title compound (205 mg) as a crude product as a colorless oil.

[0578] Reference Example 48: The corresponding starting compounds were treated in the same manner as in Reference Example 47 to give the compounds listed in Table 4 below as crude products.

[0579]

[0580] Reference Example 49: Preparation of methyl 2-(1-ethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)acetate

[0581]

[0582] (1) Triethylamine (2.8 ml) was added to a dichloromethane solution (24.99 ml) of 2-(3-bromophenyl)ethanamine (1.84 g) at room temperature, and propanoyl chloride (0.48 ml) was added under ice cooling and stirred for 30 minutes. Aqueous ammonium chloride solution was added to the reaction mixture, which was then extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give N-[2-(3-bromophenyl)ethyl]propanamide (1.28 g; yield 100%) as a colorless oil. MS (ESI) m / z: 256.1 / 258.1 [M+H] +

[0583] (2) Polyphosphoric acid (5 ml) was added to the N-[2-(3-bromophenyl)ethyl]propanamide (1.2802 g) obtained in (1) above, and the mixture was stirred at an external temperature of 160°C for 5 hours. The reaction solution was added to ice water, and the pH was adjusted to 8 with 1 mol / l aqueous sodium hydroxide solution, after which the aqueous layer was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to obtain 6-bromo-1-ethyl-3,4-dihydroisoquinoline (1.1901 g; yield 100%) as a yellow oil. MS (ESI) m / z: 238.0 / 240.0 [M+H] +

[0584] (3) After ice-cooling a solution of 6-bromo-1-ethyl-3,4-dihydroisoquinoline (1.19 g) obtained in (2) above in methanol (16.66 ml), sodium borohydride (208 mg) was added and the mixture was stirred for 30 minutes. Aqueous ammonium chloride solution was added to the reaction mixture, and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The resulting residue was purified by NH silica gel column chromatography (chloroform / methanol = 100 / 0 to 85 / 15) to obtain 6-bromo-1-ethyl-1,2,3,4-tetrahydroisoquinoline (594 mg; yield 49%) as a colorless oil. MS (ESI) m / z: 240.1 / 242.1 [M+H] +

[0585] (4) To a dichloromethane (4 ml) solution of 6-bromo-1-ethyl-1,2,3,4-tetrahydroisoquinoline (325 mg) obtained in (3) above, triethylamine (0.3 ml) and benzyl chloroformate (0.23 ml) were added at room temperature, and the mixture was stirred for 30 minutes. An aqueous ammonium chloride solution was added to the reaction mixture, and the aqueous layer was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate = 100 / 0 to 80 / 20) to obtain benzyl 6-bromo-1-ethyl-3,4-dihydro-1H-isoquinoline-2-carboxylate (360 mg; yield 71%) as a colorless oil. MS (ESI) m / z: 374.1 / 376.1 [M+H] +

[0586] (5) To a solution of benzyl 6-bromo-1-ethyl-3,4-dihydro-1H-isoquinoline-2-carboxylate (730 mg) obtained in (4) above in DMF (2 ml), 1-(tert-butyldimethylsilyloxy)-1-methoxyethene (1.26 ml), potassium carbonate (530 mg), and bis(tri-tert-butylphosphine)palladium (245 mg) were added, and the mixture was stirred at 110°C for 1 hour under microwave irradiation. An aqueous ammonium chloride solution was added to the reaction mixture, and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate=80 / 20 to 65 / 35) to give benzyl 1-ethyl-6-(2-methoxy-2-oxoethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (360 mg; yield 71%) as a yellow oil. MS (ESI) m / z: 366.1 [M-H] -

[0587] (6) To a solution of benzyl 1-ethyl-6-(2-methoxy-2-oxoethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (520 mg) obtained in (5) above in methanol (4 ml) was added palladium hydroxide (65 mg) at room temperature, and the mixture was stirred for 5 hours under a hydrogen atmosphere at an external temperature of 60° C. After allowing the reaction mixture to cool, it was filtered through Celite and washed with methanol, and the filtrate was concentrated under reduced pressure to obtain a crude product of the title compound (330.1 mg) as a yellow solid.

[0588] Reference Example 50: Preparation of methyl 2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)acetate hydrochloride

[0589]

[0590] (1) To a solution (2.6 ml) of tert-butyl 7-amino-3,4-dihydro-1H-isoquinoline-2-carboxylate (200 mg) in acetonitrile, diisopropylethylamine (0.2 ml) and methyl bromoacetate (0.09 ml) were added at room temperature, and the mixture was stirred overnight. A 10% aqueous potassium carbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform / methanol = 100 / 0 to 93 / 7), and the fractions containing the target product were concentrated under reduced pressure to give tert-butyl 7-[(2-methoxy-2-oxoethyl)amino]-3,4-dihydro-1H-isoquinoline-2-carboxylate (200 mg; yield 78%) as a yellow oil. MS (ESI) m / z: 321.2 [M+H] +

[0591] (2) To a solution of tert-butyl 7-[(2-methoxy-2-oxoethyl)amino]-3,4-dihydro-1H-isoquinoline-2-carboxylate (170 mg) obtained in (1) above in dichloromethane (0.5 ml) was added trifluoroacetic acid (1 ml) at room temperature and stirred for 1 hour. The reaction mixture was concentrated under reduced pressure, and then a 4N hydrogen chloride-ethyl acetate solution (2 ml) was added. The resulting solid was collected by filtration, washed with diisopropyl ether, and dried at 60°C under reduced pressure to obtain a crude product (125 mg) of the title compound as a beige solid.

[0592] Reference Example 51: Preparation of methyl 2-(1,2,3,4-tetrahydroisoquinolin-6-ylamino)acetate hydrochloride

[0593]

[0594] (1) To a solution (2.7 ml) of tert-butyl 6-amino-3,4-dihydro-1H-isoquinoline-2-carboxylate (200 mg) in acetonitrile, N,N-diisopropylethylamine (0.2 ml) and methyl bromoacetate (0.09 ml) were added at room temperature, and the mixture was stirred overnight. A 10% aqueous potassium carbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform / methanol = 100 / 0 to 93 / 7), and the fractions containing the target product were concentrated under reduced pressure to give tert-butyl 6-[(2-methoxy-2-oxoethyl)amino]-3,4-dihydro-1H-isoquinoline-2-carboxylate (190 mg; yield 74%) as a yellow oil. MS (ESI) m / z: 321.2 [M+H] +

[0595] (2) To a solution of tert-butyl 6-[(2-methoxy-2-oxoethyl)amino]-3,4-dihydro-1H-isoquinoline-2-carboxylate (170 mg) obtained in (1) above in dichloromethane (0.5 ml) was added trifluoroacetic acid (1 ml) at room temperature and stirred for 1 hour. The reaction mixture was concentrated under reduced pressure, and then a 4N hydrogen chloride-ethyl acetate solution (2 ml) was added to cause crystallization. The solid was collected by filtration, washed with diisopropyl ether, and dried at 60°C under reduced pressure to obtain a crude product (150 mg) of the title compound as a beige solid.

[0596] Reference Example 52: Preparation of methyl 2-(3-methyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl)acetate hydrochloride

[0597]

[0598] (1) To a DMF solution (20 ml) of tert-butyl 3-methyl-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate (200 mg), methyl bromoacetate (3.90 g), potassium carbonate (1.5 g), and potassium iodide (1.4 g) were added at room temperature, and the mixture was stirred for 30 minutes. After further stirring at 80°C for 1 hour, water was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform / methanol = 100 / 0 to 95 / 5), and the fractions containing the target product were concentrated under reduced pressure to give tert-butyl 1-(2-methoxy-2-oxoethyl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carboxylate (2.6 g; yield 100%) (a 2:1 mixture of regioisomers) as a brown oil. MS (ESI) m / z: 310.2 [M+H] +

[0599] (2) To a solution of tert-butyl 1-(2-methoxy-2-oxoethyl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carboxylate (2.6 g) obtained in (1) above in methanol (10 ml), 4N hydrogen chloride-dioxane solution (20 ml) was added at room temperature and stirred for 1 hour. The reaction mixture was evaporated under reduced pressure, and then acetonitrile was added to cause crystallization, and the solvent was evaporated under reduced pressure. Ethyl acetate was added to the residue, and the resulting solid was collected by filtration and dried under reduced pressure to obtain the title compound (1.56 g; yield 76%) (a 2:1 mixture of regioisomers) as a white solid. MS (ESI) m / z: 210.1 [M+H] +

[0600] Reference Example 53:...

Claims

1. Formula (I): [In the formula, R is an optionally substituted C 6-10 R represents an aryl-ethenyl group; 1 represents a carboxy group or a group biologically equivalent to a carboxy group; L is optionally further substituted; C 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 A represents a divalent organic group containing a group selected from the group consisting of an alkynylene group, and a 3- to 14-membered divalent non-aromatic heterocyclic group; and A represents an optionally further substituted divalent nitrogen-containing heterocyclic group, or a pharma- ceutically acceptable salt thereof.

2. In the formula (I), R is a halogen atom, an optionally substituted C 1-6 Alkyl group, optionally substituted C 3-8 Cycloalkyl group, optionally substituted C 1-6 Alkoxy group, optionally substituted C 3-8 Cycloalkyloxy group, optionally substituted C 1-6 Alkylsulfanyl group, optionally substituted C 3-8 R is a 2-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of a cycloalkylsulfanyl group, and a pentafluorosulfanyl group; 1 is a carboxy group or a group bioisosteric thereto; L is -NR 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group; —O—, —S—, —C(═O)—, C 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 C may have one or more divalent groups selected from the group consisting of an alkynylene group and a 3- to 14-membered divalent non-aromatic heterocyclic group at its internal or terminal positions, and may be further substituted with 1 to 3 substituents selected from the substituent group a; 1-6 Alkylene group, C 6-10 Arylene group, C 3-14 Cycloalkylene group, C 2-6 Alkenylene group, C 2-6 A is an alkynylene group or a 3- to 14-membered divalent non-aromatic heterocyclic group; and A is a group represented by the following formula, which may be further substituted with 1 to 3 substituents selected from the substituent group a: (In the formula, ** represents the bonding site with the carbonyl group, *** represents the bonding site with group L, and ring A 1 represents a 3- to 10-membered monocyclic ring, an 8- to 14-membered fused ring, a 6- to 16-membered spiro ring, or a 6- to 14-membered bridged ring, and may contain, as ring-constituting atoms, a heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom in addition to a nitrogen atom and a carbon atom.) The compound according to claim 1, or a pharma- ceutical acceptable salt thereof. (Substituent group a): A halogen atom; A hydroxy group; A cyano group; An oxo group; A halogen atom, a hydroxy group, a cyano group, C 1-6 Alkoxy group, C 6-14 Aryl group, carboxy group, C 1-6 Alkoxy-carbonyl group, 1 to 2 C 1-6 A carbamoyl group optionally substituted with an alkyl group, and 6-14 C, which may be substituted with a substituent selected from the group consisting of aryloxy groups; 1-6 Alkyl group; C optionally substituted with a halogen atom 1-6 Alkoxy group; C optionally substituted with a halogen atom 1-6 Alkylsulfonyl group; 1-6 Alkyl-carbonyl group; C 1-6 Alkoxy-carbonyl group; halogen atom, hydroxy group, diC 1-6 Alkylamino group and C 1-6 1 to 2 C optionally substituted with a substituent selected from the group consisting of an alkoxy group. 1-6 A carbamoyl group optionally substituted with an alkyl group; 1-6 an alkylamino group; a tri-substituted silyl group; a tri-substituted silyloxy group; a C optionally substituted with 1 to 3 substituents selected from the substituent group b 6-14 a hydrocarbon ring group; a 5- to 14-membered aromatic heterocyclic group which may be substituted with 1 to 3 substituents selected from the substituent group b; and a 3- to 14-membered non-aromatic heterocyclic group which may be substituted with 1 to 3 substituents selected from the substituent group b. (Substituent group b): a halogen atom; a hydroxy group; a cyano group; an oxo group; a carboxy group; a halogen atom, a hydroxy group, a cyano group and C 1-6 C, which may be substituted with a substituent selected from the group consisting of alkoxy groups; 1-6 Alkyl group; halogen atom, hydroxy group, cyano group and C 1-6 C, which may be substituted with a substituent selected from the group consisting of alkoxy groups; 3-8 Cycloalkyl group; halogen atom, hydroxy group, cyano group, C 1-6 Alkyl group and C 1-6 C, which may be substituted with a substituent selected from the group consisting of alkoxy groups; 6-10 Aryl group; halogen atom, hydroxy group, cyano group, C 1-6 Alkyl group and C 1-6 a 5- to 14-membered aromatic heterocyclic group optionally substituted by a substituent selected from the group consisting of an alkoxy group; a halogen atom, a hydroxy group, a cyano group, C 1-6 Alkyl group and C 1-6 a 3- to 14-membered non-aromatic heterocyclic group optionally substituted by a substituent selected from the group consisting of an alkoxy group; a halogen atom, a hydroxy group, a cyano group, and C 1-6 C, which may be substituted with a substituent selected from the group consisting of alkoxy groups; 1-6 Alkoxy group; halogen atom, hydroxy group, cyano group and C 1-6 C, which may be substituted with a substituent selected from the group consisting of alkoxy groups; 1-6 Alkylsulfanyl group; halogen atom, hydroxy group, cyano group and C 1-6 C, which may be substituted with a substituent selected from the group consisting of alkoxy groups; 3-8 Cycloalkyloxy group; C optionally substituted with a halogen atom 1-6 Alkylsulfonyl group; C optionally substituted with a halogen atom 1-6 Alkyl-carbonyl group; C 1-6 Alkoxy-carbonyl group; halogen atom, hydroxy group, diC 1-6 Alkylamino group and C 1-6 1 to 2 C optionally substituted with a substituent selected from the group consisting of an alkoxy group. 1-6 A carbamoyl group optionally substituted by an alkyl group; a halogen atom, a hydroxyl group, a cyano group, and C 1-6 each of which may be substituted with 1 to 3 substituents selected from the group consisting of an alkoxy group; 1-6 Alkyl group, C 3-8 a sulfamoyl group substituted with one substituent selected from the group consisting of a cycloalkyl group and a non-aromatic heterocyclic group; and a pentafluorosulfanyl group.

3. In the formula (I), R is a halogen atom, a C optionally substituted by a halogen atom 1-6 R is a 2-(E)-phenylethenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of an alkyl group and a pentafluorosulfanyl group; 1 is a carboxy group or a group bioisosteric thereto; L is -NR 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group; —O—, —S—, —C(═O)—, C 6-10 Arylene group, C 3-10 Cycloalkylene group, C 2-6 C may have one or more divalent groups selected from the group consisting of alkynylene groups and 3- to 8-membered divalent non-aromatic heterocyclic groups at its internal or terminal positions and may be further substituted with 1 to 3 substituents selected from the substituent group a. 1-6 an alkylene group, optionally further substituted with 1 to 3 substituents selected from the substituent group a; 6-10 an arylene group, C which may be further substituted with 1 to 3 substituents selected from the substituent group a 3-10 a cycloalkylene group, C optionally further substituted with 1 to 3 substituents selected from the substituent group a 2-4 an alkynylene group, or a 3- to 8-membered divalent non-aromatic heterocyclic group which may be further substituted with 1 to 3 substituents selected from the substituent group a; and A is a group represented by the following formula: (In the formula, the wavy line represents a bonding site of the group represented by the above chemical formula, represents a single bond or a double bond, and each Y is independently a nitrogen atom or CR 3 (Here, R 3 is a hydrogen atom or C 1-6 represents an alkyl group; Z represents an oxygen atom, a sulfur atom, NR 4 Or CR 5 R 6 (Here, R 4 , R 5 and R 6 are each independently a hydrogen atom or C 1-6 represents an alkyl group; n represents an integer of 0 to 2; m represents an integer of 0 to 2; n 1 and n 2 Each independently represents an integer of 0 to 2; m 1 and m 2 each independently represents an integer of 0 to 2, ** represents the bonding site with the carbonyl group, and *** represents a bonding site to group L. The compound according to claim 1 , or a pharma- ceutically acceptable salt thereof, wherein R is a nitrogen-containing divalent non-aromatic heterocyclic group represented by the following formula:

4. In the formula (I), L is -NR 2 - (where R 2 is a hydrogen atom or C 1-6 represents an alkyl group; —O—, —S—, C 3-10 C may have one or more divalent groups selected from the group consisting of a cycloalkylene group and a 3- to 8-membered divalent non-aromatic heterocyclic group at its internal or terminal end, and may be further substituted with 1 to 3 substituents selected from the substituent group a. 1-6 an alkylene group, C which may be further substituted with 1 to 3 substituents selected from the substituent group a 3-10 The compound according to claim 3, which is a cycloalkylene group, or a 3- to 8-membered divalent non-aromatic heterocyclic group optionally further substituted with 1 to 3 substituents selected from the substituent group a, or a pharma- ceutically acceptable salt thereof.

5. In the formula (I), L is C which may be further substituted with 1 to 3 substituents selected from the substituent group a. 1-6 4. The compound of claim 3, or a pharma- ceutically acceptable salt thereof, which is an alkylene group.

6. In the formula (I), A is the following formula, which may be further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a:

6. The compound according to claim 5, which is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula: (wherein each symbol has the same meaning as defined above), or a pharma- ceutically acceptable salt thereof.

7. In the formula (I), A is the following formula, which may be further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a: (The definitions of each symbol in the formula are the same as those defined above. However, Z is CR 5 R 6 In the case where the substituent is C which may be further substituted, the substituent which may be further substituted is C which may be substituted with 1 to 3 substituents selected from the substituent group b among the substituents in the substituent group a. 6-14 6. The compound according to claim 5 , or a pharma- ceutically acceptable salt thereof, wherein the nitrogen-containing heterocyclic group is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the formula (I) or (II), 8. The compound represented by the formula (I), wherein A is the following formula, which may be further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a:

6. The compound according to claim 5, which is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula: (wherein each symbol has the same meaning as defined above), or a pharma- ceutically acceptable salt thereof.

9. The compound represented by the formula (I), wherein A is the following formula, which may be further substituted with 1 to 3 substituents selected from the substituent group a:

6. The compound according to claim 5, which is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula: (wherein each symbol has the same meaning as defined above), or a pharma- ceutically acceptable salt thereof.

10. The compound represented by the formula (I), wherein A is the following formula, which may be further substituted with 1 to 3 substituents selected from the above-mentioned substituent group a:

6. The compound according to claim 5, which is a divalent nitrogen-containing non-aromatic heterocyclic group represented by the following formula: (wherein each symbol has the same meaning as defined above), or a pharma- ceutically acceptable salt thereof.

11. In formula (I), R 1 is a carboxy group, an optionally substituted C 1-6 The compound according to any one of claims 1 to 10, which is an alkoxy-carbonyl group, or an optionally substituted carbamoyl group, or a pharma- ceutically acceptable salt thereof.

12. 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 3-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid; N,N-dimethyl-3-[5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]propanamide; 1-[7-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,8-dihydro-5H-2,7-naphthyridin-3-yl]piperidine-4-carboxylic acid; 3-[3-bromo-5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]propanoic acid; 2-[[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]oxy]acetic acid; 2-[2-[2-[[(E)-3-[4-(pentafluoro-lambda 6-sulfanyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; (1R*, 2R*)-2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]cyclopropane-1-carboxylic acid and both enantiomers thereof; 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid; 2-[7-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[7-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,8-dihydro-5H-2,7-naphthyridin-3-yl]acetic acid;3-[3-bromo-5-[2-[[(E)-3-[4-(pentafluoro-lambda 6-sulfanyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl]propanoic acid; 2-[2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]amino]acetic acid; 2-[2-[2-[[(E)-3-(4-iodophenyl)prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[5-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-cyano-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-(2-fluoro-4-iodophenyl)prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-(4-iodophenyl)prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid;2-[8-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[[5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridin-2-yl]sulfanyl]acetic acid; 2-[7-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-cyano-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[5-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; (E)-N-[2-[6-(2-amino-2-oxoethyl)-3,4-dihydro-1H-isoquinolin-2-yl]-2-oxoethyl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide; 2-[5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-[1,3]thiazolo[4,5-c]pyridin-2-yl]acetic acid; (E)-N-[2-[6-[2-(methylamino)-2-oxoethyl]-3,4-dihydro-1H-isoquinolin-2-yl]-2-oxoethyl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide; 4-[4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3-phenylpiperazin-1-yl]butanoic acid and both enantiomers thereof; 2-[[1-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2,3-dihydroindol-4-yl]oxy]acetic acid; 1-[1-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperidin-3-yl]bicyclo[2.1.1]hexane-5-carboxylic acid; 2-[[8-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]oxy]-2-methylpropanoic acid; 3-[[8-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]oxy]-2,2-dimethylpropanoic acid; 4-[4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(3S)-3-(4-bromophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid;4-[3-(3-bromophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 3-[[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]methyl]cyclobutane-1-carboxylic acid and both enantiomers thereof; 4-[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]-2,2-dimethylbutanoic acid; 4-[3-(3-cyclopropylphenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid and both enantiomers thereof; 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]butanoic acid; 4-[(3S)-3-(4-cyclopropylphenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(4-chloro-3-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid;4-[(2R,5S)-5-(3,4-difluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(3,4-difluorophenyl)-2-methyl-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(4-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(3-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-2-ethyl-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-5-phenylpiperazin-1-yl]butanoic acid; and 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]-2,2-dimethylbutanoic acid, or a pharma-ceutically acceptable salt thereof.

13. 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 3-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid; N,N-dimethyl-3-[5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]propanamide; 2-[2-[2-[[(E)-3-[4-(pentafluoro-lambda 6-sulfanyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; (1R*, 2R*)-2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]cyclopropane-1-carboxylic acid and both enantiomers thereof; 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid; 2-[7-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[2-[2-[[(E)-3-(4-iodophenyl)prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[5-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid;2-[8-fluoro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-cyano-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-(2-fluoro-4-iodophenyl)prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[7-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[5-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-[1,3]thiazolo[4,5-c]pyridin-2-yl]acetic acid; 4-[(3S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3-phenylpiperazin-1-yl]butanoic acid; 1-[1-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperidin-3-yl]bicyclo[2.1.1]hexane-5-carboxylic acid; 4-[(3S)-3-(4-bromophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid;4-[3-(3-bromophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 3-[[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]methyl]cyclobutane-1-carboxylic acid and both enantiomers thereof; 4-[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid and both enantiomers; 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]butanoic acid; 4-[(3S)-3-(4-cyclopropylphenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(4-chloro-3-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(3,4-difluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(3,4-difluorophenyl)-2-methyl-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(4-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(3-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-2-ethyl-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-5-phenylpiperazin-1-yl]butanoic acid; and 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]-2,2-dimethylbutanoic acid, or a pharma-ceutically acceptable salt thereof.

14. 2-[7-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid; 2-[2-[2-[[(E)-3-(4-iodophenyl)prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[5-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-fluoro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[7-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid;2-[5-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 4-[(3S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3-phenylpiperazin-1-yl]butanoic acid; 1-[1-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperidin-3-yl]bicyclo[2.1.1]hexane-5-carboxylic acid; 4-[(3S)-3-(4-bromophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(3-bromophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]butanoic acid; 4-[(3S)-3-(4-cyclopropylphenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(3,4-difluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(3,4-difluorophenyl)-2-methyl-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid;4-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-5-(4-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 4-[(2R,5S)-5-(3-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; A compound selected from the group consisting of 4-[(2R,5S)-2-ethyl-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-5-phenylpiperazin-1-yl]butanoic acid; and 4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]-2,2-dimethylbutanoic acid, or a pharma-ceutically acceptable salt thereof; 15. 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 3-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid; N,N-dimethyl-3-[5-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-3-yl]propanamide; 2-[2-[2-[[(E)-3-[4-(pentafluoro-lambda 6-sulfanyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propanoic acid; 2-[8-fluoro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 2-[8-chloro-2-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]acetic acid; 4-[(3R)-3-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid;4-[(2R,5S)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methyl-5-phenylpiperazin-1-yl]butanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; 3-[(2R,5S)-5-(4-chlorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]propanoic acid; A compound selected from the group consisting of 4-[(2R,5S)-5-(3-fluorophenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-2-methylpiperazin-1-yl]butanoic acid; 4-[(2R,5S)-2-ethyl-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]-5-phenylpiperazin-1-yl]butanoic acid; and 4-[(3S)-3-(4-cyclopropylphenyl)-4-[2-[[(E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]prop-2-enoyl]amino]acetyl]piperazin-1-yl]butanoic acid, or a pharma- ceutically acceptable salt thereof.

16. A B0AT1 inhibitor comprising a compound according to any one of claims 1 to 15 or a pharma- ceutically acceptable salt thereof.

17. A pharmaceutical composition comprising a compound according to any one of claims 1 to 15 or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier.

18. The pharmaceutical composition according to claim 17, for the prevention and / or treatment of a disease whose symptoms can be alleviated by inhibiting B0AT1.

19. The pharmaceutical composition according to claim 18, wherein the disease whose symptoms can be alleviated by inhibiting B0AT1 is an amino acid metabolic disorder.

20. The pharmaceutical composition according to claim 19, wherein the amino acid metabolism disorder is phenylketonuria, urea cycle disorder, hypertyrosinemia (types 1-3), hypermethioninemia, maple syrup urine disease, homocystinuria, nonketotic hyperglycinemia, propionic acidemia, methylmalonic acidemia or isovaleric acidemia.

21. The pharmaceutical composition according to claim 19, wherein the amino acid metabolism disorder is phenylketonuria.